Unnamed: 0,GENE,MUTATION_REMARK,GENOMIC_MUTATION_ID,FUSION_ID,MUTATION_AA_SYNTAX,DISEASE,ACTIONABILITY_RANK,DEVELOPMENT_STATUS,DRUG_COMBINATION,TESTING_REQUIRED,TRIAL_STATUS,TRIAL_ID,TRIAL_NAME,COMPLETION_STATUS,TRIAL_PRIMARY_COMPLETION_DATE,PATIENT_PRESCREENING,RESULTS_AVAILABILITY,PROGRESSION_REMARK,SOURCE_TYPE,SOURCE,TREATMENT_HISTORY,PATIENT_AGE,PRIMARY_OUTCOME_MEASURE,NUMBER_OF_PATIENTS,TREATED_NUMBER,CONTROL_NUMBER,CONTROL_TREATMENT,ORR_TREAT,ORR_CON,ORR_CI,ORR_PVAL,DOR_TREAT,DOR_CON,DOR_CI,DOR_PVAL,PFS_TREAT,PFS_CON,PFS_HR,PFS_CI,PFS_PVAL,TTP_TREAT,TTP_CON,TTP_HR,TTP_CI,TTP_PVAL,DCR_TREAT,DCR_CON,DCR_PVAL,OS_TREAT,OS_CON,OS_HR,OS_CI,OS_PVAL,OBJ_RR_TREAT,CR_COUNT,PR_COUNT,SD_COUNT,RFS_TREAT,RFS_CON,RFS_HR,RFS_CI,RFS_PVAL,BLOOD_RESPONSE,RESPONSE_VALUE,TIMEPOINT,CLASSIFICATION_ID,LAST_UPDATED,COSMIC_PHENOTYPE_ID,SITE_PRIMARY_COSMIC,SITE_SUBTYPE1_COSMIC,SITE_SUBTYPE2_COSMIC,SITE_SUBTYPE3_COSMIC,HISTOLOGY_COSMIC,HIST_SUBTYPE1_COSMIC,HIST_SUBTYPE2_COSMIC,HIST_SUBTYPE3_COSMIC
5135.0,ERBB2,ERBB2_unspecified,,,,breast / carcinoma / NS,2.0,Phase 2,Afatinib,,Completed,NCT00431067,,PCD,2009Aug01,Expression confirmed,Yes,,4.0,NCT00431067,Previously-treated,,Overall Response Rate,41.0,41.0,,,9.8,,,,,,,,3.49,,,1.87-3.85,,,,,,,,,,14.0,,,,,,,,,,,,,,,,,COSO28394862,2021Oct11,COSO28394862,breast,NS,NS,NS,carcinoma,NS,NS,NS
5136.0,ERBB2,ERBB2_unspecified,,,,breast / carcinoma / NS,2.0,Phase 2,Afatinib,,Completed,NCT00431067,,PCD,2009Aug01,Expression confirmed,Yes,,4.0,NCT00431067,Previously-treated,,Overall Response Rate,41.0,41.0,,,9.8,,,,,,,,3.49,,,1.87-3.85,,,,,,,,,,14.0,,,,,,,,,,,,,,,,,COSO28394862,2021Oct11,COSO28394862,breast,NS,NS,NS,carcinoma,NS,NS,NS
5137.0,ERBB2,ERBB2_unspecified,,,,breast / carcinoma / NS,2.0,Phase 2,Afatinib,,Completed,NCT00431067,,PCD,2009Aug01,Expression confirmed,Yes,,4.0,NCT00431067,Previously-treated,,Overall Response Rate,41.0,41.0,,,9.8,,,,,,,,3.49,,,1.87-3.85,,,,,,,,,,14.0,,,,,,,,,,,,,,,,,COSO28394862,2021Oct11,COSO28394862,breast,NS,NS,NS,carcinoma,NS,NS,NS
5138.0,ERBB2,ERBB2_unspecified,,,,breast / carcinoma / NS,2.0,Phase 2,Afatinib,,Completed,NCT00431067,,PCD,2009Aug01,Expression confirmed,Yes,,4.0,NCT00431067,Previously-treated,,Overall Response Rate,41.0,41.0,,,9.8,,,,,,,,3.49,,,1.87-3.85,,,,,,,,,,14.0,,,,,,,,,,,,,,,,,COSO28394862,2021Oct11,COSO28394862,breast,NS,NS,NS,carcinoma,NS,NS,NS
5139.0,ERBB2,ERBB2_unspecified,,,,breast / carcinoma / NS,2.0,Phase 2,Afatinib,,Completed,NCT00431067,,PCD,2009Aug01,Expression confirmed,Yes,,4.0,NCT00431067,Previously-treated,,Overall Response Rate,41.0,41.0,,,9.8,,,,,,,,3.49,,,1.87-3.85,,,,,,,,,,14.0,,,,,,,,,,,,,,,,,COSO28394862,2021Oct11,COSO28394862,breast,NS,NS,NS,carcinoma,NS,NS,NS
5140.0,ERBB2,ERBB2_unspecified,,,,breast / carcinoma / NS,2.0,Phase 2,Afatinib,,Completed,NCT00431067,,PCD,2009Aug01,Expression confirmed,Yes,,4.0,NCT00431067,Previously-treated,,Overall Response Rate,41.0,41.0,,,9.8,,,,,,,,3.49,,,1.87-3.85,,,,,,,,,,14.0,,,,,,,,,,,,,,,,,COSO28394862,2021Oct11,COSO28394862,breast,NS,NS,NS,carcinoma,NS,NS,NS
5141.0,ERBB2,ERBB2_unspecified,,,,breast / carcinoma / NS,2.0,Phase 2,Afatinib,,Completed,NCT00431067,,PCD,2009Aug01,Expression confirmed,Yes,,4.0,NCT00431067,Previously-treated,,Overall Response Rate,41.0,41.0,,,9.8,,,,,,,,3.49,,,1.87-3.85,,,,,,,,,,14.0,,,,,,,,,,,,,,,,,COSO28394862,2021Oct11,COSO28394862,breast,NS,NS,NS,carcinoma,NS,NS,NS
5142.0,ERBB2,ERBB2_unspecified,,,,breast / carcinoma / NS,2.0,Phase 2,Afatinib,,Completed,NCT00431067,,PCD,2009Aug01,Expression confirmed,Yes,,4.0,NCT00431067,Previously-treated,,Overall Response Rate,41.0,41.0,,,9.8,,,,,,,,3.49,,,1.87-3.85,,,,,,,,,,14.0,,,,,,,,,,,,,,,,,COSO28394862,2021Oct11,COSO28394862,breast,NS,NS,NS,carcinoma,NS,NS,NS
5143.0,ERBB2,ERBB2_unspecified,,,,breast / carcinoma / NS,2.0,Phase 2,Afatinib,,Completed,NCT00431067,,PCD,2009Aug01,Expression confirmed,Yes,,4.0,NCT00431067,Previously-treated,,Overall Response Rate,41.0,41.0,,,9.8,,,,,,,,3.49,,,1.87-3.85,,,,,,,,,,14.0,,,,,,,,,,,,,,,,,COSO28394862,2021Oct11,COSO28394862,breast,NS,NS,NS,carcinoma,NS,NS,NS
5144.0,ERBB2,ERBB2_unspecified,,,,breast / carcinoma / NS,2.0,Phase 2,Afatinib,,Completed,NCT00431067,,PCD,2009Aug01,Expression confirmed,Yes,,4.0,NCT00431067,Previously-treated,,Overall Response Rate,41.0,41.0,,,9.8,,,,,,,,3.49,,,1.87-3.85,,,,,,,,,,14.0,,,,,,,,,,,,,,,,,COSO28394862,2021Oct11,COSO28394862,breast,NS,NS,NS,carcinoma,NS,NS,NS
5145.0,ERBB2,ERBB2_unspecified,,,,breast / carcinoma / NS,2.0,Phase 2,Afatinib,,Completed,NCT00431067,,PCD,2009Aug01,Expression confirmed,Yes,,4.0,NCT00431067,Previously-treated,,Overall Response Rate,41.0,41.0,,,9.8,,,,,,,,3.49,,,1.87-3.85,,,,,,,,,,14.0,,,,,,,,,,,,,,,,,COSO28394862,2021Oct11,COSO28394862,breast,NS,NS,NS,carcinoma,NS,NS,NS
5146.0,ERBB2,ERBB2_unspecified,,,,breast / carcinoma / NS,2.0,Phase 2,Afatinib,,Completed,NCT00431067,,PCD,2009Aug01,Expression confirmed,Yes,,4.0,NCT00431067,Previously-treated,,Overall Response Rate,41.0,41.0,,,9.8,,,,,,,,3.49,,,1.87-3.85,,,,,,,,,,14.0,,,,,,,,,,,,,,,,,COSO28394862,2021Oct11,COSO28394862,breast,NS,NS,NS,carcinoma,NS,NS,NS
5147.0,ERBB2,ERBB2_unspecified,,,,breast / carcinoma / NS,2.0,Phase 2,Afatinib,,Completed,NCT00431067,,PCD,2009Aug01,Expression confirmed,Yes,,4.0,NCT00431067,Previously-treated,,Overall Response Rate,41.0,41.0,,,9.8,,,,,,,,3.49,,,1.87-3.85,,,,,,,,,,14.0,,,,,,,,,,,,,,,,,COSO28394862,2021Oct11,COSO28394862,breast,NS,NS,NS,carcinoma,NS,NS,NS
13442.0,ERBB2,ERBB2_unspecified,,,,breast / carcinoma / NS,2.0,Phase 2,Afatinib,,Completed,NCT01441596,,PCD,2014Feb01,Overexpression,Yes,CNSN 12w 30.0 v 41.9%,4.0,NCT01441596,Previously-treated,,No CNS progression,83.0,40.0,43.0,Physician's choice,,,,,,,,,2.75,4.25,,,,,,,,,,,,13.32,12.02,,,,,,,,,,,,,,,,COSO28394862,2022Nov28,COSO28394862,breast,NS,NS,NS,carcinoma,NS,NS,NS
13443.0,ERBB2,ERBB2_unspecified,,,,breast / carcinoma / NS,2.0,Phase 2,Afatinib,,Completed,NCT01441596,,PCD,2014Feb01,Overexpression,Yes,CNSN 12w 30.0 v 41.9%,4.0,NCT01441596,Previously-treated,,No CNS progression,83.0,40.0,43.0,Physician's choice,,,,,,,,,2.75,4.25,,,,,,,,,,,,13.32,12.02,,,,,,,,,,,,,,,,COSO28394862,2022Nov28,COSO28394862,breast,NS,NS,NS,carcinoma,NS,NS,NS
13444.0,ERBB2,ERBB2_unspecified,,,,breast / carcinoma / NS,2.0,Phase 2,Afatinib,,Completed,NCT01441596,,PCD,2014Feb01,Overexpression,Yes,CNSN 12w 30.0 v 41.9%,4.0,NCT01441596,Previously-treated,,No CNS progression,83.0,40.0,43.0,Physician's choice,,,,,,,,,2.75,4.25,,,,,,,,,,,,13.32,12.02,,,,,,,,,,,,,,,,COSO28394862,2022Nov28,COSO28394862,breast,NS,NS,NS,carcinoma,NS,NS,NS
13445.0,ERBB2,ERBB2_unspecified,,,,breast / carcinoma / NS,2.0,Phase 2,Afatinib,,Completed,NCT01441596,,PCD,2014Feb01,Overexpression,Yes,CNSN 12w 30.0 v 41.9%,4.0,NCT01441596,Previously-treated,,No CNS progression,83.0,40.0,43.0,Physician's choice,,,,,,,,,2.75,4.25,,,,,,,,,,,,13.32,12.02,,,,,,,,,,,,,,,,COSO28394862,2022Nov28,COSO28394862,breast,NS,NS,NS,carcinoma,NS,NS,NS
13446.0,ERBB2,ERBB2_unspecified,,,,breast / carcinoma / NS,2.0,Phase 2,Afatinib,,Completed,NCT01441596,,PCD,2014Feb01,Overexpression,Yes,CNSN 12w 30.0 v 41.9%,4.0,NCT01441596,Previously-treated,,No CNS progression,83.0,40.0,43.0,Physician's choice,,,,,,,,,2.75,4.25,,,,,,,,,,,,13.32,12.02,,,,,,,,,,,,,,,,COSO28394862,2022Nov28,COSO28394862,breast,NS,NS,NS,carcinoma,NS,NS,NS
13447.0,ERBB2,ERBB2_unspecified,,,,breast / carcinoma / NS,2.0,Phase 2,Afatinib,,Completed,NCT01441596,,PCD,2014Feb01,Overexpression,Yes,CNSN 12w 30.0 v 41.9%,4.0,NCT01441596,Previously-treated,,No CNS progression,83.0,40.0,43.0,Physician's choice,,,,,,,,,2.75,4.25,,,,,,,,,,,,13.32,12.02,,,,,,,,,,,,,,,,COSO28394862,2022Nov28,COSO28394862,breast,NS,NS,NS,carcinoma,NS,NS,NS
13448.0,ERBB2,ERBB2_unspecified,,,,breast / carcinoma / NS,2.0,Phase 2,Afatinib,,Completed,NCT01441596,,PCD,2014Feb01,Overexpression,Yes,CNSN 12w 30.0 v 41.9%,4.0,NCT01441596,Previously-treated,,No CNS progression,83.0,40.0,43.0,Physician's choice,,,,,,,,,2.75,4.25,,,,,,,,,,,,13.32,12.02,,,,,,,,,,,,,,,,COSO28394862,2022Nov28,COSO28394862,breast,NS,NS,NS,carcinoma,NS,NS,NS
13449.0,ERBB2,ERBB2_unspecified,,,,breast / carcinoma / NS,2.0,Phase 2,Afatinib,,Completed,NCT01441596,,PCD,2014Feb01,Overexpression,Yes,CNSN 12w 30.0 v 41.9%,4.0,NCT01441596,Previously-treated,,No CNS progression,83.0,40.0,43.0,Physician's choice,,,,,,,,,2.75,4.25,,,,,,,,,,,,13.32,12.02,,,,,,,,,,,,,,,,COSO28394862,2022Nov28,COSO28394862,breast,NS,NS,NS,carcinoma,NS,NS,NS
13450.0,ERBB2,ERBB2_unspecified,,,,breast / carcinoma / NS,2.0,Phase 2,Afatinib,,Completed,NCT01441596,,PCD,2014Feb01,Overexpression,Yes,CNSN 12w 30.0 v 41.9%,4.0,NCT01441596,Previously-treated,,No CNS progression,83.0,40.0,43.0,Physician's choice,,,,,,,,,2.75,4.25,,,,,,,,,,,,13.32,12.02,,,,,,,,,,,,,,,,COSO28394862,2022Nov28,COSO28394862,breast,NS,NS,NS,carcinoma,NS,NS,NS
13451.0,ERBB2,ERBB2_unspecified,,,,breast / carcinoma / NS,2.0,Phase 2,Afatinib,,Completed,NCT01441596,,PCD,2014Feb01,Overexpression,Yes,CNSN 12w 30.0 v 41.9%,4.0,NCT01441596,Previously-treated,,No CNS progression,83.0,40.0,43.0,Physician's choice,,,,,,,,,2.75,4.25,,,,,,,,,,,,13.32,12.02,,,,,,,,,,,,,,,,COSO28394862,2022Nov28,COSO28394862,breast,NS,NS,NS,carcinoma,NS,NS,NS
13452.0,ERBB2,ERBB2_unspecified,,,,breast / carcinoma / NS,2.0,Phase 2,Afatinib,,Completed,NCT01441596,,PCD,2014Feb01,Overexpression,Yes,CNSN 12w 30.0 v 41.9%,4.0,NCT01441596,Previously-treated,,No CNS progression,83.0,40.0,43.0,Physician's choice,,,,,,,,,2.75,4.25,,,,,,,,,,,,13.32,12.02,,,,,,,,,,,,,,,,COSO28394862,2022Nov28,COSO28394862,breast,NS,NS,NS,carcinoma,NS,NS,NS
13453.0,ERBB2,ERBB2_unspecified,,,,breast / carcinoma / NS,2.0,Phase 2,Afatinib,,Completed,NCT01441596,,PCD,2014Feb01,Overexpression,Yes,CNSN 12w 30.0 v 41.9%,4.0,NCT01441596,Previously-treated,,No CNS progression,83.0,40.0,43.0,Physician's choice,,,,,,,,,2.75,4.25,,,,,,,,,,,,13.32,12.02,,,,,,,,,,,,,,,,COSO28394862,2022Nov28,COSO28394862,breast,NS,NS,NS,carcinoma,NS,NS,NS
13454.0,ERBB2,ERBB2_unspecified,,,,breast / carcinoma / NS,2.0,Phase 2,Afatinib,,Completed,NCT01441596,,PCD,2014Feb01,Overexpression,Yes,CNSN 12w 30.0 v 41.9%,4.0,NCT01441596,Previously-treated,,No CNS progression,83.0,40.0,43.0,Physician's choice,,,,,,,,,2.75,4.25,,,,,,,,,,,,13.32,12.02,,,,,,,,,,,,,,,,COSO28394862,2022Nov28,COSO28394862,breast,NS,NS,NS,carcinoma,NS,NS,NS
13455.0,ERBB2,ERBB2_unspecified,,,,breast / carcinoma / NS,2.0,Phase 2,Afatinib,,Completed,NCT01325428,,PCD,2014Nov01,Overexpression,Yes,,4.0,NCT01325428,,,"Disease control rate, Clinical benefit rate",26.0,26.0,,,31.0,,14-52,,,,,,,,,,,,,,,,35.0,,,,,,,,,,,,,,,,,,,,COSO28394862,2022Nov28,COSO28394862,breast,NS,NS,NS,carcinoma,NS,NS,NS
13456.0,ERBB2,ERBB2_unspecified,,,,breast / carcinoma / NS,2.0,Phase 2,Afatinib,,Completed,NCT01325428,,PCD,2014Nov01,Overexpression,Yes,,4.0,NCT01325428,,,"Disease control rate, Clinical benefit rate",26.0,26.0,,,31.0,,14-52,,,,,,,,,,,,,,,,35.0,,,,,,,,,,,,,,,,,,,,COSO28394862,2022Nov28,COSO28394862,breast,NS,NS,NS,carcinoma,NS,NS,NS
13457.0,ERBB2,ERBB2_unspecified,,,,breast / carcinoma / NS,2.0,Phase 2,Afatinib,,Completed,NCT01325428,,PCD,2014Nov01,Overexpression,Yes,,4.0,NCT01325428,,,"Disease control rate, Clinical benefit rate",26.0,26.0,,,31.0,,14-52,,,,,,,,,,,,,,,,35.0,,,,,,,,,,,,,,,,,,,,COSO28394862,2022Nov28,COSO28394862,breast,NS,NS,NS,carcinoma,NS,NS,NS
13458.0,ERBB2,ERBB2_unspecified,,,,breast / carcinoma / NS,2.0,Phase 2,Afatinib,,Completed,NCT01325428,,PCD,2014Nov01,Overexpression,Yes,,4.0,NCT01325428,,,"Disease control rate, Clinical benefit rate",26.0,26.0,,,31.0,,14-52,,,,,,,,,,,,,,,,35.0,,,,,,,,,,,,,,,,,,,,COSO28394862,2022Nov28,COSO28394862,breast,NS,NS,NS,carcinoma,NS,NS,NS
13459.0,ERBB2,ERBB2_unspecified,,,,breast / carcinoma / NS,2.0,Phase 2,Afatinib,,Completed,NCT01325428,,PCD,2014Nov01,Overexpression,Yes,,4.0,NCT01325428,,,"Disease control rate, Clinical benefit rate",26.0,26.0,,,31.0,,14-52,,,,,,,,,,,,,,,,35.0,,,,,,,,,,,,,,,,,,,,COSO28394862,2022Nov28,COSO28394862,breast,NS,NS,NS,carcinoma,NS,NS,NS
13460.0,ERBB2,ERBB2_unspecified,,,,breast / carcinoma / NS,2.0,Phase 2,Afatinib,,Completed,NCT01325428,,PCD,2014Nov01,Overexpression,Yes,,4.0,NCT01325428,,,"Disease control rate, Clinical benefit rate",26.0,26.0,,,31.0,,14-52,,,,,,,,,,,,,,,,35.0,,,,,,,,,,,,,,,,,,,,COSO28394862,2022Nov28,COSO28394862,breast,NS,NS,NS,carcinoma,NS,NS,NS
13461.0,ERBB2,ERBB2_unspecified,,,,breast / carcinoma / NS,2.0,Phase 2,Afatinib,,Completed,NCT01325428,,PCD,2014Nov01,Overexpression,Yes,,4.0,NCT01325428,,,"Disease control rate, Clinical benefit rate",26.0,26.0,,,31.0,,14-52,,,,,,,,,,,,,,,,35.0,,,,,,,,,,,,,,,,,,,,COSO28394862,2022Nov28,COSO28394862,breast,NS,NS,NS,carcinoma,NS,NS,NS
13462.0,ERBB2,ERBB2_unspecified,,,,breast / carcinoma / NS,2.0,Phase 2,Afatinib,,Completed,NCT01325428,,PCD,2014Nov01,Overexpression,Yes,,4.0,NCT01325428,,,"Disease control rate, Clinical benefit rate",26.0,26.0,,,31.0,,14-52,,,,,,,,,,,,,,,,35.0,,,,,,,,,,,,,,,,,,,,COSO28394862,2022Nov28,COSO28394862,breast,NS,NS,NS,carcinoma,NS,NS,NS
13463.0,ERBB2,ERBB2_unspecified,,,,breast / carcinoma / NS,2.0,Phase 2,Afatinib,,Completed,NCT01325428,,PCD,2014Nov01,Overexpression,Yes,,4.0,NCT01325428,,,"Disease control rate, Clinical benefit rate",26.0,26.0,,,31.0,,14-52,,,,,,,,,,,,,,,,35.0,,,,,,,,,,,,,,,,,,,,COSO28394862,2022Nov28,COSO28394862,breast,NS,NS,NS,carcinoma,NS,NS,NS
13464.0,ERBB2,ERBB2_unspecified,,,,breast / carcinoma / NS,2.0,Phase 2,Afatinib,,Completed,NCT01325428,,PCD,2014Nov01,Overexpression,Yes,,4.0,NCT01325428,,,"Disease control rate, Clinical benefit rate",26.0,26.0,,,31.0,,14-52,,,,,,,,,,,,,,,,35.0,,,,,,,,,,,,,,,,,,,,COSO28394862,2022Nov28,COSO28394862,breast,NS,NS,NS,carcinoma,NS,NS,NS
13465.0,ERBB2,ERBB2_unspecified,,,,breast / carcinoma / NS,2.0,Phase 2,Afatinib,,Completed,NCT01325428,,PCD,2014Nov01,Overexpression,Yes,,4.0,NCT01325428,,,"Disease control rate, Clinical benefit rate",26.0,26.0,,,31.0,,14-52,,,,,,,,,,,,,,,,35.0,,,,,,,,,,,,,,,,,,,,COSO28394862,2022Nov28,COSO28394862,breast,NS,NS,NS,carcinoma,NS,NS,NS
13466.0,ERBB2,ERBB2_unspecified,,,,breast / carcinoma / NS,2.0,Phase 2,Afatinib,,Completed,NCT01325428,,PCD,2014Nov01,Overexpression,Yes,,4.0,NCT01325428,,,"Disease control rate, Clinical benefit rate",26.0,26.0,,,31.0,,14-52,,,,,,,,,,,,,,,,35.0,,,,,,,,,,,,,,,,,,,,COSO28394862,2022Nov28,COSO28394862,breast,NS,NS,NS,carcinoma,NS,NS,NS
13467.0,ERBB2,ERBB2_unspecified,,,,breast / carcinoma / NS,2.0,Phase 2,Afatinib,,Completed,NCT01325428,,PCD,2014Nov01,Overexpression,Yes,,4.0,NCT01325428,,,"Disease control rate, Clinical benefit rate",26.0,26.0,,,31.0,,14-52,,,,,,,,,,,,,,,,35.0,,,,,,,,,,,,,,,,,,,,COSO28394862,2022Nov28,COSO28394862,breast,NS,NS,NS,carcinoma,NS,NS,NS
13468.0,ERBB2,ERBB2_unspecified,,,,breast / carcinoma / NS,2.0,Phase 2,Afatinib,,Completed,NCT01271725,LUX-Breast 2,PCD,2017Mar13,Overexpression,Yes,,8.0,https://www.clinicaltrialsregister.eu/ctr-search/trial/2010-021945-29/results,Previously-treated,,,74.0,74.0,,,18.0,,10-28,,5.54,,2.80-8.32,,2.83,,,2.37-4.28,,,,,,,,,,,,,,,,,,,,,,,,,,,COSO28394862,2022Nov28,COSO28394862,breast,NS,NS,NS,carcinoma,NS,NS,NS
13469.0,ERBB2,ERBB2_unspecified,,,,breast / carcinoma / NS,2.0,Phase 2,Afatinib,,Completed,NCT01271725,LUX-Breast 2,PCD,2017Mar13,Overexpression,Yes,,8.0,https://www.clinicaltrialsregister.eu/ctr-search/trial/2010-021945-29/results,Previously-treated,,,74.0,74.0,,,18.0,,10-28,,5.54,,2.80-8.32,,2.83,,,2.37-4.28,,,,,,,,,,,,,,,,,,,,,,,,,,,COSO28394862,2022Nov28,COSO28394862,breast,NS,NS,NS,carcinoma,NS,NS,NS
13470.0,ERBB2,ERBB2_unspecified,,,,breast / carcinoma / NS,2.0,Phase 2,Afatinib,,Completed,NCT01271725,LUX-Breast 2,PCD,2017Mar13,Overexpression,Yes,,8.0,https://www.clinicaltrialsregister.eu/ctr-search/trial/2010-021945-29/results,Previously-treated,,,74.0,74.0,,,18.0,,10-28,,5.54,,2.80-8.32,,2.83,,,2.37-4.28,,,,,,,,,,,,,,,,,,,,,,,,,,,COSO28394862,2022Nov28,COSO28394862,breast,NS,NS,NS,carcinoma,NS,NS,NS
13471.0,ERBB2,ERBB2_unspecified,,,,breast / carcinoma / NS,2.0,Phase 2,Afatinib,,Completed,NCT01271725,LUX-Breast 2,PCD,2017Mar13,Overexpression,Yes,,8.0,https://www.clinicaltrialsregister.eu/ctr-search/trial/2010-021945-29/results,Previously-treated,,,74.0,74.0,,,18.0,,10-28,,5.54,,2.80-8.32,,2.83,,,2.37-4.28,,,,,,,,,,,,,,,,,,,,,,,,,,,COSO28394862,2022Nov28,COSO28394862,breast,NS,NS,NS,carcinoma,NS,NS,NS
13472.0,ERBB2,ERBB2_unspecified,,,,breast / carcinoma / NS,2.0,Phase 2,Afatinib,,Completed,NCT01271725,LUX-Breast 2,PCD,2017Mar13,Overexpression,Yes,,8.0,https://www.clinicaltrialsregister.eu/ctr-search/trial/2010-021945-29/results,Previously-treated,,,74.0,74.0,,,18.0,,10-28,,5.54,,2.80-8.32,,2.83,,,2.37-4.28,,,,,,,,,,,,,,,,,,,,,,,,,,,COSO28394862,2022Nov28,COSO28394862,breast,NS,NS,NS,carcinoma,NS,NS,NS
13473.0,ERBB2,ERBB2_unspecified,,,,breast / carcinoma / NS,2.0,Phase 2,Afatinib,,Completed,NCT01271725,LUX-Breast 2,PCD,2017Mar13,Overexpression,Yes,,8.0,https://www.clinicaltrialsregister.eu/ctr-search/trial/2010-021945-29/results,Previously-treated,,,74.0,74.0,,,18.0,,10-28,,5.54,,2.80-8.32,,2.83,,,2.37-4.28,,,,,,,,,,,,,,,,,,,,,,,,,,,COSO28394862,2022Nov28,COSO28394862,breast,NS,NS,NS,carcinoma,NS,NS,NS
13474.0,ERBB2,ERBB2_unspecified,,,,breast / carcinoma / NS,2.0,Phase 2,Afatinib,,Completed,NCT01271725,LUX-Breast 2,PCD,2017Mar13,Overexpression,Yes,,8.0,https://www.clinicaltrialsregister.eu/ctr-search/trial/2010-021945-29/results,Previously-treated,,,74.0,74.0,,,18.0,,10-28,,5.54,,2.80-8.32,,2.83,,,2.37-4.28,,,,,,,,,,,,,,,,,,,,,,,,,,,COSO28394862,2022Nov28,COSO28394862,breast,NS,NS,NS,carcinoma,NS,NS,NS
13475.0,ERBB2,ERBB2_unspecified,,,,breast / carcinoma / NS,2.0,Phase 2,Afatinib,,Completed,NCT01271725,LUX-Breast 2,PCD,2017Mar13,Overexpression,Yes,,8.0,https://www.clinicaltrialsregister.eu/ctr-search/trial/2010-021945-29/results,Previously-treated,,,74.0,74.0,,,18.0,,10-28,,5.54,,2.80-8.32,,2.83,,,2.37-4.28,,,,,,,,,,,,,,,,,,,,,,,,,,,COSO28394862,2022Nov28,COSO28394862,breast,NS,NS,NS,carcinoma,NS,NS,NS
13476.0,ERBB2,ERBB2_unspecified,,,,breast / carcinoma / NS,2.0,Phase 2,Afatinib,,Completed,NCT01271725,LUX-Breast 2,PCD,2017Mar13,Overexpression,Yes,,8.0,https://www.clinicaltrialsregister.eu/ctr-search/trial/2010-021945-29/results,Previously-treated,,,74.0,74.0,,,18.0,,10-28,,5.54,,2.80-8.32,,2.83,,,2.37-4.28,,,,,,,,,,,,,,,,,,,,,,,,,,,COSO28394862,2022Nov28,COSO28394862,breast,NS,NS,NS,carcinoma,NS,NS,NS
13477.0,ERBB2,ERBB2_unspecified,,,,breast / carcinoma / NS,2.0,Phase 2,Afatinib,,Completed,NCT01271725,LUX-Breast 2,PCD,2017Mar13,Overexpression,Yes,,8.0,https://www.clinicaltrialsregister.eu/ctr-search/trial/2010-021945-29/results,Previously-treated,,,74.0,74.0,,,18.0,,10-28,,5.54,,2.80-8.32,,2.83,,,2.37-4.28,,,,,,,,,,,,,,,,,,,,,,,,,,,COSO28394862,2022Nov28,COSO28394862,breast,NS,NS,NS,carcinoma,NS,NS,NS
13478.0,ERBB2,ERBB2_unspecified,,,,breast / carcinoma / NS,2.0,Phase 2,Afatinib,,Completed,NCT01271725,LUX-Breast 2,PCD,2017Mar13,Overexpression,Yes,,8.0,https://www.clinicaltrialsregister.eu/ctr-search/trial/2010-021945-29/results,Previously-treated,,,74.0,74.0,,,18.0,,10-28,,5.54,,2.80-8.32,,2.83,,,2.37-4.28,,,,,,,,,,,,,,,,,,,,,,,,,,,COSO28394862,2022Nov28,COSO28394862,breast,NS,NS,NS,carcinoma,NS,NS,NS
13479.0,ERBB2,ERBB2_unspecified,,,,breast / carcinoma / NS,2.0,Phase 2,Afatinib,,Completed,NCT01271725,LUX-Breast 2,PCD,2017Mar13,Overexpression,Yes,,8.0,https://www.clinicaltrialsregister.eu/ctr-search/trial/2010-021945-29/results,Previously-treated,,,74.0,74.0,,,18.0,,10-28,,5.54,,2.80-8.32,,2.83,,,2.37-4.28,,,,,,,,,,,,,,,,,,,,,,,,,,,COSO28394862,2022Nov28,COSO28394862,breast,NS,NS,NS,carcinoma,NS,NS,NS
13480.0,ERBB2,ERBB2_unspecified,,,,breast / carcinoma / NS,2.0,Phase 2,Afatinib,,Completed,NCT01271725,LUX-Breast 2,PCD,2017Mar13,Overexpression,Yes,,8.0,https://www.clinicaltrialsregister.eu/ctr-search/trial/2010-021945-29/results,Previously-treated,,,74.0,74.0,,,18.0,,10-28,,5.54,,2.80-8.32,,2.83,,,2.37-4.28,,,,,,,,,,,,,,,,,,,,,,,,,,,COSO28394862,2022Nov28,COSO28394862,breast,NS,NS,NS,carcinoma,NS,NS,NS
13481.0,ERBB2,ERBB2_unspecified,,,,breast / carcinoma / NS,2.0,Phase 2,Afatinib,,Completed,NCT00826267,,PCD,2011Aug01,Expression confirmed,Yes,,4.0,NCT00826267,Untreated,,Overall Response Rate,10.0,10.0,,,80.0,,44.4-97.5,,,,,,,,,,,,,,,,100.0,,,,,,,,,,,,,,,,,,,,COSO28394862,2022Nov28,COSO28394862,breast,NS,NS,NS,carcinoma,NS,NS,NS
13482.0,ERBB2,ERBB2_unspecified,,,,breast / carcinoma / NS,2.0,Phase 2,Afatinib,,Completed,NCT00826267,,PCD,2011Aug01,Expression confirmed,Yes,,4.0,NCT00826267,Untreated,,Overall Response Rate,10.0,10.0,,,80.0,,44.4-97.5,,,,,,,,,,,,,,,,100.0,,,,,,,,,,,,,,,,,,,,COSO28394862,2022Nov28,COSO28394862,breast,NS,NS,NS,carcinoma,NS,NS,NS
13483.0,ERBB2,ERBB2_unspecified,,,,breast / carcinoma / NS,2.0,Phase 2,Afatinib,,Completed,NCT00826267,,PCD,2011Aug01,Expression confirmed,Yes,,4.0,NCT00826267,Untreated,,Overall Response Rate,10.0,10.0,,,80.0,,44.4-97.5,,,,,,,,,,,,,,,,100.0,,,,,,,,,,,,,,,,,,,,COSO28394862,2022Nov28,COSO28394862,breast,NS,NS,NS,carcinoma,NS,NS,NS
13484.0,ERBB2,ERBB2_unspecified,,,,breast / carcinoma / NS,2.0,Phase 2,Afatinib,,Completed,NCT00826267,,PCD,2011Aug01,Expression confirmed,Yes,,4.0,NCT00826267,Untreated,,Overall Response Rate,10.0,10.0,,,80.0,,44.4-97.5,,,,,,,,,,,,,,,,100.0,,,,,,,,,,,,,,,,,,,,COSO28394862,2022Nov28,COSO28394862,breast,NS,NS,NS,carcinoma,NS,NS,NS
13485.0,ERBB2,ERBB2_unspecified,,,,breast / carcinoma / NS,2.0,Phase 2,Afatinib,,Completed,NCT00826267,,PCD,2011Aug01,Expression confirmed,Yes,,4.0,NCT00826267,Untreated,,Overall Response Rate,10.0,10.0,,,80.0,,44.4-97.5,,,,,,,,,,,,,,,,100.0,,,,,,,,,,,,,,,,,,,,COSO28394862,2022Nov28,COSO28394862,breast,NS,NS,NS,carcinoma,NS,NS,NS
13486.0,ERBB2,ERBB2_unspecified,,,,breast / carcinoma / NS,2.0,Phase 2,Afatinib,,Completed,NCT00826267,,PCD,2011Aug01,Expression confirmed,Yes,,4.0,NCT00826267,Untreated,,Overall Response Rate,10.0,10.0,,,80.0,,44.4-97.5,,,,,,,,,,,,,,,,100.0,,,,,,,,,,,,,,,,,,,,COSO28394862,2022Nov28,COSO28394862,breast,NS,NS,NS,carcinoma,NS,NS,NS
13487.0,ERBB2,ERBB2_unspecified,,,,breast / carcinoma / NS,2.0,Phase 2,Afatinib,,Completed,NCT00826267,,PCD,2011Aug01,Expression confirmed,Yes,,4.0,NCT00826267,Untreated,,Overall Response Rate,10.0,10.0,,,80.0,,44.4-97.5,,,,,,,,,,,,,,,,100.0,,,,,,,,,,,,,,,,,,,,COSO28394862,2022Nov28,COSO28394862,breast,NS,NS,NS,carcinoma,NS,NS,NS
13488.0,ERBB2,ERBB2_unspecified,,,,breast / carcinoma / NS,2.0,Phase 2,Afatinib,,Completed,NCT00826267,,PCD,2011Aug01,Expression confirmed,Yes,,4.0,NCT00826267,Untreated,,Overall Response Rate,10.0,10.0,,,80.0,,44.4-97.5,,,,,,,,,,,,,,,,100.0,,,,,,,,,,,,,,,,,,,,COSO28394862,2022Nov28,COSO28394862,breast,NS,NS,NS,carcinoma,NS,NS,NS
13489.0,ERBB2,ERBB2_unspecified,,,,breast / carcinoma / NS,2.0,Phase 2,Afatinib,,Completed,NCT00826267,,PCD,2011Aug01,Expression confirmed,Yes,,4.0,NCT00826267,Untreated,,Overall Response Rate,10.0,10.0,,,80.0,,44.4-97.5,,,,,,,,,,,,,,,,100.0,,,,,,,,,,,,,,,,,,,,COSO28394862,2022Nov28,COSO28394862,breast,NS,NS,NS,carcinoma,NS,NS,NS
13490.0,ERBB2,ERBB2_unspecified,,,,breast / carcinoma / NS,2.0,Phase 2,Afatinib,,Completed,NCT00826267,,PCD,2011Aug01,Expression confirmed,Yes,,4.0,NCT00826267,Untreated,,Overall Response Rate,10.0,10.0,,,80.0,,44.4-97.5,,,,,,,,,,,,,,,,100.0,,,,,,,,,,,,,,,,,,,,COSO28394862,2022Nov28,COSO28394862,breast,NS,NS,NS,carcinoma,NS,NS,NS
13491.0,ERBB2,ERBB2_unspecified,,,,breast / carcinoma / NS,2.0,Phase 2,Afatinib,,Completed,NCT00826267,,PCD,2011Aug01,Expression confirmed,Yes,,4.0,NCT00826267,Untreated,,Overall Response Rate,10.0,10.0,,,80.0,,44.4-97.5,,,,,,,,,,,,,,,,100.0,,,,,,,,,,,,,,,,,,,,COSO28394862,2022Nov28,COSO28394862,breast,NS,NS,NS,carcinoma,NS,NS,NS
13492.0,ERBB2,ERBB2_unspecified,,,,breast / carcinoma / NS,2.0,Phase 2,Afatinib,,Completed,NCT00826267,,PCD,2011Aug01,Expression confirmed,Yes,,4.0,NCT00826267,Untreated,,Overall Response Rate,10.0,10.0,,,80.0,,44.4-97.5,,,,,,,,,,,,,,,,100.0,,,,,,,,,,,,,,,,,,,,COSO28394862,2022Nov28,COSO28394862,breast,NS,NS,NS,carcinoma,NS,NS,NS
13493.0,ERBB2,ERBB2_unspecified,,,,breast / carcinoma / NS,2.0,Phase 2,Afatinib,,Completed,NCT00826267,,PCD,2011Aug01,Expression confirmed,Yes,,4.0,NCT00826267,Untreated,,Overall Response Rate,10.0,10.0,,,80.0,,44.4-97.5,,,,,,,,,,,,,,,,100.0,,,,,,,,,,,,,,,,,,,,COSO28394862,2022Nov28,COSO28394862,breast,NS,NS,NS,carcinoma,NS,NS,NS
19903.0,EGFR,EGFR_unspecified,,,,breast / carcinoma / basal (triple-negative) carcinoma,3.0,Phase 2,Gefitinib,,Unknown,NCT01732276,,ECD,2015Apr01,Expression confirmed,No,,4.0,NCT01732276,,,"Disease control rate, Clinical benefit rate",50.0,50.0,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,COSO283911696,2022Nov28,COSO283911696,breast,NS,NS,NS,carcinoma,basal_(triple-negative)_carcinoma,NS,NS
19904.0,EGFR,EGFR_unspecified,,,,breast / carcinoma / basal (triple-negative) carcinoma,3.0,Phase 2,Gefitinib,,Unknown,NCT01732276,,ECD,2015Apr01,Expression confirmed,No,,4.0,NCT01732276,,,"Disease control rate, Clinical benefit rate",50.0,50.0,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,COSO283911696,2022Nov28,COSO283911696,breast,NS,NS,NS,carcinoma,basal_(triple-negative)_carcinoma,NS,NS
19905.0,EGFR,EGFR_unspecified,,,,breast / carcinoma / basal (triple-negative) carcinoma,3.0,Phase 2,Gefitinib,,Unknown,NCT01732276,,ECD,2015Apr01,Expression confirmed,No,,4.0,NCT01732276,,,"Disease control rate, Clinical benefit rate",50.0,50.0,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,COSO283911696,2022Nov28,COSO283911696,breast,NS,NS,NS,carcinoma,basal_(triple-negative)_carcinoma,NS,NS
19906.0,EGFR,EGFR_unspecified,,,,breast / carcinoma / basal (triple-negative) carcinoma,3.0,Phase 2,Gefitinib,,Unknown,NCT01732276,,ECD,2015Apr01,Expression confirmed,No,,4.0,NCT01732276,,,"Disease control rate, Clinical benefit rate",50.0,50.0,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,COSO283911696,2022Nov28,COSO283911696,breast,NS,NS,NS,carcinoma,basal_(triple-negative)_carcinoma,NS,NS
19907.0,EGFR,EGFR_unspecified,,,,breast / carcinoma / basal (triple-negative) carcinoma,3.0,Phase 2,Gefitinib,,Unknown,NCT01732276,,ECD,2015Apr01,Expression confirmed,No,,4.0,NCT01732276,,,"Disease control rate, Clinical benefit rate",50.0,50.0,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,COSO283911696,2022Nov28,COSO283911696,breast,NS,NS,NS,carcinoma,basal_(triple-negative)_carcinoma,NS,NS
19908.0,EGFR,EGFR_unspecified,,,,breast / carcinoma / basal (triple-negative) carcinoma,3.0,Phase 2,Gefitinib,,Unknown,NCT01732276,,ECD,2015Apr01,Expression confirmed,No,,4.0,NCT01732276,,,"Disease control rate, Clinical benefit rate",50.0,50.0,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,COSO283911696,2022Nov28,COSO283911696,breast,NS,NS,NS,carcinoma,basal_(triple-negative)_carcinoma,NS,NS
19909.0,EGFR,EGFR_unspecified,,,,breast / carcinoma / basal (triple-negative) carcinoma,3.0,Phase 2,Gefitinib,,Unknown,NCT01732276,,ECD,2015Apr01,Expression confirmed,No,,4.0,NCT01732276,,,"Disease control rate, Clinical benefit rate",50.0,50.0,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,COSO283911696,2022Nov28,COSO283911696,breast,NS,NS,NS,carcinoma,basal_(triple-negative)_carcinoma,NS,NS
19910.0,EGFR,EGFR_unspecified,,,,breast / carcinoma / basal (triple-negative) carcinoma,3.0,Phase 2,Gefitinib,,Unknown,NCT01732276,,ECD,2015Apr01,Expression confirmed,No,,4.0,NCT01732276,,,"Disease control rate, Clinical benefit rate",50.0,50.0,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,COSO283911696,2022Nov28,COSO283911696,breast,NS,NS,NS,carcinoma,basal_(triple-negative)_carcinoma,NS,NS
19911.0,EGFR,EGFR_unspecified,,,,breast / carcinoma / basal (triple-negative) carcinoma,3.0,Phase 2,Gefitinib,,Unknown,NCT01732276,,ECD,2015Apr01,Expression confirmed,No,,4.0,NCT01732276,,,"Disease control rate, Clinical benefit rate",50.0,50.0,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,COSO283911696,2022Nov28,COSO283911696,breast,NS,NS,NS,carcinoma,basal_(triple-negative)_carcinoma,NS,NS
19912.0,EGFR,EGFR_unspecified,,,,breast / carcinoma / basal (triple-negative) carcinoma,3.0,Phase 2,Gefitinib,,Unknown,NCT01732276,,ECD,2015Apr01,Expression confirmed,No,,4.0,NCT01732276,,,"Disease control rate, Clinical benefit rate",50.0,50.0,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,COSO283911696,2022Nov28,COSO283911696,breast,NS,NS,NS,carcinoma,basal_(triple-negative)_carcinoma,NS,NS
19913.0,EGFR,EGFR_unspecified,,,,breast / carcinoma / basal (triple-negative) carcinoma,3.0,Phase 2,Gefitinib,,Unknown,NCT01732276,,ECD,2015Apr01,Expression confirmed,No,,4.0,NCT01732276,,,"Disease control rate, Clinical benefit rate",50.0,50.0,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,COSO283911696,2022Nov28,COSO283911696,breast,NS,NS,NS,carcinoma,basal_(triple-negative)_carcinoma,NS,NS
19914.0,EGFR,EGFR_unspecified,,,,breast / carcinoma / basal (triple-negative) carcinoma,3.0,Phase 2,Gefitinib,,Unknown,NCT01732276,,ECD,2015Apr01,Expression confirmed,No,,4.0,NCT01732276,,,"Disease control rate, Clinical benefit rate",50.0,50.0,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,COSO283911696,2022Nov28,COSO283911696,breast,NS,NS,NS,carcinoma,basal_(triple-negative)_carcinoma,NS,NS
19915.0,EGFR,EGFR_unspecified,,,,breast / carcinoma / basal (triple-negative) carcinoma,3.0,Phase 2,Gefitinib,,Unknown,NCT01732276,,ECD,2015Apr01,Expression confirmed,No,,4.0,NCT01732276,,,"Disease control rate, Clinical benefit rate",50.0,50.0,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,COSO283911696,2022Nov28,COSO283911696,breast,NS,NS,NS,carcinoma,basal_(triple-negative)_carcinoma,NS,NS
2938.0,ERBB2,ERBB2_unspecified,,,,breast / carcinoma / NS,2.0,Phase 1,Lapatinib,,Completed,NCT00462956,,PCD,2006Dec20,Overexpression,No,,4.0,NCT00462956,,,Response rate,59.0,59.0,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,COSO28394862,2021Oct15,COSO28394862,breast,NS,NS,NS,carcinoma,NS,NS,NS
2939.0,ERBB2,ERBB2_unspecified,,,,breast / carcinoma / NS,2.0,Phase 1,Lapatinib,,Completed,NCT00462956,,PCD,2006Dec20,Overexpression,No,,4.0,NCT00462956,,,Response rate,59.0,59.0,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,COSO28394862,2021Oct15,COSO28394862,breast,NS,NS,NS,carcinoma,NS,NS,NS
2940.0,ERBB2,ERBB2_unspecified,,,,breast / carcinoma / NS,2.0,Phase 1,Lapatinib,,Completed,NCT00462956,,PCD,2006Dec20,Overexpression,No,,4.0,NCT00462956,,,Response rate,59.0,59.0,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,COSO28394862,2021Oct15,COSO28394862,breast,NS,NS,NS,carcinoma,NS,NS,NS
2941.0,ERBB2,ERBB2_unspecified,,,,breast / carcinoma / NS,2.0,Phase 1,Lapatinib,,Completed,NCT00462956,,PCD,2006Dec20,Overexpression,No,,4.0,NCT00462956,,,Response rate,59.0,59.0,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,COSO28394862,2021Oct15,COSO28394862,breast,NS,NS,NS,carcinoma,NS,NS,NS
2942.0,ERBB2,ERBB2_unspecified,,,,breast / carcinoma / NS,2.0,Phase 1,Lapatinib,,Completed,NCT00462956,,PCD,2006Dec20,Overexpression,No,,4.0,NCT00462956,,,Response rate,59.0,59.0,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,COSO28394862,2021Oct15,COSO28394862,breast,NS,NS,NS,carcinoma,NS,NS,NS
2943.0,ERBB2,ERBB2_unspecified,,,,breast / carcinoma / NS,2.0,Phase 1,Lapatinib,,Completed,NCT00462956,,PCD,2006Dec20,Overexpression,No,,4.0,NCT00462956,,,Response rate,59.0,59.0,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,COSO28394862,2021Oct15,COSO28394862,breast,NS,NS,NS,carcinoma,NS,NS,NS
2944.0,ERBB2,ERBB2_unspecified,,,,breast / carcinoma / NS,2.0,Phase 1,Lapatinib,,Completed,NCT00462956,,PCD,2006Dec20,Overexpression,No,,4.0,NCT00462956,,,Response rate,59.0,59.0,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,COSO28394862,2021Oct15,COSO28394862,breast,NS,NS,NS,carcinoma,NS,NS,NS
2945.0,ERBB2,ERBB2_unspecified,,,,breast / carcinoma / NS,2.0,Phase 1,Lapatinib,,Completed,NCT00462956,,PCD,2006Dec20,Overexpression,No,,4.0,NCT00462956,,,Response rate,59.0,59.0,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,COSO28394862,2021Oct15,COSO28394862,breast,NS,NS,NS,carcinoma,NS,NS,NS
2946.0,ERBB2,ERBB2_unspecified,,,,breast / carcinoma / NS,2.0,Phase 1,Lapatinib,,Completed,NCT00462956,,PCD,2006Dec20,Overexpression,No,,4.0,NCT00462956,,,Response rate,59.0,59.0,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,COSO28394862,2021Oct15,COSO28394862,breast,NS,NS,NS,carcinoma,NS,NS,NS
2947.0,ERBB2,ERBB2_unspecified,,,,breast / carcinoma / NS,2.0,Phase 1,Lapatinib,,Completed,NCT00462956,,PCD,2006Dec20,Overexpression,No,,4.0,NCT00462956,,,Response rate,59.0,59.0,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,COSO28394862,2021Oct15,COSO28394862,breast,NS,NS,NS,carcinoma,NS,NS,NS
2948.0,ERBB2,ERBB2_unspecified,,,,breast / carcinoma / NS,2.0,Phase 1,Lapatinib,,Completed,NCT00462956,,PCD,2006Dec20,Overexpression,No,,4.0,NCT00462956,,,Response rate,59.0,59.0,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,COSO28394862,2021Oct15,COSO28394862,breast,NS,NS,NS,carcinoma,NS,NS,NS
2949.0,ERBB2,ERBB2_unspecified,,,,breast / carcinoma / NS,2.0,Phase 1,Lapatinib,,Completed,NCT00462956,,PCD,2006Dec20,Overexpression,No,,4.0,NCT00462956,,,Response rate,59.0,59.0,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,COSO28394862,2021Oct15,COSO28394862,breast,NS,NS,NS,carcinoma,NS,NS,NS
2950.0,ERBB2,ERBB2_unspecified,,,,breast / carcinoma / NS,2.0,Phase 1,Lapatinib,,Completed,NCT00462956,,PCD,2006Dec20,Overexpression,No,,4.0,NCT00462956,,,Response rate,59.0,59.0,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,COSO28394862,2021Oct15,COSO28394862,breast,NS,NS,NS,carcinoma,NS,NS,NS
5122.0,ERBB2,ERBB2_unspecified,,,,breast / carcinoma / NS,2.0,Phase 1,Lapatinib,,Completed,NCT00544804,,PCD,2013Jun01,Overexpression,Yes,,1.0,24711549,Previously-treated,,Maximum tolerated dose/toxicity,30.0,30.0,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,2.0,4.0,,,,,,,,,,COSO28394862,2022Nov28,COSO28394862,breast,NS,NS,NS,carcinoma,NS,NS,NS
5123.0,ERBB2,ERBB2_unspecified,,,,breast / carcinoma / NS,2.0,Phase 1,Lapatinib,,Completed,NCT00544804,,PCD,2013Jun01,Overexpression,Yes,,1.0,24711549,Previously-treated,,Maximum tolerated dose/toxicity,30.0,30.0,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,2.0,4.0,,,,,,,,,,COSO28394862,2022Nov28,COSO28394862,breast,NS,NS,NS,carcinoma,NS,NS,NS
5124.0,ERBB2,ERBB2_unspecified,,,,breast / carcinoma / NS,2.0,Phase 1,Lapatinib,,Completed,NCT00544804,,PCD,2013Jun01,Overexpression,Yes,,1.0,24711549,Previously-treated,,Maximum tolerated dose/toxicity,30.0,30.0,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,2.0,4.0,,,,,,,,,,COSO28394862,2022Nov28,COSO28394862,breast,NS,NS,NS,carcinoma,NS,NS,NS
5125.0,ERBB2,ERBB2_unspecified,,,,breast / carcinoma / NS,2.0,Phase 1,Lapatinib,,Completed,NCT00544804,,PCD,2013Jun01,Overexpression,Yes,,1.0,24711549,Previously-treated,,Maximum tolerated dose/toxicity,30.0,30.0,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,2.0,4.0,,,,,,,,,,COSO28394862,2022Nov28,COSO28394862,breast,NS,NS,NS,carcinoma,NS,NS,NS
5126.0,ERBB2,ERBB2_unspecified,,,,breast / carcinoma / NS,2.0,Phase 1,Lapatinib,,Completed,NCT00544804,,PCD,2013Jun01,Overexpression,Yes,,1.0,24711549,Previously-treated,,Maximum tolerated dose/toxicity,30.0,30.0,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,2.0,4.0,,,,,,,,,,COSO28394862,2022Nov28,COSO28394862,breast,NS,NS,NS,carcinoma,NS,NS,NS
5127.0,ERBB2,ERBB2_unspecified,,,,breast / carcinoma / NS,2.0,Phase 1,Lapatinib,,Completed,NCT00544804,,PCD,2013Jun01,Overexpression,Yes,,1.0,24711549,Previously-treated,,Maximum tolerated dose/toxicity,30.0,30.0,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,2.0,4.0,,,,,,,,,,COSO28394862,2022Nov28,COSO28394862,breast,NS,NS,NS,carcinoma,NS,NS,NS
5128.0,ERBB2,ERBB2_unspecified,,,,breast / carcinoma / NS,2.0,Phase 1,Lapatinib,,Completed,NCT00544804,,PCD,2013Jun01,Overexpression,Yes,,1.0,24711549,Previously-treated,,Maximum tolerated dose/toxicity,30.0,30.0,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,2.0,4.0,,,,,,,,,,COSO28394862,2022Nov28,COSO28394862,breast,NS,NS,NS,carcinoma,NS,NS,NS
5129.0,ERBB2,ERBB2_unspecified,,,,breast / carcinoma / NS,2.0,Phase 1,Lapatinib,,Completed,NCT00544804,,PCD,2013Jun01,Overexpression,Yes,,1.0,24711549,Previously-treated,,Maximum tolerated dose/toxicity,30.0,30.0,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,2.0,4.0,,,,,,,,,,COSO28394862,2022Nov28,COSO28394862,breast,NS,NS,NS,carcinoma,NS,NS,NS
5130.0,ERBB2,ERBB2_unspecified,,,,breast / carcinoma / NS,2.0,Phase 1,Lapatinib,,Completed,NCT00544804,,PCD,2013Jun01,Overexpression,Yes,,1.0,24711549,Previously-treated,,Maximum tolerated dose/toxicity,30.0,30.0,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,2.0,4.0,,,,,,,,,,COSO28394862,2022Nov28,COSO28394862,breast,NS,NS,NS,carcinoma,NS,NS,NS
5131.0,ERBB2,ERBB2_unspecified,,,,breast / carcinoma / NS,2.0,Phase 1,Lapatinib,,Completed,NCT00544804,,PCD,2013Jun01,Overexpression,Yes,,1.0,24711549,Previously-treated,,Maximum tolerated dose/toxicity,30.0,30.0,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,2.0,4.0,,,,,,,,,,COSO28394862,2022Nov28,COSO28394862,breast,NS,NS,NS,carcinoma,NS,NS,NS
5132.0,ERBB2,ERBB2_unspecified,,,,breast / carcinoma / NS,2.0,Phase 1,Lapatinib,,Completed,NCT00544804,,PCD,2013Jun01,Overexpression,Yes,,1.0,24711549,Previously-treated,,Maximum tolerated dose/toxicity,30.0,30.0,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,2.0,4.0,,,,,,,,,,COSO28394862,2022Nov28,COSO28394862,breast,NS,NS,NS,carcinoma,NS,NS,NS
5133.0,ERBB2,ERBB2_unspecified,,,,breast / carcinoma / NS,2.0,Phase 1,Lapatinib,,Completed,NCT00544804,,PCD,2013Jun01,Overexpression,Yes,,1.0,24711549,Previously-treated,,Maximum tolerated dose/toxicity,30.0,30.0,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,2.0,4.0,,,,,,,,,,COSO28394862,2022Nov28,COSO28394862,breast,NS,NS,NS,carcinoma,NS,NS,NS
5134.0,ERBB2,ERBB2_unspecified,,,,breast / carcinoma / NS,2.0,Phase 1,Lapatinib,,Completed,NCT00544804,,PCD,2013Jun01,Overexpression,Yes,,1.0,24711549,Previously-treated,,Maximum tolerated dose/toxicity,30.0,30.0,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,2.0,4.0,,,,,,,,,,COSO28394862,2022Nov28,COSO28394862,breast,NS,NS,NS,carcinoma,NS,NS,NS
13299.0,ERBB2,ERBB2_unspecified,,,,breast / carcinoma / NS,2.0,Phase 2,Lapatinib,,Completed,NCT00051103,,PCD,2005Jun01,Overexpression,Yes,,1.0,19179558,Previously-treated,,,78.0,78.0,,,5.1,,,,,,,,,,,,,3.53,,,,,9.0,,,18.23,,,,,,,,,,,,,,,,,COSO28394862,2022Nov28,COSO28394862,breast,NS,NS,NS,carcinoma,NS,NS,NS
13300.0,ERBB2,ERBB2_unspecified,,,,breast / carcinoma / NS,2.0,Phase 2,Lapatinib,,Completed,NCT00051103,,PCD,2005Jun01,Overexpression,Yes,,1.0,19179558,Previously-treated,,,78.0,78.0,,,5.1,,,,,,,,,,,,,3.53,,,,,9.0,,,18.23,,,,,,,,,,,,,,,,,COSO28394862,2022Nov28,COSO28394862,breast,NS,NS,NS,carcinoma,NS,NS,NS
13301.0,ERBB2,ERBB2_unspecified,,,,breast / carcinoma / NS,2.0,Phase 2,Lapatinib,,Completed,NCT00051103,,PCD,2005Jun01,Overexpression,Yes,,1.0,19179558,Previously-treated,,,78.0,78.0,,,5.1,,,,,,,,,,,,,3.53,,,,,9.0,,,18.23,,,,,,,,,,,,,,,,,COSO28394862,2022Nov28,COSO28394862,breast,NS,NS,NS,carcinoma,NS,NS,NS
13302.0,ERBB2,ERBB2_unspecified,,,,breast / carcinoma / NS,2.0,Phase 2,Lapatinib,,Completed,NCT00051103,,PCD,2005Jun01,Overexpression,Yes,,1.0,19179558,Previously-treated,,,78.0,78.0,,,5.1,,,,,,,,,,,,,3.53,,,,,9.0,,,18.23,,,,,,,,,,,,,,,,,COSO28394862,2022Nov28,COSO28394862,breast,NS,NS,NS,carcinoma,NS,NS,NS
13303.0,ERBB2,ERBB2_unspecified,,,,breast / carcinoma / NS,2.0,Phase 2,Lapatinib,,Completed,NCT00051103,,PCD,2005Jun01,Overexpression,Yes,,1.0,19179558,Previously-treated,,,78.0,78.0,,,5.1,,,,,,,,,,,,,3.53,,,,,9.0,,,18.23,,,,,,,,,,,,,,,,,COSO28394862,2022Nov28,COSO28394862,breast,NS,NS,NS,carcinoma,NS,NS,NS
13304.0,ERBB2,ERBB2_unspecified,,,,breast / carcinoma / NS,2.0,Phase 2,Lapatinib,,Completed,NCT00051103,,PCD,2005Jun01,Overexpression,Yes,,1.0,19179558,Previously-treated,,,78.0,78.0,,,5.1,,,,,,,,,,,,,3.53,,,,,9.0,,,18.23,,,,,,,,,,,,,,,,,COSO28394862,2022Nov28,COSO28394862,breast,NS,NS,NS,carcinoma,NS,NS,NS
13305.0,ERBB2,ERBB2_unspecified,,,,breast / carcinoma / NS,2.0,Phase 2,Lapatinib,,Completed,NCT00051103,,PCD,2005Jun01,Overexpression,Yes,,1.0,19179558,Previously-treated,,,78.0,78.0,,,5.1,,,,,,,,,,,,,3.53,,,,,9.0,,,18.23,,,,,,,,,,,,,,,,,COSO28394862,2022Nov28,COSO28394862,breast,NS,NS,NS,carcinoma,NS,NS,NS
13306.0,ERBB2,ERBB2_unspecified,,,,breast / carcinoma / NS,2.0,Phase 2,Lapatinib,,Completed,NCT00051103,,PCD,2005Jun01,Overexpression,Yes,,1.0,19179558,Previously-treated,,,78.0,78.0,,,5.1,,,,,,,,,,,,,3.53,,,,,9.0,,,18.23,,,,,,,,,,,,,,,,,COSO28394862,2022Nov28,COSO28394862,breast,NS,NS,NS,carcinoma,NS,NS,NS
13307.0,ERBB2,ERBB2_unspecified,,,,breast / carcinoma / NS,2.0,Phase 2,Lapatinib,,Completed,NCT00051103,,PCD,2005Jun01,Overexpression,Yes,,1.0,19179558,Previously-treated,,,78.0,78.0,,,5.1,,,,,,,,,,,,,3.53,,,,,9.0,,,18.23,,,,,,,,,,,,,,,,,COSO28394862,2022Nov28,COSO28394862,breast,NS,NS,NS,carcinoma,NS,NS,NS
13308.0,ERBB2,ERBB2_unspecified,,,,breast / carcinoma / NS,2.0,Phase 2,Lapatinib,,Completed,NCT00051103,,PCD,2005Jun01,Overexpression,Yes,,1.0,19179558,Previously-treated,,,78.0,78.0,,,5.1,,,,,,,,,,,,,3.53,,,,,9.0,,,18.23,,,,,,,,,,,,,,,,,COSO28394862,2022Nov28,COSO28394862,breast,NS,NS,NS,carcinoma,NS,NS,NS
13309.0,ERBB2,ERBB2_unspecified,,,,breast / carcinoma / NS,2.0,Phase 2,Lapatinib,,Completed,NCT00051103,,PCD,2005Jun01,Overexpression,Yes,,1.0,19179558,Previously-treated,,,78.0,78.0,,,5.1,,,,,,,,,,,,,3.53,,,,,9.0,,,18.23,,,,,,,,,,,,,,,,,COSO28394862,2022Nov28,COSO28394862,breast,NS,NS,NS,carcinoma,NS,NS,NS
13310.0,ERBB2,ERBB2_unspecified,,,,breast / carcinoma / NS,2.0,Phase 2,Lapatinib,,Completed,NCT00051103,,PCD,2005Jun01,Overexpression,Yes,,1.0,19179558,Previously-treated,,,78.0,78.0,,,5.1,,,,,,,,,,,,,3.53,,,,,9.0,,,18.23,,,,,,,,,,,,,,,,,COSO28394862,2022Nov28,COSO28394862,breast,NS,NS,NS,carcinoma,NS,NS,NS
13311.0,ERBB2,ERBB2_unspecified,,,,breast / carcinoma / NS,2.0,Phase 2,Lapatinib,,Completed,NCT00051103,,PCD,2005Jun01,Overexpression,Yes,,1.0,19179558,Previously-treated,,,78.0,78.0,,,5.1,,,,,,,,,,,,,3.53,,,,,9.0,,,18.23,,,,,,,,,,,,,,,,,COSO28394862,2022Nov28,COSO28394862,breast,NS,NS,NS,carcinoma,NS,NS,NS
13312.0,ERBB2,ERBB2_unspecified,,,,breast / carcinoma / NS,2.0,Phase 2,Lapatinib,,Completed,NCT00089999,,PCD,2008Mar01,Expression confirmed,Yes,,4.0,NCT00089999,,,Overall Response Rate,69.0,69.0,,,,,,,6.7,,3.6-8.3,,5.6,,,4.6-8.3,,3.9,,,3.0-4.7,,33.3,,,,,,,,,0.0,18.0,,,,,,,,,,COSO28394862,2022Nov28,COSO28394862,breast,NS,NS,NS,carcinoma,NS,NS,NS
13313.0,ERBB2,ERBB2_unspecified,,,,breast / carcinoma / NS,2.0,Phase 2,Lapatinib,,Completed,NCT00089999,,PCD,2008Mar01,Expression confirmed,Yes,,4.0,NCT00089999,,,Overall Response Rate,69.0,69.0,,,,,,,6.7,,3.6-8.3,,5.6,,,4.6-8.3,,3.9,,,3.0-4.7,,33.3,,,,,,,,,0.0,18.0,,,,,,,,,,COSO28394862,2022Nov28,COSO28394862,breast,NS,NS,NS,carcinoma,NS,NS,NS
13314.0,ERBB2,ERBB2_unspecified,,,,breast / carcinoma / NS,2.0,Phase 2,Lapatinib,,Completed,NCT00089999,,PCD,2008Mar01,Expression confirmed,Yes,,4.0,NCT00089999,,,Overall Response Rate,69.0,69.0,,,,,,,6.7,,3.6-8.3,,5.6,,,4.6-8.3,,3.9,,,3.0-4.7,,33.3,,,,,,,,,0.0,18.0,,,,,,,,,,COSO28394862,2022Nov28,COSO28394862,breast,NS,NS,NS,carcinoma,NS,NS,NS
13315.0,ERBB2,ERBB2_unspecified,,,,breast / carcinoma / NS,2.0,Phase 2,Lapatinib,,Completed,NCT00089999,,PCD,2008Mar01,Expression confirmed,Yes,,4.0,NCT00089999,,,Overall Response Rate,69.0,69.0,,,,,,,6.7,,3.6-8.3,,5.6,,,4.6-8.3,,3.9,,,3.0-4.7,,33.3,,,,,,,,,0.0,18.0,,,,,,,,,,COSO28394862,2022Nov28,COSO28394862,breast,NS,NS,NS,carcinoma,NS,NS,NS
13316.0,ERBB2,ERBB2_unspecified,,,,breast / carcinoma / NS,2.0,Phase 2,Lapatinib,,Completed,NCT00089999,,PCD,2008Mar01,Expression confirmed,Yes,,4.0,NCT00089999,,,Overall Response Rate,69.0,69.0,,,,,,,6.7,,3.6-8.3,,5.6,,,4.6-8.3,,3.9,,,3.0-4.7,,33.3,,,,,,,,,0.0,18.0,,,,,,,,,,COSO28394862,2022Nov28,COSO28394862,breast,NS,NS,NS,carcinoma,NS,NS,NS
13317.0,ERBB2,ERBB2_unspecified,,,,breast / carcinoma / NS,2.0,Phase 2,Lapatinib,,Completed,NCT00089999,,PCD,2008Mar01,Expression confirmed,Yes,,4.0,NCT00089999,,,Overall Response Rate,69.0,69.0,,,,,,,6.7,,3.6-8.3,,5.6,,,4.6-8.3,,3.9,,,3.0-4.7,,33.3,,,,,,,,,0.0,18.0,,,,,,,,,,COSO28394862,2022Nov28,COSO28394862,breast,NS,NS,NS,carcinoma,NS,NS,NS
13318.0,ERBB2,ERBB2_unspecified,,,,breast / carcinoma / NS,2.0,Phase 2,Lapatinib,,Completed,NCT00089999,,PCD,2008Mar01,Expression confirmed,Yes,,4.0,NCT00089999,,,Overall Response Rate,69.0,69.0,,,,,,,6.7,,3.6-8.3,,5.6,,,4.6-8.3,,3.9,,,3.0-4.7,,33.3,,,,,,,,,0.0,18.0,,,,,,,,,,COSO28394862,2022Nov28,COSO28394862,breast,NS,NS,NS,carcinoma,NS,NS,NS
13319.0,ERBB2,ERBB2_unspecified,,,,breast / carcinoma / NS,2.0,Phase 2,Lapatinib,,Completed,NCT00089999,,PCD,2008Mar01,Expression confirmed,Yes,,4.0,NCT00089999,,,Overall Response Rate,69.0,69.0,,,,,,,6.7,,3.6-8.3,,5.6,,,4.6-8.3,,3.9,,,3.0-4.7,,33.3,,,,,,,,,0.0,18.0,,,,,,,,,,COSO28394862,2022Nov28,COSO28394862,breast,NS,NS,NS,carcinoma,NS,NS,NS
13320.0,ERBB2,ERBB2_unspecified,,,,breast / carcinoma / NS,2.0,Phase 2,Lapatinib,,Completed,NCT00089999,,PCD,2008Mar01,Expression confirmed,Yes,,4.0,NCT00089999,,,Overall Response Rate,69.0,69.0,,,,,,,6.7,,3.6-8.3,,5.6,,,4.6-8.3,,3.9,,,3.0-4.7,,33.3,,,,,,,,,0.0,18.0,,,,,,,,,,COSO28394862,2022Nov28,COSO28394862,breast,NS,NS,NS,carcinoma,NS,NS,NS
13321.0,ERBB2,ERBB2_unspecified,,,,breast / carcinoma / NS,2.0,Phase 2,Lapatinib,,Completed,NCT00089999,,PCD,2008Mar01,Expression confirmed,Yes,,4.0,NCT00089999,,,Overall Response Rate,69.0,69.0,,,,,,,6.7,,3.6-8.3,,5.6,,,4.6-8.3,,3.9,,,3.0-4.7,,33.3,,,,,,,,,0.0,18.0,,,,,,,,,,COSO28394862,2022Nov28,COSO28394862,breast,NS,NS,NS,carcinoma,NS,NS,NS
13322.0,ERBB2,ERBB2_unspecified,,,,breast / carcinoma / NS,2.0,Phase 2,Lapatinib,,Completed,NCT00089999,,PCD,2008Mar01,Expression confirmed,Yes,,4.0,NCT00089999,,,Overall Response Rate,69.0,69.0,,,,,,,6.7,,3.6-8.3,,5.6,,,4.6-8.3,,3.9,,,3.0-4.7,,33.3,,,,,,,,,0.0,18.0,,,,,,,,,,COSO28394862,2022Nov28,COSO28394862,breast,NS,NS,NS,carcinoma,NS,NS,NS
13323.0,ERBB2,ERBB2_unspecified,,,,breast / carcinoma / NS,2.0,Phase 2,Lapatinib,,Completed,NCT00089999,,PCD,2008Mar01,Expression confirmed,Yes,,4.0,NCT00089999,,,Overall Response Rate,69.0,69.0,,,,,,,6.7,,3.6-8.3,,5.6,,,4.6-8.3,,3.9,,,3.0-4.7,,33.3,,,,,,,,,0.0,18.0,,,,,,,,,,COSO28394862,2022Nov28,COSO28394862,breast,NS,NS,NS,carcinoma,NS,NS,NS
13324.0,ERBB2,ERBB2_unspecified,,,,breast / carcinoma / NS,2.0,Phase 2,Lapatinib,,Completed,NCT00089999,,PCD,2008Mar01,Expression confirmed,Yes,,4.0,NCT00089999,,,Overall Response Rate,69.0,69.0,,,,,,,6.7,,3.6-8.3,,5.6,,,4.6-8.3,,3.9,,,3.0-4.7,,33.3,,,,,,,,,0.0,18.0,,,,,,,,,,COSO28394862,2022Nov28,COSO28394862,breast,NS,NS,NS,carcinoma,NS,NS,NS
13325.0,ERBB2,ERBB2_unspecified,,,,breast / carcinoma / NS,2.0,Phase 2,Lapatinib,,Completed,NCT00826267,,PCD,2011Aug01,Expression confirmed,Yes,,4.0,NCT00826267,Untreated,,Overall Response Rate,8.0,8.0,,,75.0,,34.9-96.8,,,,,,,,,,,,,,,,100.0,,,,,,,,,,,,,,,,,,,,COSO28394862,2022Nov28,COSO28394862,breast,NS,NS,NS,carcinoma,NS,NS,NS
13326.0,ERBB2,ERBB2_unspecified,,,,breast / carcinoma / NS,2.0,Phase 2,Lapatinib,,Completed,NCT00826267,,PCD,2011Aug01,Expression confirmed,Yes,,4.0,NCT00826267,Untreated,,Overall Response Rate,8.0,8.0,,,75.0,,34.9-96.8,,,,,,,,,,,,,,,,100.0,,,,,,,,,,,,,,,,,,,,COSO28394862,2022Nov28,COSO28394862,breast,NS,NS,NS,carcinoma,NS,NS,NS
13327.0,ERBB2,ERBB2_unspecified,,,,breast / carcinoma / NS,2.0,Phase 2,Lapatinib,,Completed,NCT00826267,,PCD,2011Aug01,Expression confirmed,Yes,,4.0,NCT00826267,Untreated,,Overall Response Rate,8.0,8.0,,,75.0,,34.9-96.8,,,,,,,,,,,,,,,,100.0,,,,,,,,,,,,,,,,,,,,COSO28394862,2022Nov28,COSO28394862,breast,NS,NS,NS,carcinoma,NS,NS,NS
13328.0,ERBB2,ERBB2_unspecified,,,,breast / carcinoma / NS,2.0,Phase 2,Lapatinib,,Completed,NCT00826267,,PCD,2011Aug01,Expression confirmed,Yes,,4.0,NCT00826267,Untreated,,Overall Response Rate,8.0,8.0,,,75.0,,34.9-96.8,,,,,,,,,,,,,,,,100.0,,,,,,,,,,,,,,,,,,,,COSO28394862,2022Nov28,COSO28394862,breast,NS,NS,NS,carcinoma,NS,NS,NS
13329.0,ERBB2,ERBB2_unspecified,,,,breast / carcinoma / NS,2.0,Phase 2,Lapatinib,,Completed,NCT00826267,,PCD,2011Aug01,Expression confirmed,Yes,,4.0,NCT00826267,Untreated,,Overall Response Rate,8.0,8.0,,,75.0,,34.9-96.8,,,,,,,,,,,,,,,,100.0,,,,,,,,,,,,,,,,,,,,COSO28394862,2022Nov28,COSO28394862,breast,NS,NS,NS,carcinoma,NS,NS,NS
13330.0,ERBB2,ERBB2_unspecified,,,,breast / carcinoma / NS,2.0,Phase 2,Lapatinib,,Completed,NCT00826267,,PCD,2011Aug01,Expression confirmed,Yes,,4.0,NCT00826267,Untreated,,Overall Response Rate,8.0,8.0,,,75.0,,34.9-96.8,,,,,,,,,,,,,,,,100.0,,,,,,,,,,,,,,,,,,,,COSO28394862,2022Nov28,COSO28394862,breast,NS,NS,NS,carcinoma,NS,NS,NS
13331.0,ERBB2,ERBB2_unspecified,,,,breast / carcinoma / NS,2.0,Phase 2,Lapatinib,,Completed,NCT00826267,,PCD,2011Aug01,Expression confirmed,Yes,,4.0,NCT00826267,Untreated,,Overall Response Rate,8.0,8.0,,,75.0,,34.9-96.8,,,,,,,,,,,,,,,,100.0,,,,,,,,,,,,,,,,,,,,COSO28394862,2022Nov28,COSO28394862,breast,NS,NS,NS,carcinoma,NS,NS,NS
13332.0,ERBB2,ERBB2_unspecified,,,,breast / carcinoma / NS,2.0,Phase 2,Lapatinib,,Completed,NCT00826267,,PCD,2011Aug01,Expression confirmed,Yes,,4.0,NCT00826267,Untreated,,Overall Response Rate,8.0,8.0,,,75.0,,34.9-96.8,,,,,,,,,,,,,,,,100.0,,,,,,,,,,,,,,,,,,,,COSO28394862,2022Nov28,COSO28394862,breast,NS,NS,NS,carcinoma,NS,NS,NS
13333.0,ERBB2,ERBB2_unspecified,,,,breast / carcinoma / NS,2.0,Phase 2,Lapatinib,,Completed,NCT00826267,,PCD,2011Aug01,Expression confirmed,Yes,,4.0,NCT00826267,Untreated,,Overall Response Rate,8.0,8.0,,,75.0,,34.9-96.8,,,,,,,,,,,,,,,,100.0,,,,,,,,,,,,,,,,,,,,COSO28394862,2022Nov28,COSO28394862,breast,NS,NS,NS,carcinoma,NS,NS,NS
13334.0,ERBB2,ERBB2_unspecified,,,,breast / carcinoma / NS,2.0,Phase 2,Lapatinib,,Completed,NCT00826267,,PCD,2011Aug01,Expression confirmed,Yes,,4.0,NCT00826267,Untreated,,Overall Response Rate,8.0,8.0,,,75.0,,34.9-96.8,,,,,,,,,,,,,,,,100.0,,,,,,,,,,,,,,,,,,,,COSO28394862,2022Nov28,COSO28394862,breast,NS,NS,NS,carcinoma,NS,NS,NS
13335.0,ERBB2,ERBB2_unspecified,,,,breast / carcinoma / NS,2.0,Phase 2,Lapatinib,,Completed,NCT00826267,,PCD,2011Aug01,Expression confirmed,Yes,,4.0,NCT00826267,Untreated,,Overall Response Rate,8.0,8.0,,,75.0,,34.9-96.8,,,,,,,,,,,,,,,,100.0,,,,,,,,,,,,,,,,,,,,COSO28394862,2022Nov28,COSO28394862,breast,NS,NS,NS,carcinoma,NS,NS,NS
13336.0,ERBB2,ERBB2_unspecified,,,,breast / carcinoma / NS,2.0,Phase 2,Lapatinib,,Completed,NCT00826267,,PCD,2011Aug01,Expression confirmed,Yes,,4.0,NCT00826267,Untreated,,Overall Response Rate,8.0,8.0,,,75.0,,34.9-96.8,,,,,,,,,,,,,,,,100.0,,,,,,,,,,,,,,,,,,,,COSO28394862,2022Nov28,COSO28394862,breast,NS,NS,NS,carcinoma,NS,NS,NS
13337.0,ERBB2,ERBB2_unspecified,,,,breast / carcinoma / NS,2.0,Phase 2,Lapatinib,,Completed,NCT00826267,,PCD,2011Aug01,Expression confirmed,Yes,,4.0,NCT00826267,Untreated,,Overall Response Rate,8.0,8.0,,,75.0,,34.9-96.8,,,,,,,,,,,,,,,,100.0,,,,,,,,,,,,,,,,,,,,COSO28394862,2022Nov28,COSO28394862,breast,NS,NS,NS,carcinoma,NS,NS,NS
13338.0,ERBB2,ERBB2_unspecified,,,,breast / carcinoma / NS,2.0,Phase 2,Lapatinib,,Terminated,NCT00820924,,PCD,2011Jul01,Expression confirmed,Yes,,1.0,22476856,,,Clinical activity,7.0,7.0,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,1.0,,,,,,,,,COSO28394862,2022Nov28,COSO28394862,breast,NS,NS,NS,carcinoma,NS,NS,NS
13339.0,ERBB2,ERBB2_unspecified,,,,breast / carcinoma / NS,2.0,Phase 2,Lapatinib,,Terminated,NCT00820924,,PCD,2011Jul01,Expression confirmed,Yes,,1.0,22476856,,,Clinical activity,7.0,7.0,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,1.0,,,,,,,,,COSO28394862,2022Nov28,COSO28394862,breast,NS,NS,NS,carcinoma,NS,NS,NS
13340.0,ERBB2,ERBB2_unspecified,,,,breast / carcinoma / NS,2.0,Phase 2,Lapatinib,,Terminated,NCT00820924,,PCD,2011Jul01,Expression confirmed,Yes,,1.0,22476856,,,Clinical activity,7.0,7.0,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,1.0,,,,,,,,,COSO28394862,2022Nov28,COSO28394862,breast,NS,NS,NS,carcinoma,NS,NS,NS
13341.0,ERBB2,ERBB2_unspecified,,,,breast / carcinoma / NS,2.0,Phase 2,Lapatinib,,Terminated,NCT00820924,,PCD,2011Jul01,Expression confirmed,Yes,,1.0,22476856,,,Clinical activity,7.0,7.0,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,1.0,,,,,,,,,COSO28394862,2022Nov28,COSO28394862,breast,NS,NS,NS,carcinoma,NS,NS,NS
13342.0,ERBB2,ERBB2_unspecified,,,,breast / carcinoma / NS,2.0,Phase 2,Lapatinib,,Terminated,NCT00820924,,PCD,2011Jul01,Expression confirmed,Yes,,1.0,22476856,,,Clinical activity,7.0,7.0,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,1.0,,,,,,,,,COSO28394862,2022Nov28,COSO28394862,breast,NS,NS,NS,carcinoma,NS,NS,NS
13343.0,ERBB2,ERBB2_unspecified,,,,breast / carcinoma / NS,2.0,Phase 2,Lapatinib,,Terminated,NCT00820924,,PCD,2011Jul01,Expression confirmed,Yes,,1.0,22476856,,,Clinical activity,7.0,7.0,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,1.0,,,,,,,,,COSO28394862,2022Nov28,COSO28394862,breast,NS,NS,NS,carcinoma,NS,NS,NS
13344.0,ERBB2,ERBB2_unspecified,,,,breast / carcinoma / NS,2.0,Phase 2,Lapatinib,,Terminated,NCT00820924,,PCD,2011Jul01,Expression confirmed,Yes,,1.0,22476856,,,Clinical activity,7.0,7.0,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,1.0,,,,,,,,,COSO28394862,2022Nov28,COSO28394862,breast,NS,NS,NS,carcinoma,NS,NS,NS
13345.0,ERBB2,ERBB2_unspecified,,,,breast / carcinoma / NS,2.0,Phase 2,Lapatinib,,Terminated,NCT00820924,,PCD,2011Jul01,Expression confirmed,Yes,,1.0,22476856,,,Clinical activity,7.0,7.0,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,1.0,,,,,,,,,COSO28394862,2022Nov28,COSO28394862,breast,NS,NS,NS,carcinoma,NS,NS,NS
13346.0,ERBB2,ERBB2_unspecified,,,,breast / carcinoma / NS,2.0,Phase 2,Lapatinib,,Terminated,NCT00820924,,PCD,2011Jul01,Expression confirmed,Yes,,1.0,22476856,,,Clinical activity,7.0,7.0,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,1.0,,,,,,,,,COSO28394862,2022Nov28,COSO28394862,breast,NS,NS,NS,carcinoma,NS,NS,NS
13347.0,ERBB2,ERBB2_unspecified,,,,breast / carcinoma / NS,2.0,Phase 2,Lapatinib,,Terminated,NCT00820924,,PCD,2011Jul01,Expression confirmed,Yes,,1.0,22476856,,,Clinical activity,7.0,7.0,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,1.0,,,,,,,,,COSO28394862,2022Nov28,COSO28394862,breast,NS,NS,NS,carcinoma,NS,NS,NS
13348.0,ERBB2,ERBB2_unspecified,,,,breast / carcinoma / NS,2.0,Phase 2,Lapatinib,,Terminated,NCT00820924,,PCD,2011Jul01,Expression confirmed,Yes,,1.0,22476856,,,Clinical activity,7.0,7.0,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,1.0,,,,,,,,,COSO28394862,2022Nov28,COSO28394862,breast,NS,NS,NS,carcinoma,NS,NS,NS
13349.0,ERBB2,ERBB2_unspecified,,,,breast / carcinoma / NS,2.0,Phase 2,Lapatinib,,Terminated,NCT00820924,,PCD,2011Jul01,Expression confirmed,Yes,,1.0,22476856,,,Clinical activity,7.0,7.0,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,1.0,,,,,,,,,COSO28394862,2022Nov28,COSO28394862,breast,NS,NS,NS,carcinoma,NS,NS,NS
13350.0,ERBB2,ERBB2_unspecified,,,,breast / carcinoma / NS,2.0,Phase 2,Lapatinib,,Terminated,NCT00820924,,PCD,2011Jul01,Expression confirmed,Yes,,1.0,22476856,,,Clinical activity,7.0,7.0,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,1.0,,,,,,,,,COSO28394862,2022Nov28,COSO28394862,breast,NS,NS,NS,carcinoma,NS,NS,NS
13351.0,ERBB2,ERBB2_unspecified,,,,breast / carcinoma / NS,2.0,Phase 2,Lapatinib,,Completed,NCT00555152,,PCD,2014Aug28,Expression confirmed,No,,4.0,NCT00555152,,,Change in Ki-67 expression,22.0,22.0,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,COSO28394862,2021Oct14,COSO28394862,breast,NS,NS,NS,carcinoma,NS,NS,NS
13352.0,ERBB2,ERBB2_unspecified,,,,breast / carcinoma / NS,2.0,Phase 2,Lapatinib,,Completed,NCT00555152,,PCD,2014Aug28,Expression confirmed,No,,4.0,NCT00555152,,,Change in Ki-67 expression,22.0,22.0,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,COSO28394862,2021Oct14,COSO28394862,breast,NS,NS,NS,carcinoma,NS,NS,NS
13353.0,ERBB2,ERBB2_unspecified,,,,breast / carcinoma / NS,2.0,Phase 2,Lapatinib,,Completed,NCT00555152,,PCD,2014Aug28,Expression confirmed,No,,4.0,NCT00555152,,,Change in Ki-67 expression,22.0,22.0,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,COSO28394862,2021Oct14,COSO28394862,breast,NS,NS,NS,carcinoma,NS,NS,NS
13354.0,ERBB2,ERBB2_unspecified,,,,breast / carcinoma / NS,2.0,Phase 2,Lapatinib,,Completed,NCT00555152,,PCD,2014Aug28,Expression confirmed,No,,4.0,NCT00555152,,,Change in Ki-67 expression,22.0,22.0,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,COSO28394862,2021Oct14,COSO28394862,breast,NS,NS,NS,carcinoma,NS,NS,NS
13355.0,ERBB2,ERBB2_unspecified,,,,breast / carcinoma / NS,2.0,Phase 2,Lapatinib,,Completed,NCT00555152,,PCD,2014Aug28,Expression confirmed,No,,4.0,NCT00555152,,,Change in Ki-67 expression,22.0,22.0,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,COSO28394862,2021Oct14,COSO28394862,breast,NS,NS,NS,carcinoma,NS,NS,NS
13356.0,ERBB2,ERBB2_unspecified,,,,breast / carcinoma / NS,2.0,Phase 2,Lapatinib,,Completed,NCT00555152,,PCD,2014Aug28,Expression confirmed,No,,4.0,NCT00555152,,,Change in Ki-67 expression,22.0,22.0,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,COSO28394862,2021Oct14,COSO28394862,breast,NS,NS,NS,carcinoma,NS,NS,NS
13357.0,ERBB2,ERBB2_unspecified,,,,breast / carcinoma / NS,2.0,Phase 2,Lapatinib,,Completed,NCT00555152,,PCD,2014Aug28,Expression confirmed,No,,4.0,NCT00555152,,,Change in Ki-67 expression,22.0,22.0,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,COSO28394862,2021Oct14,COSO28394862,breast,NS,NS,NS,carcinoma,NS,NS,NS
13358.0,ERBB2,ERBB2_unspecified,,,,breast / carcinoma / NS,2.0,Phase 2,Lapatinib,,Completed,NCT00555152,,PCD,2014Aug28,Expression confirmed,No,,4.0,NCT00555152,,,Change in Ki-67 expression,22.0,22.0,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,COSO28394862,2021Oct14,COSO28394862,breast,NS,NS,NS,carcinoma,NS,NS,NS
13359.0,ERBB2,ERBB2_unspecified,,,,breast / carcinoma / NS,2.0,Phase 2,Lapatinib,,Completed,NCT00555152,,PCD,2014Aug28,Expression confirmed,No,,4.0,NCT00555152,,,Change in Ki-67 expression,22.0,22.0,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,COSO28394862,2021Oct14,COSO28394862,breast,NS,NS,NS,carcinoma,NS,NS,NS
13360.0,ERBB2,ERBB2_unspecified,,,,breast / carcinoma / NS,2.0,Phase 2,Lapatinib,,Completed,NCT00555152,,PCD,2014Aug28,Expression confirmed,No,,4.0,NCT00555152,,,Change in Ki-67 expression,22.0,22.0,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,COSO28394862,2021Oct14,COSO28394862,breast,NS,NS,NS,carcinoma,NS,NS,NS
13361.0,ERBB2,ERBB2_unspecified,,,,breast / carcinoma / NS,2.0,Phase 2,Lapatinib,,Completed,NCT00555152,,PCD,2014Aug28,Expression confirmed,No,,4.0,NCT00555152,,,Change in Ki-67 expression,22.0,22.0,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,COSO28394862,2021Oct14,COSO28394862,breast,NS,NS,NS,carcinoma,NS,NS,NS
13362.0,ERBB2,ERBB2_unspecified,,,,breast / carcinoma / NS,2.0,Phase 2,Lapatinib,,Completed,NCT00555152,,PCD,2014Aug28,Expression confirmed,No,,4.0,NCT00555152,,,Change in Ki-67 expression,22.0,22.0,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,COSO28394862,2021Oct14,COSO28394862,breast,NS,NS,NS,carcinoma,NS,NS,NS
13363.0,ERBB2,ERBB2_unspecified,,,,breast / carcinoma / NS,2.0,Phase 2,Lapatinib,,Completed,NCT00555152,,PCD,2014Aug28,Expression confirmed,No,,4.0,NCT00555152,,,Change in Ki-67 expression,22.0,22.0,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,COSO28394862,2021Oct14,COSO28394862,breast,NS,NS,NS,carcinoma,NS,NS,NS
13364.0,ERBB2,ERBB2_unspecified,,,,breast / carcinoma / NS,2.0,Phase 2,Lapatinib,,Completed,NCT00320411,,PCD,2009Apr01,Overexpression,Yes,,4.0,NCT00320411,,,Overall Response Rate,58.0,58.0,,,,,,,,,,,,,,,,1.94,,,1.71-5.51,,17.2,,,,,,,,,1.0,8.0,18.0,,,,,,,,,COSO28394862,2022Nov28,COSO28394862,breast,NS,NS,NS,carcinoma,NS,NS,NS
13365.0,ERBB2,ERBB2_unspecified,,,,breast / carcinoma / NS,2.0,Phase 2,Lapatinib,,Completed,NCT00320411,,PCD,2009Apr01,Overexpression,Yes,,4.0,NCT00320411,,,Overall Response Rate,58.0,58.0,,,,,,,,,,,,,,,,1.94,,,1.71-5.51,,17.2,,,,,,,,,1.0,8.0,18.0,,,,,,,,,COSO28394862,2022Nov28,COSO28394862,breast,NS,NS,NS,carcinoma,NS,NS,NS
13366.0,ERBB2,ERBB2_unspecified,,,,breast / carcinoma / NS,2.0,Phase 2,Lapatinib,,Completed,NCT00320411,,PCD,2009Apr01,Overexpression,Yes,,4.0,NCT00320411,,,Overall Response Rate,58.0,58.0,,,,,,,,,,,,,,,,1.94,,,1.71-5.51,,17.2,,,,,,,,,1.0,8.0,18.0,,,,,,,,,COSO28394862,2022Nov28,COSO28394862,breast,NS,NS,NS,carcinoma,NS,NS,NS
13367.0,ERBB2,ERBB2_unspecified,,,,breast / carcinoma / NS,2.0,Phase 2,Lapatinib,,Completed,NCT00320411,,PCD,2009Apr01,Overexpression,Yes,,4.0,NCT00320411,,,Overall Response Rate,58.0,58.0,,,,,,,,,,,,,,,,1.94,,,1.71-5.51,,17.2,,,,,,,,,1.0,8.0,18.0,,,,,,,,,COSO28394862,2022Nov28,COSO28394862,breast,NS,NS,NS,carcinoma,NS,NS,NS
13368.0,ERBB2,ERBB2_unspecified,,,,breast / carcinoma / NS,2.0,Phase 2,Lapatinib,,Completed,NCT00320411,,PCD,2009Apr01,Overexpression,Yes,,4.0,NCT00320411,,,Overall Response Rate,58.0,58.0,,,,,,,,,,,,,,,,1.94,,,1.71-5.51,,17.2,,,,,,,,,1.0,8.0,18.0,,,,,,,,,COSO28394862,2022Nov28,COSO28394862,breast,NS,NS,NS,carcinoma,NS,NS,NS
13369.0,ERBB2,ERBB2_unspecified,,,,breast / carcinoma / NS,2.0,Phase 2,Lapatinib,,Completed,NCT00320411,,PCD,2009Apr01,Overexpression,Yes,,4.0,NCT00320411,,,Overall Response Rate,58.0,58.0,,,,,,,,,,,,,,,,1.94,,,1.71-5.51,,17.2,,,,,,,,,1.0,8.0,18.0,,,,,,,,,COSO28394862,2022Nov28,COSO28394862,breast,NS,NS,NS,carcinoma,NS,NS,NS
13370.0,ERBB2,ERBB2_unspecified,,,,breast / carcinoma / NS,2.0,Phase 2,Lapatinib,,Completed,NCT00320411,,PCD,2009Apr01,Overexpression,Yes,,4.0,NCT00320411,,,Overall Response Rate,58.0,58.0,,,,,,,,,,,,,,,,1.94,,,1.71-5.51,,17.2,,,,,,,,,1.0,8.0,18.0,,,,,,,,,COSO28394862,2022Nov28,COSO28394862,breast,NS,NS,NS,carcinoma,NS,NS,NS
13371.0,ERBB2,ERBB2_unspecified,,,,breast / carcinoma / NS,2.0,Phase 2,Lapatinib,,Completed,NCT00320411,,PCD,2009Apr01,Overexpression,Yes,,4.0,NCT00320411,,,Overall Response Rate,58.0,58.0,,,,,,,,,,,,,,,,1.94,,,1.71-5.51,,17.2,,,,,,,,,1.0,8.0,18.0,,,,,,,,,COSO28394862,2022Nov28,COSO28394862,breast,NS,NS,NS,carcinoma,NS,NS,NS
13372.0,ERBB2,ERBB2_unspecified,,,,breast / carcinoma / NS,2.0,Phase 2,Lapatinib,,Completed,NCT00320411,,PCD,2009Apr01,Overexpression,Yes,,4.0,NCT00320411,,,Overall Response Rate,58.0,58.0,,,,,,,,,,,,,,,,1.94,,,1.71-5.51,,17.2,,,,,,,,,1.0,8.0,18.0,,,,,,,,,COSO28394862,2022Nov28,COSO28394862,breast,NS,NS,NS,carcinoma,NS,NS,NS
13373.0,ERBB2,ERBB2_unspecified,,,,breast / carcinoma / NS,2.0,Phase 2,Lapatinib,,Completed,NCT00320411,,PCD,2009Apr01,Overexpression,Yes,,4.0,NCT00320411,,,Overall Response Rate,58.0,58.0,,,,,,,,,,,,,,,,1.94,,,1.71-5.51,,17.2,,,,,,,,,1.0,8.0,18.0,,,,,,,,,COSO28394862,2022Nov28,COSO28394862,breast,NS,NS,NS,carcinoma,NS,NS,NS
13374.0,ERBB2,ERBB2_unspecified,,,,breast / carcinoma / NS,2.0,Phase 2,Lapatinib,,Completed,NCT00320411,,PCD,2009Apr01,Overexpression,Yes,,4.0,NCT00320411,,,Overall Response Rate,58.0,58.0,,,,,,,,,,,,,,,,1.94,,,1.71-5.51,,17.2,,,,,,,,,1.0,8.0,18.0,,,,,,,,,COSO28394862,2022Nov28,COSO28394862,breast,NS,NS,NS,carcinoma,NS,NS,NS
13375.0,ERBB2,ERBB2_unspecified,,,,breast / carcinoma / NS,2.0,Phase 2,Lapatinib,,Completed,NCT00320411,,PCD,2009Apr01,Overexpression,Yes,,4.0,NCT00320411,,,Overall Response Rate,58.0,58.0,,,,,,,,,,,,,,,,1.94,,,1.71-5.51,,17.2,,,,,,,,,1.0,8.0,18.0,,,,,,,,,COSO28394862,2022Nov28,COSO28394862,breast,NS,NS,NS,carcinoma,NS,NS,NS
13376.0,ERBB2,ERBB2_unspecified,,,,breast / carcinoma / NS,2.0,Phase 2,Lapatinib,,Completed,NCT00320411,,PCD,2009Apr01,Overexpression,Yes,,4.0,NCT00320411,,,Overall Response Rate,58.0,58.0,,,,,,,,,,,,,,,,1.94,,,1.71-5.51,,17.2,,,,,,,,,1.0,8.0,18.0,,,,,,,,,COSO28394862,2022Nov28,COSO28394862,breast,NS,NS,NS,carcinoma,NS,NS,NS
13377.0,ERBB2,ERBB2_unspecified,,,,breast / carcinoma / NS,2.0,Phase 2,Lapatinib,,Completed,NCT00105950,EGF103009,PCD,2007Sep01,Overexpression,Yes,,1.0,19394894,,,Overall Response Rate,126.0,126.0,,,39.0,,,,4.8,,2.9-7.4,,3.37,,,2.8-3.7,,,,,,,,,,,,,,,,0.0,49.0,,,,,,,,,,COSO28394862,2021Oct05,COSO28394862,breast,NS,NS,NS,carcinoma,NS,NS,NS
13378.0,ERBB2,ERBB2_unspecified,,,,breast / carcinoma / NS,2.0,Phase 2,Lapatinib,,Completed,NCT00105950,EGF103009,PCD,2007Sep01,Overexpression,Yes,,1.0,19394894,,,Overall Response Rate,126.0,126.0,,,39.0,,,,4.8,,2.9-7.4,,3.37,,,2.8-3.7,,,,,,,,,,,,,,,,0.0,49.0,,,,,,,,,,COSO28394862,2021Oct05,COSO28394862,breast,NS,NS,NS,carcinoma,NS,NS,NS
13379.0,ERBB2,ERBB2_unspecified,,,,breast / carcinoma / NS,2.0,Phase 2,Lapatinib,,Completed,NCT00105950,EGF103009,PCD,2007Sep01,Overexpression,Yes,,1.0,19394894,,,Overall Response Rate,126.0,126.0,,,39.0,,,,4.8,,2.9-7.4,,3.37,,,2.8-3.7,,,,,,,,,,,,,,,,0.0,49.0,,,,,,,,,,COSO28394862,2021Oct05,COSO28394862,breast,NS,NS,NS,carcinoma,NS,NS,NS
13380.0,ERBB2,ERBB2_unspecified,,,,breast / carcinoma / NS,2.0,Phase 2,Lapatinib,,Completed,NCT00105950,EGF103009,PCD,2007Sep01,Overexpression,Yes,,1.0,19394894,,,Overall Response Rate,126.0,126.0,,,39.0,,,,4.8,,2.9-7.4,,3.37,,,2.8-3.7,,,,,,,,,,,,,,,,0.0,49.0,,,,,,,,,,COSO28394862,2021Oct05,COSO28394862,breast,NS,NS,NS,carcinoma,NS,NS,NS
13381.0,ERBB2,ERBB2_unspecified,,,,breast / carcinoma / NS,2.0,Phase 2,Lapatinib,,Completed,NCT00105950,EGF103009,PCD,2007Sep01,Overexpression,Yes,,1.0,19394894,,,Overall Response Rate,126.0,126.0,,,39.0,,,,4.8,,2.9-7.4,,3.37,,,2.8-3.7,,,,,,,,,,,,,,,,0.0,49.0,,,,,,,,,,COSO28394862,2021Oct05,COSO28394862,breast,NS,NS,NS,carcinoma,NS,NS,NS
13382.0,ERBB2,ERBB2_unspecified,,,,breast / carcinoma / NS,2.0,Phase 2,Lapatinib,,Completed,NCT00105950,EGF103009,PCD,2007Sep01,Overexpression,Yes,,1.0,19394894,,,Overall Response Rate,126.0,126.0,,,39.0,,,,4.8,,2.9-7.4,,3.37,,,2.8-3.7,,,,,,,,,,,,,,,,0.0,49.0,,,,,,,,,,COSO28394862,2021Oct05,COSO28394862,breast,NS,NS,NS,carcinoma,NS,NS,NS
13383.0,ERBB2,ERBB2_unspecified,,,,breast / carcinoma / NS,2.0,Phase 2,Lapatinib,,Completed,NCT00105950,EGF103009,PCD,2007Sep01,Overexpression,Yes,,1.0,19394894,,,Overall Response Rate,126.0,126.0,,,39.0,,,,4.8,,2.9-7.4,,3.37,,,2.8-3.7,,,,,,,,,,,,,,,,0.0,49.0,,,,,,,,,,COSO28394862,2021Oct05,COSO28394862,breast,NS,NS,NS,carcinoma,NS,NS,NS
13384.0,ERBB2,ERBB2_unspecified,,,,breast / carcinoma / NS,2.0,Phase 2,Lapatinib,,Completed,NCT00105950,EGF103009,PCD,2007Sep01,Overexpression,Yes,,1.0,19394894,,,Overall Response Rate,126.0,126.0,,,39.0,,,,4.8,,2.9-7.4,,3.37,,,2.8-3.7,,,,,,,,,,,,,,,,0.0,49.0,,,,,,,,,,COSO28394862,2021Oct05,COSO28394862,breast,NS,NS,NS,carcinoma,NS,NS,NS
13385.0,ERBB2,ERBB2_unspecified,,,,breast / carcinoma / NS,2.0,Phase 2,Lapatinib,,Completed,NCT00105950,EGF103009,PCD,2007Sep01,Overexpression,Yes,,1.0,19394894,,,Overall Response Rate,126.0,126.0,,,39.0,,,,4.8,,2.9-7.4,,3.37,,,2.8-3.7,,,,,,,,,,,,,,,,0.0,49.0,,,,,,,,,,COSO28394862,2021Oct05,COSO28394862,breast,NS,NS,NS,carcinoma,NS,NS,NS
13386.0,ERBB2,ERBB2_unspecified,,,,breast / carcinoma / NS,2.0,Phase 2,Lapatinib,,Completed,NCT00105950,EGF103009,PCD,2007Sep01,Overexpression,Yes,,1.0,19394894,,,Overall Response Rate,126.0,126.0,,,39.0,,,,4.8,,2.9-7.4,,3.37,,,2.8-3.7,,,,,,,,,,,,,,,,0.0,49.0,,,,,,,,,,COSO28394862,2021Oct05,COSO28394862,breast,NS,NS,NS,carcinoma,NS,NS,NS
13387.0,ERBB2,ERBB2_unspecified,,,,breast / carcinoma / NS,2.0,Phase 2,Lapatinib,,Completed,NCT00105950,EGF103009,PCD,2007Sep01,Overexpression,Yes,,1.0,19394894,,,Overall Response Rate,126.0,126.0,,,39.0,,,,4.8,,2.9-7.4,,3.37,,,2.8-3.7,,,,,,,,,,,,,,,,0.0,49.0,,,,,,,,,,COSO28394862,2021Oct05,COSO28394862,breast,NS,NS,NS,carcinoma,NS,NS,NS
13388.0,ERBB2,ERBB2_unspecified,,,,breast / carcinoma / NS,2.0,Phase 2,Lapatinib,,Completed,NCT00105950,EGF103009,PCD,2007Sep01,Overexpression,Yes,,1.0,19394894,,,Overall Response Rate,126.0,126.0,,,39.0,,,,4.8,,2.9-7.4,,3.37,,,2.8-3.7,,,,,,,,,,,,,,,,0.0,49.0,,,,,,,,,,COSO28394862,2021Oct05,COSO28394862,breast,NS,NS,NS,carcinoma,NS,NS,NS
13389.0,ERBB2,ERBB2_unspecified,,,,breast / carcinoma / NS,2.0,Phase 2,Lapatinib,,Completed,NCT00105950,EGF103009,PCD,2007Sep01,Overexpression,Yes,,1.0,19394894,,,Overall Response Rate,126.0,126.0,,,39.0,,,,4.8,,2.9-7.4,,3.37,,,2.8-3.7,,,,,,,,,,,,,,,,0.0,49.0,,,,,,,,,,COSO28394862,2021Oct05,COSO28394862,breast,NS,NS,NS,carcinoma,NS,NS,NS
13390.0,ERBB2,ERBB2_unspecified,,,,breast / carcinoma / NS,2.0,Phase 2,Lapatinib,,Completed,NCT00263588,,PCD,2007Sep25,Overexpression,Yes,,4.0,NCT00263588,,,Overall Response Rate,143.0,143.0,,,6.0,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,COSO28394862,2022Nov28,COSO28394862,breast,NS,NS,NS,carcinoma,NS,NS,NS
13391.0,ERBB2,ERBB2_unspecified,,,,breast / carcinoma / NS,2.0,Phase 2,Lapatinib,,Completed,NCT00263588,,PCD,2007Sep25,Overexpression,Yes,,4.0,NCT00263588,,,Overall Response Rate,143.0,143.0,,,6.0,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,COSO28394862,2022Nov28,COSO28394862,breast,NS,NS,NS,carcinoma,NS,NS,NS
13392.0,ERBB2,ERBB2_unspecified,,,,breast / carcinoma / NS,2.0,Phase 2,Lapatinib,,Completed,NCT00263588,,PCD,2007Sep25,Overexpression,Yes,,4.0,NCT00263588,,,Overall Response Rate,143.0,143.0,,,6.0,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,COSO28394862,2022Nov28,COSO28394862,breast,NS,NS,NS,carcinoma,NS,NS,NS
13393.0,ERBB2,ERBB2_unspecified,,,,breast / carcinoma / NS,2.0,Phase 2,Lapatinib,,Completed,NCT00263588,,PCD,2007Sep25,Overexpression,Yes,,4.0,NCT00263588,,,Overall Response Rate,143.0,143.0,,,6.0,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,COSO28394862,2022Nov28,COSO28394862,breast,NS,NS,NS,carcinoma,NS,NS,NS
13394.0,ERBB2,ERBB2_unspecified,,,,breast / carcinoma / NS,2.0,Phase 2,Lapatinib,,Completed,NCT00263588,,PCD,2007Sep25,Overexpression,Yes,,4.0,NCT00263588,,,Overall Response Rate,143.0,143.0,,,6.0,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,COSO28394862,2022Nov28,COSO28394862,breast,NS,NS,NS,carcinoma,NS,NS,NS
13395.0,ERBB2,ERBB2_unspecified,,,,breast / carcinoma / NS,2.0,Phase 2,Lapatinib,,Completed,NCT00263588,,PCD,2007Sep25,Overexpression,Yes,,4.0,NCT00263588,,,Overall Response Rate,143.0,143.0,,,6.0,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,COSO28394862,2022Nov28,COSO28394862,breast,NS,NS,NS,carcinoma,NS,NS,NS
13396.0,ERBB2,ERBB2_unspecified,,,,breast / carcinoma / NS,2.0,Phase 2,Lapatinib,,Completed,NCT00263588,,PCD,2007Sep25,Overexpression,Yes,,4.0,NCT00263588,,,Overall Response Rate,143.0,143.0,,,6.0,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,COSO28394862,2022Nov28,COSO28394862,breast,NS,NS,NS,carcinoma,NS,NS,NS
13397.0,ERBB2,ERBB2_unspecified,,,,breast / carcinoma / NS,2.0,Phase 2,Lapatinib,,Completed,NCT00263588,,PCD,2007Sep25,Overexpression,Yes,,4.0,NCT00263588,,,Overall Response Rate,143.0,143.0,,,6.0,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,COSO28394862,2022Nov28,COSO28394862,breast,NS,NS,NS,carcinoma,NS,NS,NS
13398.0,ERBB2,ERBB2_unspecified,,,,breast / carcinoma / NS,2.0,Phase 2,Lapatinib,,Completed,NCT00263588,,PCD,2007Sep25,Overexpression,Yes,,4.0,NCT00263588,,,Overall Response Rate,143.0,143.0,,,6.0,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,COSO28394862,2022Nov28,COSO28394862,breast,NS,NS,NS,carcinoma,NS,NS,NS
13399.0,ERBB2,ERBB2_unspecified,,,,breast / carcinoma / NS,2.0,Phase 2,Lapatinib,,Completed,NCT00263588,,PCD,2007Sep25,Overexpression,Yes,,4.0,NCT00263588,,,Overall Response Rate,143.0,143.0,,,6.0,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,COSO28394862,2022Nov28,COSO28394862,breast,NS,NS,NS,carcinoma,NS,NS,NS
13400.0,ERBB2,ERBB2_unspecified,,,,breast / carcinoma / NS,2.0,Phase 2,Lapatinib,,Completed,NCT00263588,,PCD,2007Sep25,Overexpression,Yes,,4.0,NCT00263588,,,Overall Response Rate,143.0,143.0,,,6.0,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,COSO28394862,2022Nov28,COSO28394862,breast,NS,NS,NS,carcinoma,NS,NS,NS
13401.0,ERBB2,ERBB2_unspecified,,,,breast / carcinoma / NS,2.0,Phase 2,Lapatinib,,Completed,NCT00263588,,PCD,2007Sep25,Overexpression,Yes,,4.0,NCT00263588,,,Overall Response Rate,143.0,143.0,,,6.0,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,COSO28394862,2022Nov28,COSO28394862,breast,NS,NS,NS,carcinoma,NS,NS,NS
13402.0,ERBB2,ERBB2_unspecified,,,,breast / carcinoma / NS,2.0,Phase 2,Lapatinib,,Completed,NCT00263588,,PCD,2007Sep25,Overexpression,Yes,,4.0,NCT00263588,,,Overall Response Rate,143.0,143.0,,,6.0,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,COSO28394862,2022Nov28,COSO28394862,breast,NS,NS,NS,carcinoma,NS,NS,NS
13403.0,ERBB2,ERBB2_unspecified,,,,breast / carcinoma / NS,2.0,Phase 2,Lapatinib,,Completed,NCT00206427,,PCD,2011Jun01,Overexpression,Yes,,4.0,NCT00206427,,,Clinical activity,47.0,47.0,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,3.0,30.0,11.0,,,,,,,,,COSO28394862,2022Nov28,COSO28394862,breast,NS,NS,NS,carcinoma,NS,NS,NS
13404.0,ERBB2,ERBB2_unspecified,,,,breast / carcinoma / NS,2.0,Phase 2,Lapatinib,,Completed,NCT00206427,,PCD,2011Jun01,Overexpression,Yes,,4.0,NCT00206427,,,Clinical activity,47.0,47.0,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,3.0,30.0,11.0,,,,,,,,,COSO28394862,2022Nov28,COSO28394862,breast,NS,NS,NS,carcinoma,NS,NS,NS
13405.0,ERBB2,ERBB2_unspecified,,,,breast / carcinoma / NS,2.0,Phase 2,Lapatinib,,Completed,NCT00206427,,PCD,2011Jun01,Overexpression,Yes,,4.0,NCT00206427,,,Clinical activity,47.0,47.0,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,3.0,30.0,11.0,,,,,,,,,COSO28394862,2022Nov28,COSO28394862,breast,NS,NS,NS,carcinoma,NS,NS,NS
13406.0,ERBB2,ERBB2_unspecified,,,,breast / carcinoma / NS,2.0,Phase 2,Lapatinib,,Completed,NCT00206427,,PCD,2011Jun01,Overexpression,Yes,,4.0,NCT00206427,,,Clinical activity,47.0,47.0,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,3.0,30.0,11.0,,,,,,,,,COSO28394862,2022Nov28,COSO28394862,breast,NS,NS,NS,carcinoma,NS,NS,NS
13407.0,ERBB2,ERBB2_unspecified,,,,breast / carcinoma / NS,2.0,Phase 2,Lapatinib,,Completed,NCT00206427,,PCD,2011Jun01,Overexpression,Yes,,4.0,NCT00206427,,,Clinical activity,47.0,47.0,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,3.0,30.0,11.0,,,,,,,,,COSO28394862,2022Nov28,COSO28394862,breast,NS,NS,NS,carcinoma,NS,NS,NS
13408.0,ERBB2,ERBB2_unspecified,,,,breast / carcinoma / NS,2.0,Phase 2,Lapatinib,,Completed,NCT00206427,,PCD,2011Jun01,Overexpression,Yes,,4.0,NCT00206427,,,Clinical activity,47.0,47.0,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,3.0,30.0,11.0,,,,,,,,,COSO28394862,2022Nov28,COSO28394862,breast,NS,NS,NS,carcinoma,NS,NS,NS
13409.0,ERBB2,ERBB2_unspecified,,,,breast / carcinoma / NS,2.0,Phase 2,Lapatinib,,Completed,NCT00206427,,PCD,2011Jun01,Overexpression,Yes,,4.0,NCT00206427,,,Clinical activity,47.0,47.0,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,3.0,30.0,11.0,,,,,,,,,COSO28394862,2022Nov28,COSO28394862,breast,NS,NS,NS,carcinoma,NS,NS,NS
13410.0,ERBB2,ERBB2_unspecified,,,,breast / carcinoma / NS,2.0,Phase 2,Lapatinib,,Completed,NCT00206427,,PCD,2011Jun01,Overexpression,Yes,,4.0,NCT00206427,,,Clinical activity,47.0,47.0,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,3.0,30.0,11.0,,,,,,,,,COSO28394862,2022Nov28,COSO28394862,breast,NS,NS,NS,carcinoma,NS,NS,NS
13411.0,ERBB2,ERBB2_unspecified,,,,breast / carcinoma / NS,2.0,Phase 2,Lapatinib,,Completed,NCT00206427,,PCD,2011Jun01,Overexpression,Yes,,4.0,NCT00206427,,,Clinical activity,47.0,47.0,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,3.0,30.0,11.0,,,,,,,,,COSO28394862,2022Nov28,COSO28394862,breast,NS,NS,NS,carcinoma,NS,NS,NS
13412.0,ERBB2,ERBB2_unspecified,,,,breast / carcinoma / NS,2.0,Phase 2,Lapatinib,,Completed,NCT00206427,,PCD,2011Jun01,Overexpression,Yes,,4.0,NCT00206427,,,Clinical activity,47.0,47.0,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,3.0,30.0,11.0,,,,,,,,,COSO28394862,2022Nov28,COSO28394862,breast,NS,NS,NS,carcinoma,NS,NS,NS
13413.0,ERBB2,ERBB2_unspecified,,,,breast / carcinoma / NS,2.0,Phase 2,Lapatinib,,Completed,NCT00206427,,PCD,2011Jun01,Overexpression,Yes,,4.0,NCT00206427,,,Clinical activity,47.0,47.0,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,3.0,30.0,11.0,,,,,,,,,COSO28394862,2022Nov28,COSO28394862,breast,NS,NS,NS,carcinoma,NS,NS,NS
13414.0,ERBB2,ERBB2_unspecified,,,,breast / carcinoma / NS,2.0,Phase 2,Lapatinib,,Completed,NCT00206427,,PCD,2011Jun01,Overexpression,Yes,,4.0,NCT00206427,,,Clinical activity,47.0,47.0,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,3.0,30.0,11.0,,,,,,,,,COSO28394862,2022Nov28,COSO28394862,breast,NS,NS,NS,carcinoma,NS,NS,NS
13415.0,ERBB2,ERBB2_unspecified,,,,breast / carcinoma / NS,2.0,Phase 2,Lapatinib,,Completed,NCT00206427,,PCD,2011Jun01,Overexpression,Yes,,4.0,NCT00206427,,,Clinical activity,47.0,47.0,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,3.0,30.0,11.0,,,,,,,,,COSO28394862,2022Nov28,COSO28394862,breast,NS,NS,NS,carcinoma,NS,NS,NS
13416.0,ERBB2,ERBB2_unspecified,,,,breast / carcinoma / NS,2.0,Phase 2,Lapatinib,,Completed,NCT00098605,,PCD,2006Sep01,Overexpression,No,,4.0,NCT00098605,,,Overall Response Rate,37.0,37.0,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,COSO28394862,2021Sep29,COSO28394862,breast,NS,NS,NS,carcinoma,NS,NS,NS
13417.0,ERBB2,ERBB2_unspecified,,,,breast / carcinoma / NS,2.0,Phase 2,Lapatinib,,Completed,NCT00098605,,PCD,2006Sep01,Overexpression,No,,4.0,NCT00098605,,,Overall Response Rate,37.0,37.0,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,COSO28394862,2021Sep29,COSO28394862,breast,NS,NS,NS,carcinoma,NS,NS,NS
13418.0,ERBB2,ERBB2_unspecified,,,,breast / carcinoma / NS,2.0,Phase 2,Lapatinib,,Completed,NCT00098605,,PCD,2006Sep01,Overexpression,No,,4.0,NCT00098605,,,Overall Response Rate,37.0,37.0,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,COSO28394862,2021Sep29,COSO28394862,breast,NS,NS,NS,carcinoma,NS,NS,NS
13419.0,ERBB2,ERBB2_unspecified,,,,breast / carcinoma / NS,2.0,Phase 2,Lapatinib,,Completed,NCT00098605,,PCD,2006Sep01,Overexpression,No,,4.0,NCT00098605,,,Overall Response Rate,37.0,37.0,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,COSO28394862,2021Sep29,COSO28394862,breast,NS,NS,NS,carcinoma,NS,NS,NS
13420.0,ERBB2,ERBB2_unspecified,,,,breast / carcinoma / NS,2.0,Phase 2,Lapatinib,,Completed,NCT00098605,,PCD,2006Sep01,Overexpression,No,,4.0,NCT00098605,,,Overall Response Rate,37.0,37.0,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,COSO28394862,2021Sep29,COSO28394862,breast,NS,NS,NS,carcinoma,NS,NS,NS
13421.0,ERBB2,ERBB2_unspecified,,,,breast / carcinoma / NS,2.0,Phase 2,Lapatinib,,Completed,NCT00098605,,PCD,2006Sep01,Overexpression,No,,4.0,NCT00098605,,,Overall Response Rate,37.0,37.0,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,COSO28394862,2021Sep29,COSO28394862,breast,NS,NS,NS,carcinoma,NS,NS,NS
13422.0,ERBB2,ERBB2_unspecified,,,,breast / carcinoma / NS,2.0,Phase 2,Lapatinib,,Completed,NCT00098605,,PCD,2006Sep01,Overexpression,No,,4.0,NCT00098605,,,Overall Response Rate,37.0,37.0,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,COSO28394862,2021Sep29,COSO28394862,breast,NS,NS,NS,carcinoma,NS,NS,NS
13423.0,ERBB2,ERBB2_unspecified,,,,breast / carcinoma / NS,2.0,Phase 2,Lapatinib,,Completed,NCT00098605,,PCD,2006Sep01,Overexpression,No,,4.0,NCT00098605,,,Overall Response Rate,37.0,37.0,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,COSO28394862,2021Sep29,COSO28394862,breast,NS,NS,NS,carcinoma,NS,NS,NS
13424.0,ERBB2,ERBB2_unspecified,,,,breast / carcinoma / NS,2.0,Phase 2,Lapatinib,,Completed,NCT00098605,,PCD,2006Sep01,Overexpression,No,,4.0,NCT00098605,,,Overall Response Rate,37.0,37.0,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,COSO28394862,2021Sep29,COSO28394862,breast,NS,NS,NS,carcinoma,NS,NS,NS
13425.0,ERBB2,ERBB2_unspecified,,,,breast / carcinoma / NS,2.0,Phase 2,Lapatinib,,Completed,NCT00098605,,PCD,2006Sep01,Overexpression,No,,4.0,NCT00098605,,,Overall Response Rate,37.0,37.0,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,COSO28394862,2021Sep29,COSO28394862,breast,NS,NS,NS,carcinoma,NS,NS,NS
13426.0,ERBB2,ERBB2_unspecified,,,,breast / carcinoma / NS,2.0,Phase 2,Lapatinib,,Completed,NCT00098605,,PCD,2006Sep01,Overexpression,No,,4.0,NCT00098605,,,Overall Response Rate,37.0,37.0,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,COSO28394862,2021Sep29,COSO28394862,breast,NS,NS,NS,carcinoma,NS,NS,NS
13427.0,ERBB2,ERBB2_unspecified,,,,breast / carcinoma / NS,2.0,Phase 2,Lapatinib,,Completed,NCT00098605,,PCD,2006Sep01,Overexpression,No,,4.0,NCT00098605,,,Overall Response Rate,37.0,37.0,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,COSO28394862,2021Sep29,COSO28394862,breast,NS,NS,NS,carcinoma,NS,NS,NS
13428.0,ERBB2,ERBB2_unspecified,,,,breast / carcinoma / NS,2.0,Phase 2,Lapatinib,,Completed,NCT00098605,,PCD,2006Sep01,Overexpression,No,,4.0,NCT00098605,,,Overall Response Rate,37.0,37.0,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,COSO28394862,2021Sep29,COSO28394862,breast,NS,NS,NS,carcinoma,NS,NS,NS
13429.0,ERBB2,ERBB2_unspecified,,,,breast / carcinoma / NS,2.0,Phase 2,Lapatinib,,Completed,NCT00062686,,PCD,2005Feb01,Overexpression,No,,4.0,NCT00062686,,,Response rate,200.0,200.0,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,COSO28394862,2021Sep28,COSO28394862,breast,NS,NS,NS,carcinoma,NS,NS,NS
13430.0,ERBB2,ERBB2_unspecified,,,,breast / carcinoma / NS,2.0,Phase 2,Lapatinib,,Completed,NCT00062686,,PCD,2005Feb01,Overexpression,No,,4.0,NCT00062686,,,Response rate,200.0,200.0,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,COSO28394862,2021Sep28,COSO28394862,breast,NS,NS,NS,carcinoma,NS,NS,NS
13431.0,ERBB2,ERBB2_unspecified,,,,breast / carcinoma / NS,2.0,Phase 2,Lapatinib,,Completed,NCT00062686,,PCD,2005Feb01,Overexpression,No,,4.0,NCT00062686,,,Response rate,200.0,200.0,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,COSO28394862,2021Sep28,COSO28394862,breast,NS,NS,NS,carcinoma,NS,NS,NS
13432.0,ERBB2,ERBB2_unspecified,,,,breast / carcinoma / NS,2.0,Phase 2,Lapatinib,,Completed,NCT00062686,,PCD,2005Feb01,Overexpression,No,,4.0,NCT00062686,,,Response rate,200.0,200.0,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,COSO28394862,2021Sep28,COSO28394862,breast,NS,NS,NS,carcinoma,NS,NS,NS
13433.0,ERBB2,ERBB2_unspecified,,,,breast / carcinoma / NS,2.0,Phase 2,Lapatinib,,Completed,NCT00062686,,PCD,2005Feb01,Overexpression,No,,4.0,NCT00062686,,,Response rate,200.0,200.0,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,COSO28394862,2021Sep28,COSO28394862,breast,NS,NS,NS,carcinoma,NS,NS,NS
13434.0,ERBB2,ERBB2_unspecified,,,,breast / carcinoma / NS,2.0,Phase 2,Lapatinib,,Completed,NCT00062686,,PCD,2005Feb01,Overexpression,No,,4.0,NCT00062686,,,Response rate,200.0,200.0,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,COSO28394862,2021Sep28,COSO28394862,breast,NS,NS,NS,carcinoma,NS,NS,NS
13435.0,ERBB2,ERBB2_unspecified,,,,breast / carcinoma / NS,2.0,Phase 2,Lapatinib,,Completed,NCT00062686,,PCD,2005Feb01,Overexpression,No,,4.0,NCT00062686,,,Response rate,200.0,200.0,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,COSO28394862,2021Sep28,COSO28394862,breast,NS,NS,NS,carcinoma,NS,NS,NS
13436.0,ERBB2,ERBB2_unspecified,,,,breast / carcinoma / NS,2.0,Phase 2,Lapatinib,,Completed,NCT00062686,,PCD,2005Feb01,Overexpression,No,,4.0,NCT00062686,,,Response rate,200.0,200.0,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,COSO28394862,2021Sep28,COSO28394862,breast,NS,NS,NS,carcinoma,NS,NS,NS
13437.0,ERBB2,ERBB2_unspecified,,,,breast / carcinoma / NS,2.0,Phase 2,Lapatinib,,Completed,NCT00062686,,PCD,2005Feb01,Overexpression,No,,4.0,NCT00062686,,,Response rate,200.0,200.0,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,COSO28394862,2021Sep28,COSO28394862,breast,NS,NS,NS,carcinoma,NS,NS,NS
13438.0,ERBB2,ERBB2_unspecified,,,,breast / carcinoma / NS,2.0,Phase 2,Lapatinib,,Completed,NCT00062686,,PCD,2005Feb01,Overexpression,No,,4.0,NCT00062686,,,Response rate,200.0,200.0,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,COSO28394862,2021Sep28,COSO28394862,breast,NS,NS,NS,carcinoma,NS,NS,NS
13439.0,ERBB2,ERBB2_unspecified,,,,breast / carcinoma / NS,2.0,Phase 2,Lapatinib,,Completed,NCT00062686,,PCD,2005Feb01,Overexpression,No,,4.0,NCT00062686,,,Response rate,200.0,200.0,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,COSO28394862,2021Sep28,COSO28394862,breast,NS,NS,NS,carcinoma,NS,NS,NS
13440.0,ERBB2,ERBB2_unspecified,,,,breast / carcinoma / NS,2.0,Phase 2,Lapatinib,,Completed,NCT00062686,,PCD,2005Feb01,Overexpression,No,,4.0,NCT00062686,,,Response rate,200.0,200.0,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,COSO28394862,2021Sep28,COSO28394862,breast,NS,NS,NS,carcinoma,NS,NS,NS
13441.0,ERBB2,ERBB2_unspecified,,,,breast / carcinoma / NS,2.0,Phase 2,Lapatinib,,Completed,NCT00062686,,PCD,2005Feb01,Overexpression,No,,4.0,NCT00062686,,,Response rate,200.0,200.0,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,COSO28394862,2021Sep28,COSO28394862,breast,NS,NS,NS,carcinoma,NS,NS,NS
13494.0,ERBB2,ERBB2_unspecified,,,,breast / carcinoma / NS,2.0,Phase 3,Lapatinib,,Completed,NCT00553358,Neo ALTTO,PCD,2010May27,Overexpression,Yes,"pCR 24.7 v 29.5, p=0.34",4.0,NCT00553358,Untreated,,"Complete response, Pathological complete response",303.0,154.0,149.0,Trastuzumab,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,COSO28394862,2022Nov28,COSO28394862,breast,NS,NS,NS,carcinoma,NS,NS,NS
13495.0,ERBB2,ERBB2_unspecified,,,,breast / carcinoma / NS,2.0,Phase 3,Lapatinib,,Completed,NCT00553358,Neo ALTTO,PCD,2010May27,Overexpression,Yes,"pCR 24.7 v 29.5, p=0.34",4.0,NCT00553358,Untreated,,"Complete response, Pathological complete response",303.0,154.0,149.0,Trastuzumab,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,COSO28394862,2022Nov28,COSO28394862,breast,NS,NS,NS,carcinoma,NS,NS,NS
13496.0,ERBB2,ERBB2_unspecified,,,,breast / carcinoma / NS,2.0,Phase 3,Lapatinib,,Completed,NCT00553358,Neo ALTTO,PCD,2010May27,Overexpression,Yes,"pCR 24.7 v 29.5, p=0.34",4.0,NCT00553358,Untreated,,"Complete response, Pathological complete response",303.0,154.0,149.0,Trastuzumab,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,COSO28394862,2022Nov28,COSO28394862,breast,NS,NS,NS,carcinoma,NS,NS,NS
13497.0,ERBB2,ERBB2_unspecified,,,,breast / carcinoma / NS,2.0,Phase 3,Lapatinib,,Completed,NCT00553358,Neo ALTTO,PCD,2010May27,Overexpression,Yes,"pCR 24.7 v 29.5, p=0.34",4.0,NCT00553358,Untreated,,"Complete response, Pathological complete response",303.0,154.0,149.0,Trastuzumab,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,COSO28394862,2022Nov28,COSO28394862,breast,NS,NS,NS,carcinoma,NS,NS,NS
13498.0,ERBB2,ERBB2_unspecified,,,,breast / carcinoma / NS,2.0,Phase 3,Lapatinib,,Completed,NCT00553358,Neo ALTTO,PCD,2010May27,Overexpression,Yes,"pCR 24.7 v 29.5, p=0.34",4.0,NCT00553358,Untreated,,"Complete response, Pathological complete response",303.0,154.0,149.0,Trastuzumab,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,COSO28394862,2022Nov28,COSO28394862,breast,NS,NS,NS,carcinoma,NS,NS,NS
13499.0,ERBB2,ERBB2_unspecified,,,,breast / carcinoma / NS,2.0,Phase 3,Lapatinib,,Completed,NCT00553358,Neo ALTTO,PCD,2010May27,Overexpression,Yes,"pCR 24.7 v 29.5, p=0.34",4.0,NCT00553358,Untreated,,"Complete response, Pathological complete response",303.0,154.0,149.0,Trastuzumab,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,COSO28394862,2022Nov28,COSO28394862,breast,NS,NS,NS,carcinoma,NS,NS,NS
13500.0,ERBB2,ERBB2_unspecified,,,,breast / carcinoma / NS,2.0,Phase 3,Lapatinib,,Completed,NCT00553358,Neo ALTTO,PCD,2010May27,Overexpression,Yes,"pCR 24.7 v 29.5, p=0.34",4.0,NCT00553358,Untreated,,"Complete response, Pathological complete response",303.0,154.0,149.0,Trastuzumab,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,COSO28394862,2022Nov28,COSO28394862,breast,NS,NS,NS,carcinoma,NS,NS,NS
13501.0,ERBB2,ERBB2_unspecified,,,,breast / carcinoma / NS,2.0,Phase 3,Lapatinib,,Completed,NCT00553358,Neo ALTTO,PCD,2010May27,Overexpression,Yes,"pCR 24.7 v 29.5, p=0.34",4.0,NCT00553358,Untreated,,"Complete response, Pathological complete response",303.0,154.0,149.0,Trastuzumab,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,COSO28394862,2022Nov28,COSO28394862,breast,NS,NS,NS,carcinoma,NS,NS,NS
13502.0,ERBB2,ERBB2_unspecified,,,,breast / carcinoma / NS,2.0,Phase 3,Lapatinib,,Completed,NCT00553358,Neo ALTTO,PCD,2010May27,Overexpression,Yes,"pCR 24.7 v 29.5, p=0.34",4.0,NCT00553358,Untreated,,"Complete response, Pathological complete response",303.0,154.0,149.0,Trastuzumab,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,COSO28394862,2022Nov28,COSO28394862,breast,NS,NS,NS,carcinoma,NS,NS,NS
13503.0,ERBB2,ERBB2_unspecified,,,,breast / carcinoma / NS,2.0,Phase 3,Lapatinib,,Completed,NCT00553358,Neo ALTTO,PCD,2010May27,Overexpression,Yes,"pCR 24.7 v 29.5, p=0.34",4.0,NCT00553358,Untreated,,"Complete response, Pathological complete response",303.0,154.0,149.0,Trastuzumab,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,COSO28394862,2022Nov28,COSO28394862,breast,NS,NS,NS,carcinoma,NS,NS,NS
13504.0,ERBB2,ERBB2_unspecified,,,,breast / carcinoma / NS,2.0,Phase 3,Lapatinib,,Completed,NCT00553358,Neo ALTTO,PCD,2010May27,Overexpression,Yes,"pCR 24.7 v 29.5, p=0.34",4.0,NCT00553358,Untreated,,"Complete response, Pathological complete response",303.0,154.0,149.0,Trastuzumab,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,COSO28394862,2022Nov28,COSO28394862,breast,NS,NS,NS,carcinoma,NS,NS,NS
13505.0,ERBB2,ERBB2_unspecified,,,,breast / carcinoma / NS,2.0,Phase 3,Lapatinib,,Completed,NCT00553358,Neo ALTTO,PCD,2010May27,Overexpression,Yes,"pCR 24.7 v 29.5, p=0.34",4.0,NCT00553358,Untreated,,"Complete response, Pathological complete response",303.0,154.0,149.0,Trastuzumab,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,COSO28394862,2022Nov28,COSO28394862,breast,NS,NS,NS,carcinoma,NS,NS,NS
13506.0,ERBB2,ERBB2_unspecified,,,,breast / carcinoma / NS,2.0,Phase 3,Lapatinib,,Completed,NCT00553358,Neo ALTTO,PCD,2010May27,Overexpression,Yes,"pCR 24.7 v 29.5, p=0.34",4.0,NCT00553358,Untreated,,"Complete response, Pathological complete response",303.0,154.0,149.0,Trastuzumab,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,COSO28394862,2022Nov28,COSO28394862,breast,NS,NS,NS,carcinoma,NS,NS,NS
15678.0,ERBB2,ERBB2_unspecified,,,,breast / carcinoma / NS,2.0,Phase 3,Lapatinib,,Completed,NCT00374322,TEACH,PCD,2011Sep01,Overexpression,Yes,DFS 84 vs 81.5% p=0.286,4.0,NCT00374322,,,"Disease free survival, relapse free survival, regression free survival, recurrence free survival",3147.0,1571.0,1576.0,Placebo,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,COSO28394862,2022Nov28,COSO28394862,breast,NS,NS,NS,carcinoma,NS,NS,NS
15679.0,ERBB2,ERBB2_unspecified,,,,breast / carcinoma / NS,2.0,Phase 3,Lapatinib,,Completed,NCT00374322,TEACH,PCD,2011Sep01,Overexpression,Yes,DFS 84 vs 81.5% p=0.286,4.0,NCT00374322,,,"Disease free survival, relapse free survival, regression free survival, recurrence free survival",3147.0,1571.0,1576.0,Placebo,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,COSO28394862,2022Nov28,COSO28394862,breast,NS,NS,NS,carcinoma,NS,NS,NS
15680.0,ERBB2,ERBB2_unspecified,,,,breast / carcinoma / NS,2.0,Phase 3,Lapatinib,,Completed,NCT00374322,TEACH,PCD,2011Sep01,Overexpression,Yes,DFS 84 vs 81.5% p=0.286,4.0,NCT00374322,,,"Disease free survival, relapse free survival, regression free survival, recurrence free survival",3147.0,1571.0,1576.0,Placebo,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,COSO28394862,2022Nov28,COSO28394862,breast,NS,NS,NS,carcinoma,NS,NS,NS
15681.0,ERBB2,ERBB2_unspecified,,,,breast / carcinoma / NS,2.0,Phase 3,Lapatinib,,Completed,NCT00374322,TEACH,PCD,2011Sep01,Overexpression,Yes,DFS 84 vs 81.5% p=0.286,4.0,NCT00374322,,,"Disease free survival, relapse free survival, regression free survival, recurrence free survival",3147.0,1571.0,1576.0,Placebo,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,COSO28394862,2022Nov28,COSO28394862,breast,NS,NS,NS,carcinoma,NS,NS,NS
15682.0,ERBB2,ERBB2_unspecified,,,,breast / carcinoma / NS,2.0,Phase 3,Lapatinib,,Completed,NCT00374322,TEACH,PCD,2011Sep01,Overexpression,Yes,DFS 84 vs 81.5% p=0.286,4.0,NCT00374322,,,"Disease free survival, relapse free survival, regression free survival, recurrence free survival",3147.0,1571.0,1576.0,Placebo,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,COSO28394862,2022Nov28,COSO28394862,breast,NS,NS,NS,carcinoma,NS,NS,NS
15683.0,ERBB2,ERBB2_unspecified,,,,breast / carcinoma / NS,2.0,Phase 3,Lapatinib,,Completed,NCT00374322,TEACH,PCD,2011Sep01,Overexpression,Yes,DFS 84 vs 81.5% p=0.286,4.0,NCT00374322,,,"Disease free survival, relapse free survival, regression free survival, recurrence free survival",3147.0,1571.0,1576.0,Placebo,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,COSO28394862,2022Nov28,COSO28394862,breast,NS,NS,NS,carcinoma,NS,NS,NS
15684.0,ERBB2,ERBB2_unspecified,,,,breast / carcinoma / NS,2.0,Phase 3,Lapatinib,,Completed,NCT00374322,TEACH,PCD,2011Sep01,Overexpression,Yes,DFS 84 vs 81.5% p=0.286,4.0,NCT00374322,,,"Disease free survival, relapse free survival, regression free survival, recurrence free survival",3147.0,1571.0,1576.0,Placebo,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,COSO28394862,2022Nov28,COSO28394862,breast,NS,NS,NS,carcinoma,NS,NS,NS
15685.0,ERBB2,ERBB2_unspecified,,,,breast / carcinoma / NS,2.0,Phase 3,Lapatinib,,Completed,NCT00374322,TEACH,PCD,2011Sep01,Overexpression,Yes,DFS 84 vs 81.5% p=0.286,4.0,NCT00374322,,,"Disease free survival, relapse free survival, regression free survival, recurrence free survival",3147.0,1571.0,1576.0,Placebo,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,COSO28394862,2022Nov28,COSO28394862,breast,NS,NS,NS,carcinoma,NS,NS,NS
15686.0,ERBB2,ERBB2_unspecified,,,,breast / carcinoma / NS,2.0,Phase 3,Lapatinib,,Completed,NCT00374322,TEACH,PCD,2011Sep01,Overexpression,Yes,DFS 84 vs 81.5% p=0.286,4.0,NCT00374322,,,"Disease free survival, relapse free survival, regression free survival, recurrence free survival",3147.0,1571.0,1576.0,Placebo,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,COSO28394862,2022Nov28,COSO28394862,breast,NS,NS,NS,carcinoma,NS,NS,NS
15687.0,ERBB2,ERBB2_unspecified,,,,breast / carcinoma / NS,2.0,Phase 3,Lapatinib,,Completed,NCT00374322,TEACH,PCD,2011Sep01,Overexpression,Yes,DFS 84 vs 81.5% p=0.286,4.0,NCT00374322,,,"Disease free survival, relapse free survival, regression free survival, recurrence free survival",3147.0,1571.0,1576.0,Placebo,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,COSO28394862,2022Nov28,COSO28394862,breast,NS,NS,NS,carcinoma,NS,NS,NS
15688.0,ERBB2,ERBB2_unspecified,,,,breast / carcinoma / NS,2.0,Phase 3,Lapatinib,,Completed,NCT00374322,TEACH,PCD,2011Sep01,Overexpression,Yes,DFS 84 vs 81.5% p=0.286,4.0,NCT00374322,,,"Disease free survival, relapse free survival, regression free survival, recurrence free survival",3147.0,1571.0,1576.0,Placebo,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,COSO28394862,2022Nov28,COSO28394862,breast,NS,NS,NS,carcinoma,NS,NS,NS
15689.0,ERBB2,ERBB2_unspecified,,,,breast / carcinoma / NS,2.0,Phase 3,Lapatinib,,Completed,NCT00374322,TEACH,PCD,2011Sep01,Overexpression,Yes,DFS 84 vs 81.5% p=0.286,4.0,NCT00374322,,,"Disease free survival, relapse free survival, regression free survival, recurrence free survival",3147.0,1571.0,1576.0,Placebo,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,COSO28394862,2022Nov28,COSO28394862,breast,NS,NS,NS,carcinoma,NS,NS,NS
15690.0,ERBB2,ERBB2_unspecified,,,,breast / carcinoma / NS,2.0,Phase 3,Lapatinib,,Completed,NCT00374322,TEACH,PCD,2011Sep01,Overexpression,Yes,DFS 84 vs 81.5% p=0.286,4.0,NCT00374322,,,"Disease free survival, relapse free survival, regression free survival, recurrence free survival",3147.0,1571.0,1576.0,Placebo,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,COSO28394862,2022Nov28,COSO28394862,breast,NS,NS,NS,carcinoma,NS,NS,NS
18590.0,RET,RET_unspecified,,,,breast / carcinoma / NS,3.0,Phase 2,Lenvatinib,,Unknown,NCT03168074,,ECD,2021Mar28,No,No,,4.0,NCT03168074,,,Clinical activity,30.0,30.0,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,COSO28394862,2022May03,COSO28394862,breast,NS,NS,NS,carcinoma,NS,NS,NS
18591.0,RET,RET_unspecified,,,,breast / carcinoma / NS,3.0,Phase 2,Lenvatinib,,Unknown,NCT03168074,,ECD,2021Mar28,No,No,,4.0,NCT03168074,,,Clinical activity,30.0,30.0,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,COSO28394862,2022May03,COSO28394862,breast,NS,NS,NS,carcinoma,NS,NS,NS
18592.0,RET,RET_unspecified,,,,breast / carcinoma / NS,3.0,Phase 2,Lenvatinib,,Unknown,NCT03168074,,ECD,2021Mar28,No,No,,4.0,NCT03168074,,,Clinical activity,30.0,30.0,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,COSO28394862,2022May03,COSO28394862,breast,NS,NS,NS,carcinoma,NS,NS,NS
18593.0,RET,RET_unspecified,,,,breast / carcinoma / NS,3.0,Phase 2,Lenvatinib,,Unknown,NCT03168074,,ECD,2021Mar28,No,No,,4.0,NCT03168074,,,Clinical activity,30.0,30.0,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,COSO28394862,2022May03,COSO28394862,breast,NS,NS,NS,carcinoma,NS,NS,NS
18594.0,RET,RET_unspecified,,,,breast / carcinoma / NS,3.0,Phase 2,Lenvatinib,,Unknown,NCT03168074,,ECD,2021Mar28,No,No,,4.0,NCT03168074,,,Clinical activity,30.0,30.0,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,COSO28394862,2022May03,COSO28394862,breast,NS,NS,NS,carcinoma,NS,NS,NS
18595.0,RET,RET_unspecified,,,,breast / carcinoma / NS,3.0,Phase 2,Lenvatinib,,Unknown,NCT03168074,,ECD,2021Mar28,No,No,,4.0,NCT03168074,,,Clinical activity,30.0,30.0,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,COSO28394862,2022May03,COSO28394862,breast,NS,NS,NS,carcinoma,NS,NS,NS
18596.0,RET,RET_unspecified,,,,breast / carcinoma / NS,3.0,Phase 2,Lenvatinib,,Unknown,NCT03168074,,ECD,2021Mar28,No,No,,4.0,NCT03168074,,,Clinical activity,30.0,30.0,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,COSO28394862,2022May03,COSO28394862,breast,NS,NS,NS,carcinoma,NS,NS,NS
18597.0,RET,RET_unspecified,,,,breast / carcinoma / NS,3.0,Phase 2,Lenvatinib,,Unknown,NCT03168074,,ECD,2021Mar28,No,No,,4.0,NCT03168074,,,Clinical activity,30.0,30.0,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,COSO28394862,2022May03,COSO28394862,breast,NS,NS,NS,carcinoma,NS,NS,NS
18598.0,RET,RET_unspecified,,,,breast / carcinoma / NS,3.0,Phase 2,Lenvatinib,,Unknown,NCT03168074,,ECD,2021Mar28,No,No,,4.0,NCT03168074,,,Clinical activity,30.0,30.0,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,COSO28394862,2022May03,COSO28394862,breast,NS,NS,NS,carcinoma,NS,NS,NS
18599.0,RET,RET_unspecified,,,,breast / carcinoma / NS,3.0,Phase 2,Lenvatinib,,Unknown,NCT03168074,,ECD,2021Mar28,No,No,,4.0,NCT03168074,,,Clinical activity,30.0,30.0,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,COSO28394862,2022May03,COSO28394862,breast,NS,NS,NS,carcinoma,NS,NS,NS
18600.0,RET,RET_unspecified,,,,breast / carcinoma / NS,3.0,Phase 2,Lenvatinib,,Unknown,NCT03168074,,ECD,2021Mar28,No,No,,4.0,NCT03168074,,,Clinical activity,30.0,30.0,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,COSO28394862,2022May03,COSO28394862,breast,NS,NS,NS,carcinoma,NS,NS,NS
18601.0,RET,RET_unspecified,,,,breast / carcinoma / NS,3.0,Phase 2,Lenvatinib,,Unknown,NCT03168074,,ECD,2021Mar28,No,No,,4.0,NCT03168074,,,Clinical activity,30.0,30.0,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,COSO28394862,2022May03,COSO28394862,breast,NS,NS,NS,carcinoma,NS,NS,NS
18602.0,RET,RET_unspecified,,,,breast / carcinoma / NS,3.0,Phase 2,Lenvatinib,,Unknown,NCT03168074,,ECD,2021Mar28,No,No,,4.0,NCT03168074,,,Clinical activity,30.0,30.0,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,COSO28394862,2022May03,COSO28394862,breast,NS,NS,NS,carcinoma,NS,NS,NS
5083.0,ERBB2,ERBB2_unspecified,,,,breast / carcinoma / NS,2.0,Phase 1,Nimotuzumab,,Completed,NCT00513058,,PCD,2010May01,Overexpression,No,,4.0,NCT00513058,,,Maximum tolerated dose/toxicity,33.0,33.0,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,COSO28394862,2021Oct11,COSO28394862,breast,NS,NS,NS,carcinoma,NS,NS,NS
5084.0,ERBB2,ERBB2_unspecified,,,,breast / carcinoma / NS,2.0,Phase 1,Nimotuzumab,,Completed,NCT00513058,,PCD,2010May01,Overexpression,No,,4.0,NCT00513058,,,Maximum tolerated dose/toxicity,33.0,33.0,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,COSO28394862,2021Oct11,COSO28394862,breast,NS,NS,NS,carcinoma,NS,NS,NS
5085.0,ERBB2,ERBB2_unspecified,,,,breast / carcinoma / NS,2.0,Phase 1,Nimotuzumab,,Completed,NCT00513058,,PCD,2010May01,Overexpression,No,,4.0,NCT00513058,,,Maximum tolerated dose/toxicity,33.0,33.0,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,COSO28394862,2021Oct11,COSO28394862,breast,NS,NS,NS,carcinoma,NS,NS,NS
5086.0,ERBB2,ERBB2_unspecified,,,,breast / carcinoma / NS,2.0,Phase 1,Nimotuzumab,,Completed,NCT00513058,,PCD,2010May01,Overexpression,No,,4.0,NCT00513058,,,Maximum tolerated dose/toxicity,33.0,33.0,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,COSO28394862,2021Oct11,COSO28394862,breast,NS,NS,NS,carcinoma,NS,NS,NS
5087.0,ERBB2,ERBB2_unspecified,,,,breast / carcinoma / NS,2.0,Phase 1,Nimotuzumab,,Completed,NCT00513058,,PCD,2010May01,Overexpression,No,,4.0,NCT00513058,,,Maximum tolerated dose/toxicity,33.0,33.0,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,COSO28394862,2021Oct11,COSO28394862,breast,NS,NS,NS,carcinoma,NS,NS,NS
5088.0,ERBB2,ERBB2_unspecified,,,,breast / carcinoma / NS,2.0,Phase 1,Nimotuzumab,,Completed,NCT00513058,,PCD,2010May01,Overexpression,No,,4.0,NCT00513058,,,Maximum tolerated dose/toxicity,33.0,33.0,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,COSO28394862,2021Oct11,COSO28394862,breast,NS,NS,NS,carcinoma,NS,NS,NS
5089.0,ERBB2,ERBB2_unspecified,,,,breast / carcinoma / NS,2.0,Phase 1,Nimotuzumab,,Completed,NCT00513058,,PCD,2010May01,Overexpression,No,,4.0,NCT00513058,,,Maximum tolerated dose/toxicity,33.0,33.0,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,COSO28394862,2021Oct11,COSO28394862,breast,NS,NS,NS,carcinoma,NS,NS,NS
5090.0,ERBB2,ERBB2_unspecified,,,,breast / carcinoma / NS,2.0,Phase 1,Nimotuzumab,,Completed,NCT00513058,,PCD,2010May01,Overexpression,No,,4.0,NCT00513058,,,Maximum tolerated dose/toxicity,33.0,33.0,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,COSO28394862,2021Oct11,COSO28394862,breast,NS,NS,NS,carcinoma,NS,NS,NS
5091.0,ERBB2,ERBB2_unspecified,,,,breast / carcinoma / NS,2.0,Phase 1,Nimotuzumab,,Completed,NCT00513058,,PCD,2010May01,Overexpression,No,,4.0,NCT00513058,,,Maximum tolerated dose/toxicity,33.0,33.0,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,COSO28394862,2021Oct11,COSO28394862,breast,NS,NS,NS,carcinoma,NS,NS,NS
5092.0,ERBB2,ERBB2_unspecified,,,,breast / carcinoma / NS,2.0,Phase 1,Nimotuzumab,,Completed,NCT00513058,,PCD,2010May01,Overexpression,No,,4.0,NCT00513058,,,Maximum tolerated dose/toxicity,33.0,33.0,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,COSO28394862,2021Oct11,COSO28394862,breast,NS,NS,NS,carcinoma,NS,NS,NS
5093.0,ERBB2,ERBB2_unspecified,,,,breast / carcinoma / NS,2.0,Phase 1,Nimotuzumab,,Completed,NCT00513058,,PCD,2010May01,Overexpression,No,,4.0,NCT00513058,,,Maximum tolerated dose/toxicity,33.0,33.0,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,COSO28394862,2021Oct11,COSO28394862,breast,NS,NS,NS,carcinoma,NS,NS,NS
5094.0,ERBB2,ERBB2_unspecified,,,,breast / carcinoma / NS,2.0,Phase 1,Nimotuzumab,,Completed,NCT00513058,,PCD,2010May01,Overexpression,No,,4.0,NCT00513058,,,Maximum tolerated dose/toxicity,33.0,33.0,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,COSO28394862,2021Oct11,COSO28394862,breast,NS,NS,NS,carcinoma,NS,NS,NS
5095.0,ERBB2,ERBB2_unspecified,,,,breast / carcinoma / NS,2.0,Phase 1,Nimotuzumab,,Completed,NCT00513058,,PCD,2010May01,Overexpression,No,,4.0,NCT00513058,,,Maximum tolerated dose/toxicity,33.0,33.0,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,COSO28394862,2021Oct11,COSO28394862,breast,NS,NS,NS,carcinoma,NS,NS,NS
559.0,ATM,ATM_unspecified or ATR_unspecified or BARD1_unspecified or BRCA1_unspecified or BRCA2_unspecified or BRIP1_unspecified or CHEK2_unspecified or FANCA_unspecified or FANCC_unspecified or FANCD2_unspecified or FANCE_unspecified or FANCF_unspecified or FANCM_unspecified or MRE11A_unspecified or NBN_unspecified or PALB2_unspecified or RAD50_unspecified or RAD51C_unspecified or RAD51D_unspecified,,,,breast / carcinoma / NS,3.0,Phase 2,Olaparib,,Recruiting,NCT03344965,Olaparib Expanded Cohort 2,ECD,2022Dec30,Yes,Yes,Response correlated with gPALB2 or sBRCA mutations not ATM or CHEK2 mutations,2.0,10.1200/JCO.2020.38.15_suppl.1002,,,Overall Response Rate,26.0,26.0,,,38.5,,22.5-56.4,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,COSO28394862,2022Nov28,COSO28394862,breast,NS,NS,NS,carcinoma,NS,NS,NS
560.0,ATM,ATM_unspecified or ATR_unspecified or BARD1_unspecified or BRCA1_unspecified or BRCA2_unspecified or BRIP1_unspecified or CHEK2_unspecified or FANCA_unspecified or FANCC_unspecified or FANCD2_unspecified or FANCE_unspecified or FANCF_unspecified or FANCM_unspecified or MRE11A_unspecified or NBN_unspecified or PALB2_unspecified or RAD50_unspecified or RAD51C_unspecified or RAD51D_unspecified,,,,breast / carcinoma / NS,3.0,Phase 2,Olaparib,,Recruiting,NCT03344965,Olaparib Expanded Cohort 2,ECD,2022Dec30,Yes,Yes,Response correlated with gPALB2 or sBRCA mutations not ATM or CHEK2 mutations,2.0,10.1200/JCO.2020.38.15_suppl.1002,,,Overall Response Rate,26.0,26.0,,,38.5,,22.5-56.4,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,COSO28394862,2022Nov28,COSO28394862,breast,NS,NS,NS,carcinoma,NS,NS,NS
561.0,ATM,ATM_unspecified or ATR_unspecified or BARD1_unspecified or BRCA1_unspecified or BRCA2_unspecified or BRIP1_unspecified or CHEK2_unspecified or FANCA_unspecified or FANCC_unspecified or FANCD2_unspecified or FANCE_unspecified or FANCF_unspecified or FANCM_unspecified or MRE11A_unspecified or NBN_unspecified or PALB2_unspecified or RAD50_unspecified or RAD51C_unspecified or RAD51D_unspecified,,,,breast / carcinoma / NS,3.0,Phase 2,Olaparib,,Recruiting,NCT03344965,Olaparib Expanded Cohort 2,ECD,2022Dec30,Yes,Yes,Response correlated with gPALB2 or sBRCA mutations not ATM or CHEK2 mutations,2.0,10.1200/JCO.2020.38.15_suppl.1002,,,Overall Response Rate,26.0,26.0,,,38.5,,22.5-56.4,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,COSO28394862,2022Nov28,COSO28394862,breast,NS,NS,NS,carcinoma,NS,NS,NS
562.0,ATM,ATM_unspecified or ATR_unspecified or BARD1_unspecified or BRCA1_unspecified or BRCA2_unspecified or BRIP1_unspecified or CHEK2_unspecified or FANCA_unspecified or FANCC_unspecified or FANCD2_unspecified or FANCE_unspecified or FANCF_unspecified or FANCM_unspecified or MRE11A_unspecified or NBN_unspecified or PALB2_unspecified or RAD50_unspecified or RAD51C_unspecified or RAD51D_unspecified,,,,breast / carcinoma / NS,3.0,Phase 2,Olaparib,,Recruiting,NCT03344965,Olaparib Expanded Cohort 2,ECD,2022Dec30,Yes,Yes,Response correlated with gPALB2 or sBRCA mutations not ATM or CHEK2 mutations,2.0,10.1200/JCO.2020.38.15_suppl.1002,,,Overall Response Rate,26.0,26.0,,,38.5,,22.5-56.4,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,COSO28394862,2022Nov28,COSO28394862,breast,NS,NS,NS,carcinoma,NS,NS,NS
563.0,ATM,ATM_unspecified or ATR_unspecified or BARD1_unspecified or BRCA1_unspecified or BRCA2_unspecified or BRIP1_unspecified or CHEK2_unspecified or FANCA_unspecified or FANCC_unspecified or FANCD2_unspecified or FANCE_unspecified or FANCF_unspecified or FANCM_unspecified or MRE11A_unspecified or NBN_unspecified or PALB2_unspecified or RAD50_unspecified or RAD51C_unspecified or RAD51D_unspecified,,,,breast / carcinoma / NS,3.0,Phase 2,Olaparib,,Recruiting,NCT03344965,Olaparib Expanded Cohort 2,ECD,2022Dec30,Yes,Yes,Response correlated with gPALB2 or sBRCA mutations not ATM or CHEK2 mutations,2.0,10.1200/JCO.2020.38.15_suppl.1002,,,Overall Response Rate,26.0,26.0,,,38.5,,22.5-56.4,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,COSO28394862,2022Nov28,COSO28394862,breast,NS,NS,NS,carcinoma,NS,NS,NS
564.0,ATM,ATM_unspecified or ATR_unspecified or BARD1_unspecified or BRCA1_unspecified or BRCA2_unspecified or BRIP1_unspecified or CHEK2_unspecified or FANCA_unspecified or FANCC_unspecified or FANCD2_unspecified or FANCE_unspecified or FANCF_unspecified or FANCM_unspecified or MRE11A_unspecified or NBN_unspecified or PALB2_unspecified or RAD50_unspecified or RAD51C_unspecified or RAD51D_unspecified,,,,breast / carcinoma / NS,3.0,Phase 2,Olaparib,,Recruiting,NCT03344965,Olaparib Expanded Cohort 2,ECD,2022Dec30,Yes,Yes,Response correlated with gPALB2 or sBRCA mutations not ATM or CHEK2 mutations,2.0,10.1200/JCO.2020.38.15_suppl.1002,,,Overall Response Rate,26.0,26.0,,,38.5,,22.5-56.4,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,COSO28394862,2022Nov28,COSO28394862,breast,NS,NS,NS,carcinoma,NS,NS,NS
565.0,ATM,ATM_unspecified or ATR_unspecified or BARD1_unspecified or BRCA1_unspecified or BRCA2_unspecified or BRIP1_unspecified or CHEK2_unspecified or FANCA_unspecified or FANCC_unspecified or FANCD2_unspecified or FANCE_unspecified or FANCF_unspecified or FANCM_unspecified or MRE11A_unspecified or NBN_unspecified or PALB2_unspecified or RAD50_unspecified or RAD51C_unspecified or RAD51D_unspecified,,,,breast / carcinoma / NS,3.0,Phase 2,Olaparib,,Recruiting,NCT03344965,Olaparib Expanded Cohort 2,ECD,2022Dec30,Yes,Yes,Response correlated with gPALB2 or sBRCA mutations not ATM or CHEK2 mutations,2.0,10.1200/JCO.2020.38.15_suppl.1002,,,Overall Response Rate,26.0,26.0,,,38.5,,22.5-56.4,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,COSO28394862,2022Nov28,COSO28394862,breast,NS,NS,NS,carcinoma,NS,NS,NS
566.0,ATM,ATM_unspecified or ATR_unspecified or BARD1_unspecified or BRCA1_unspecified or BRCA2_unspecified or BRIP1_unspecified or CHEK2_unspecified or FANCA_unspecified or FANCC_unspecified or FANCD2_unspecified or FANCE_unspecified or FANCF_unspecified or FANCM_unspecified or MRE11A_unspecified or NBN_unspecified or PALB2_unspecified or RAD50_unspecified or RAD51C_unspecified or RAD51D_unspecified,,,,breast / carcinoma / NS,3.0,Phase 2,Olaparib,,Recruiting,NCT03344965,Olaparib Expanded Cohort 2,ECD,2022Dec30,Yes,Yes,Response correlated with gPALB2 or sBRCA mutations not ATM or CHEK2 mutations,2.0,10.1200/JCO.2020.38.15_suppl.1002,,,Overall Response Rate,26.0,26.0,,,38.5,,22.5-56.4,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,COSO28394862,2022Nov28,COSO28394862,breast,NS,NS,NS,carcinoma,NS,NS,NS
567.0,ATM,ATM_unspecified or ATR_unspecified or BARD1_unspecified or BRCA1_unspecified or BRCA2_unspecified or BRIP1_unspecified or CHEK2_unspecified or FANCA_unspecified or FANCC_unspecified or FANCD2_unspecified or FANCE_unspecified or FANCF_unspecified or FANCM_unspecified or MRE11A_unspecified or NBN_unspecified or PALB2_unspecified or RAD50_unspecified or RAD51C_unspecified or RAD51D_unspecified,,,,breast / carcinoma / NS,3.0,Phase 2,Olaparib,,Recruiting,NCT03344965,Olaparib Expanded Cohort 2,ECD,2022Dec30,Yes,Yes,Response correlated with gPALB2 or sBRCA mutations not ATM or CHEK2 mutations,2.0,10.1200/JCO.2020.38.15_suppl.1002,,,Overall Response Rate,26.0,26.0,,,38.5,,22.5-56.4,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,COSO28394862,2022Nov28,COSO28394862,breast,NS,NS,NS,carcinoma,NS,NS,NS
568.0,ATM,ATM_unspecified or ATR_unspecified or BARD1_unspecified or BRCA1_unspecified or BRCA2_unspecified or BRIP1_unspecified or CHEK2_unspecified or FANCA_unspecified or FANCC_unspecified or FANCD2_unspecified or FANCE_unspecified or FANCF_unspecified or FANCM_unspecified or MRE11A_unspecified or NBN_unspecified or PALB2_unspecified or RAD50_unspecified or RAD51C_unspecified or RAD51D_unspecified,,,,breast / carcinoma / NS,3.0,Phase 2,Olaparib,,Recruiting,NCT03344965,Olaparib Expanded Cohort 2,ECD,2022Dec30,Yes,Yes,Response correlated with gPALB2 or sBRCA mutations not ATM or CHEK2 mutations,2.0,10.1200/JCO.2020.38.15_suppl.1002,,,Overall Response Rate,26.0,26.0,,,38.5,,22.5-56.4,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,COSO28394862,2022Nov28,COSO28394862,breast,NS,NS,NS,carcinoma,NS,NS,NS
569.0,ATM,ATM_unspecified or ATR_unspecified or BARD1_unspecified or BRCA1_unspecified or BRCA2_unspecified or BRIP1_unspecified or CHEK2_unspecified or FANCA_unspecified or FANCC_unspecified or FANCD2_unspecified or FANCE_unspecified or FANCF_unspecified or FANCM_unspecified or MRE11A_unspecified or NBN_unspecified or PALB2_unspecified or RAD50_unspecified or RAD51C_unspecified or RAD51D_unspecified,,,,breast / carcinoma / NS,3.0,Phase 2,Olaparib,,Recruiting,NCT03344965,Olaparib Expanded Cohort 2,ECD,2022Dec30,Yes,Yes,Response correlated with gPALB2 or sBRCA mutations not ATM or CHEK2 mutations,2.0,10.1200/JCO.2020.38.15_suppl.1002,,,Overall Response Rate,26.0,26.0,,,38.5,,22.5-56.4,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,COSO28394862,2022Nov28,COSO28394862,breast,NS,NS,NS,carcinoma,NS,NS,NS
570.0,ATM,ATM_unspecified or ATR_unspecified or BARD1_unspecified or BRCA1_unspecified or BRCA2_unspecified or BRIP1_unspecified or CHEK2_unspecified or FANCA_unspecified or FANCC_unspecified or FANCD2_unspecified or FANCE_unspecified or FANCF_unspecified or FANCM_unspecified or MRE11A_unspecified or NBN_unspecified or PALB2_unspecified or RAD50_unspecified or RAD51C_unspecified or RAD51D_unspecified,,,,breast / carcinoma / NS,3.0,Phase 2,Olaparib,,Recruiting,NCT03344965,Olaparib Expanded Cohort 2,ECD,2022Dec30,Yes,Yes,Response correlated with gPALB2 or sBRCA mutations not ATM or CHEK2 mutations,2.0,10.1200/JCO.2020.38.15_suppl.1002,,,Overall Response Rate,26.0,26.0,,,38.5,,22.5-56.4,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,COSO28394862,2022Nov28,COSO28394862,breast,NS,NS,NS,carcinoma,NS,NS,NS
571.0,ATM,ATM_unspecified or ATR_unspecified or BARD1_unspecified or BRCA1_unspecified or BRCA2_unspecified or BRIP1_unspecified or CHEK2_unspecified or FANCA_unspecified or FANCC_unspecified or FANCD2_unspecified or FANCE_unspecified or FANCF_unspecified or FANCM_unspecified or MRE11A_unspecified or NBN_unspecified or PALB2_unspecified or RAD50_unspecified or RAD51C_unspecified or RAD51D_unspecified,,,,breast / carcinoma / NS,3.0,Phase 2,Olaparib,,Recruiting,NCT03344965,Olaparib Expanded Cohort 2,ECD,2022Dec30,Yes,Yes,Response correlated with gPALB2 or sBRCA mutations not ATM or CHEK2 mutations,2.0,10.1200/JCO.2020.38.15_suppl.1002,,,Overall Response Rate,26.0,26.0,,,38.5,,22.5-56.4,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,COSO28394862,2022Nov28,COSO28394862,breast,NS,NS,NS,carcinoma,NS,NS,NS
637.0,BRCA1,BRCA1_unspecified,,,,breast / carcinoma / NS,3.0,Phase 2,Olaparib,,Completed,NCT00679783,,PCD,2010Mar26,Yes,Yes,,1.0,21862407,Previously-treated,,Overall Response Rate,3.0,3.0,,,0.0,,,,,,,,,,,,,,,,,,,,,,,,,,,0.0,0.0,2.0,,,,,,,,,COSO28394862,2022Nov28,COSO28394862,breast,NS,NS,NS,carcinoma,NS,NS,NS
638.0,BRCA1,BRCA1_unspecified,,,,breast / carcinoma / NS,3.0,Phase 2,Olaparib,,Completed,NCT00679783,,PCD,2010Mar26,Yes,Yes,,1.0,21862407,Previously-treated,,Overall Response Rate,3.0,3.0,,,0.0,,,,,,,,,,,,,,,,,,,,,,,,,,,0.0,0.0,2.0,,,,,,,,,COSO28394862,2022Nov28,COSO28394862,breast,NS,NS,NS,carcinoma,NS,NS,NS
639.0,BRCA1,BRCA1_unspecified,,,,breast / carcinoma / NS,3.0,Phase 2,Olaparib,,Completed,NCT00679783,,PCD,2010Mar26,Yes,Yes,,1.0,21862407,Previously-treated,,Overall Response Rate,3.0,3.0,,,0.0,,,,,,,,,,,,,,,,,,,,,,,,,,,0.0,0.0,2.0,,,,,,,,,COSO28394862,2022Nov28,COSO28394862,breast,NS,NS,NS,carcinoma,NS,NS,NS
640.0,BRCA1,BRCA1_unspecified,,,,breast / carcinoma / NS,3.0,Phase 2,Olaparib,,Completed,NCT00679783,,PCD,2010Mar26,Yes,Yes,,1.0,21862407,Previously-treated,,Overall Response Rate,3.0,3.0,,,0.0,,,,,,,,,,,,,,,,,,,,,,,,,,,0.0,0.0,2.0,,,,,,,,,COSO28394862,2022Nov28,COSO28394862,breast,NS,NS,NS,carcinoma,NS,NS,NS
641.0,BRCA1,BRCA1_unspecified,,,,breast / carcinoma / NS,3.0,Phase 2,Olaparib,,Completed,NCT00679783,,PCD,2010Mar26,Yes,Yes,,1.0,21862407,Previously-treated,,Overall Response Rate,3.0,3.0,,,0.0,,,,,,,,,,,,,,,,,,,,,,,,,,,0.0,0.0,2.0,,,,,,,,,COSO28394862,2022Nov28,COSO28394862,breast,NS,NS,NS,carcinoma,NS,NS,NS
642.0,BRCA1,BRCA1_unspecified,,,,breast / carcinoma / NS,3.0,Phase 2,Olaparib,,Completed,NCT00679783,,PCD,2010Mar26,Yes,Yes,,1.0,21862407,Previously-treated,,Overall Response Rate,3.0,3.0,,,0.0,,,,,,,,,,,,,,,,,,,,,,,,,,,0.0,0.0,2.0,,,,,,,,,COSO28394862,2022Nov28,COSO28394862,breast,NS,NS,NS,carcinoma,NS,NS,NS
643.0,BRCA1,BRCA1_unspecified,,,,breast / carcinoma / NS,3.0,Phase 2,Olaparib,,Completed,NCT00679783,,PCD,2010Mar26,Yes,Yes,,1.0,21862407,Previously-treated,,Overall Response Rate,3.0,3.0,,,0.0,,,,,,,,,,,,,,,,,,,,,,,,,,,0.0,0.0,2.0,,,,,,,,,COSO28394862,2022Nov28,COSO28394862,breast,NS,NS,NS,carcinoma,NS,NS,NS
644.0,BRCA1,BRCA1_unspecified,,,,breast / carcinoma / NS,3.0,Phase 2,Olaparib,,Completed,NCT00679783,,PCD,2010Mar26,Yes,Yes,,1.0,21862407,Previously-treated,,Overall Response Rate,3.0,3.0,,,0.0,,,,,,,,,,,,,,,,,,,,,,,,,,,0.0,0.0,2.0,,,,,,,,,COSO28394862,2022Nov28,COSO28394862,breast,NS,NS,NS,carcinoma,NS,NS,NS
645.0,BRCA1,BRCA1_unspecified,,,,breast / carcinoma / NS,3.0,Phase 2,Olaparib,,Completed,NCT00679783,,PCD,2010Mar26,Yes,Yes,,1.0,21862407,Previously-treated,,Overall Response Rate,3.0,3.0,,,0.0,,,,,,,,,,,,,,,,,,,,,,,,,,,0.0,0.0,2.0,,,,,,,,,COSO28394862,2022Nov28,COSO28394862,breast,NS,NS,NS,carcinoma,NS,NS,NS
646.0,BRCA1,BRCA1_unspecified,,,,breast / carcinoma / NS,3.0,Phase 2,Olaparib,,Completed,NCT00679783,,PCD,2010Mar26,Yes,Yes,,1.0,21862407,Previously-treated,,Overall Response Rate,3.0,3.0,,,0.0,,,,,,,,,,,,,,,,,,,,,,,,,,,0.0,0.0,2.0,,,,,,,,,COSO28394862,2022Nov28,COSO28394862,breast,NS,NS,NS,carcinoma,NS,NS,NS
647.0,BRCA1,BRCA1_unspecified,,,,breast / carcinoma / NS,3.0,Phase 2,Olaparib,,Completed,NCT00679783,,PCD,2010Mar26,Yes,Yes,,1.0,21862407,Previously-treated,,Overall Response Rate,3.0,3.0,,,0.0,,,,,,,,,,,,,,,,,,,,,,,,,,,0.0,0.0,2.0,,,,,,,,,COSO28394862,2022Nov28,COSO28394862,breast,NS,NS,NS,carcinoma,NS,NS,NS
648.0,BRCA1,BRCA1_unspecified,,,,breast / carcinoma / NS,3.0,Phase 2,Olaparib,,Completed,NCT00679783,,PCD,2010Mar26,Yes,Yes,,1.0,21862407,Previously-treated,,Overall Response Rate,3.0,3.0,,,0.0,,,,,,,,,,,,,,,,,,,,,,,,,,,0.0,0.0,2.0,,,,,,,,,COSO28394862,2022Nov28,COSO28394862,breast,NS,NS,NS,carcinoma,NS,NS,NS
649.0,BRCA1,BRCA1_unspecified,,,,breast / carcinoma / NS,3.0,Phase 2,Olaparib,,Completed,NCT00679783,,PCD,2010Mar26,Yes,Yes,,1.0,21862407,Previously-treated,,Overall Response Rate,3.0,3.0,,,0.0,,,,,,,,,,,,,,,,,,,,,,,,,,,0.0,0.0,2.0,,,,,,,,,COSO28394862,2022Nov28,COSO28394862,breast,NS,NS,NS,carcinoma,NS,NS,NS
767.0,BRCA1,BRCA1_unspecified or BRCA2_unspecified,,,,breast / carcinoma / NS,1.0,Approved FDA,Olaparib,Required,"Active, not recruiting",NCT02000622,OlympiAD,PCD,2016Dec09,No,Yes,,1.0,28578601,,,Progression free survival,302.0,205.0,97.0,Chemotherapy,59.9,28.8,,,,,,,7.0,4.2,0.58,0.43-0.80,<0.001,,,,,,,,,19.3,17.1,0.9,,,,,,,,,,,,,,,COSO28394862,2022Feb21,COSO28394862,breast,NS,NS,NS,carcinoma,NS,NS,NS
768.0,BRCA1,BRCA1_unspecified or BRCA2_unspecified,,,,breast / carcinoma / NS,1.0,Approved FDA,Olaparib,Required,"Active, not recruiting",NCT02000622,OlympiAD,PCD,2016Dec09,No,Yes,,1.0,28578601,,,Progression free survival,302.0,205.0,97.0,Chemotherapy,59.9,28.8,,,,,,,7.0,4.2,0.58,0.43-0.80,<0.001,,,,,,,,,19.3,17.1,0.9,,,,,,,,,,,,,,,COSO28394862,2022Feb21,COSO28394862,breast,NS,NS,NS,carcinoma,NS,NS,NS
769.0,BRCA1,BRCA1_unspecified or BRCA2_unspecified,,,,breast / carcinoma / NS,1.0,Approved FDA,Olaparib,Required,"Active, not recruiting",NCT02000622,OlympiAD,PCD,2016Dec09,No,Yes,,1.0,28578601,,,Progression free survival,302.0,205.0,97.0,Chemotherapy,59.9,28.8,,,,,,,7.0,4.2,0.58,0.43-0.80,<0.001,,,,,,,,,19.3,17.1,0.9,,,,,,,,,,,,,,,COSO28394862,2022Feb21,COSO28394862,breast,NS,NS,NS,carcinoma,NS,NS,NS
770.0,BRCA1,BRCA1_unspecified or BRCA2_unspecified,,,,breast / carcinoma / NS,1.0,Approved FDA,Olaparib,Required,"Active, not recruiting",NCT02000622,OlympiAD,PCD,2016Dec09,No,Yes,,1.0,28578601,,,Progression free survival,302.0,205.0,97.0,Chemotherapy,59.9,28.8,,,,,,,7.0,4.2,0.58,0.43-0.80,<0.001,,,,,,,,,19.3,17.1,0.9,,,,,,,,,,,,,,,COSO28394862,2022Feb21,COSO28394862,breast,NS,NS,NS,carcinoma,NS,NS,NS
771.0,BRCA1,BRCA1_unspecified or BRCA2_unspecified,,,,breast / carcinoma / NS,1.0,Approved FDA,Olaparib,Required,"Active, not recruiting",NCT02000622,OlympiAD,PCD,2016Dec09,No,Yes,,1.0,28578601,,,Progression free survival,302.0,205.0,97.0,Chemotherapy,59.9,28.8,,,,,,,7.0,4.2,0.58,0.43-0.80,<0.001,,,,,,,,,19.3,17.1,0.9,,,,,,,,,,,,,,,COSO28394862,2022Feb21,COSO28394862,breast,NS,NS,NS,carcinoma,NS,NS,NS
772.0,BRCA1,BRCA1_unspecified or BRCA2_unspecified,,,,breast / carcinoma / NS,1.0,Approved FDA,Olaparib,Required,"Active, not recruiting",NCT02000622,OlympiAD,PCD,2016Dec09,No,Yes,,1.0,28578601,,,Progression free survival,302.0,205.0,97.0,Chemotherapy,59.9,28.8,,,,,,,7.0,4.2,0.58,0.43-0.80,<0.001,,,,,,,,,19.3,17.1,0.9,,,,,,,,,,,,,,,COSO28394862,2022Feb21,COSO28394862,breast,NS,NS,NS,carcinoma,NS,NS,NS
773.0,BRCA1,BRCA1_unspecified or BRCA2_unspecified,,,,breast / carcinoma / NS,1.0,Approved FDA,Olaparib,Required,"Active, not recruiting",NCT02000622,OlympiAD,PCD,2016Dec09,No,Yes,,1.0,28578601,,,Progression free survival,302.0,205.0,97.0,Chemotherapy,59.9,28.8,,,,,,,7.0,4.2,0.58,0.43-0.80,<0.001,,,,,,,,,19.3,17.1,0.9,,,,,,,,,,,,,,,COSO28394862,2022Feb21,COSO28394862,breast,NS,NS,NS,carcinoma,NS,NS,NS
774.0,BRCA1,BRCA1_unspecified or BRCA2_unspecified,,,,breast / carcinoma / NS,1.0,Approved FDA,Olaparib,Required,"Active, not recruiting",NCT02000622,OlympiAD,PCD,2016Dec09,No,Yes,,1.0,28578601,,,Progression free survival,302.0,205.0,97.0,Chemotherapy,59.9,28.8,,,,,,,7.0,4.2,0.58,0.43-0.80,<0.001,,,,,,,,,19.3,17.1,0.9,,,,,,,,,,,,,,,COSO28394862,2022Feb21,COSO28394862,breast,NS,NS,NS,carcinoma,NS,NS,NS
775.0,BRCA1,BRCA1_unspecified or BRCA2_unspecified,,,,breast / carcinoma / NS,1.0,Approved FDA,Olaparib,Required,"Active, not recruiting",NCT02000622,OlympiAD,PCD,2016Dec09,No,Yes,,1.0,28578601,,,Progression free survival,302.0,205.0,97.0,Chemotherapy,59.9,28.8,,,,,,,7.0,4.2,0.58,0.43-0.80,<0.001,,,,,,,,,19.3,17.1,0.9,,,,,,,,,,,,,,,COSO28394862,2022Feb21,COSO28394862,breast,NS,NS,NS,carcinoma,NS,NS,NS
776.0,BRCA1,BRCA1_unspecified or BRCA2_unspecified,,,,breast / carcinoma / NS,1.0,Approved FDA,Olaparib,Required,"Active, not recruiting",NCT02000622,OlympiAD,PCD,2016Dec09,No,Yes,,1.0,28578601,,,Progression free survival,302.0,205.0,97.0,Chemotherapy,59.9,28.8,,,,,,,7.0,4.2,0.58,0.43-0.80,<0.001,,,,,,,,,19.3,17.1,0.9,,,,,,,,,,,,,,,COSO28394862,2022Feb21,COSO28394862,breast,NS,NS,NS,carcinoma,NS,NS,NS
777.0,BRCA1,BRCA1_unspecified or BRCA2_unspecified,,,,breast / carcinoma / NS,1.0,Approved FDA,Olaparib,Required,"Active, not recruiting",NCT02000622,OlympiAD,PCD,2016Dec09,No,Yes,,1.0,28578601,,,Progression free survival,302.0,205.0,97.0,Chemotherapy,59.9,28.8,,,,,,,7.0,4.2,0.58,0.43-0.80,<0.001,,,,,,,,,19.3,17.1,0.9,,,,,,,,,,,,,,,COSO28394862,2022Feb21,COSO28394862,breast,NS,NS,NS,carcinoma,NS,NS,NS
778.0,BRCA1,BRCA1_unspecified or BRCA2_unspecified,,,,breast / carcinoma / NS,1.0,Approved FDA,Olaparib,Required,"Active, not recruiting",NCT02000622,OlympiAD,PCD,2016Dec09,No,Yes,,1.0,28578601,,,Progression free survival,302.0,205.0,97.0,Chemotherapy,59.9,28.8,,,,,,,7.0,4.2,0.58,0.43-0.80,<0.001,,,,,,,,,19.3,17.1,0.9,,,,,,,,,,,,,,,COSO28394862,2022Feb21,COSO28394862,breast,NS,NS,NS,carcinoma,NS,NS,NS
779.0,BRCA1,BRCA1_unspecified or BRCA2_unspecified,,,,breast / carcinoma / NS,1.0,Approved FDA,Olaparib,Required,"Active, not recruiting",NCT02000622,OlympiAD,PCD,2016Dec09,No,Yes,,1.0,28578601,,,Progression free survival,302.0,205.0,97.0,Chemotherapy,59.9,28.8,,,,,,,7.0,4.2,0.58,0.43-0.80,<0.001,,,,,,,,,19.3,17.1,0.9,,,,,,,,,,,,,,,COSO28394862,2022Feb21,COSO28394862,breast,NS,NS,NS,carcinoma,NS,NS,NS
793.0,BRCA1,BRCA1_unspecified or BRCA2_unspecified,,,,breast / carcinoma / NS,1.0,Approved FDA,Olaparib,Required,"Active, not recruiting",NCT02032823,OlympiA,PCD,2020Mar27,Yes,Yes,EFS 3y 93 v 89%,7.0,https://www.accessdata.fda.gov/drugsatfda_docs/label/2022/208558s023lbl.pdf,Previously-treated,,"Disease free survival, relapse free survival, regression free survival, recurrence free survival",1836.0,921.0,915.0,Placebo,,,,,,,,,,,,,,,,,,,,,,,,0.68,0.50-0.91,0.0091,,,,,88.0,80.0,0.58,0.46-0.74,<0.0001,,,,COSO28394862,2022Oct18,COSO28394862,breast,NS,NS,NS,carcinoma,NS,NS,NS
794.0,BRCA1,BRCA1_unspecified or BRCA2_unspecified,,,,breast / carcinoma / NS,1.0,Approved FDA,Olaparib,Required,"Active, not recruiting",NCT02032823,OlympiA,PCD,2020Mar27,Yes,Yes,EFS 3y 93 v 89%,7.0,https://www.accessdata.fda.gov/drugsatfda_docs/label/2022/208558s023lbl.pdf,Previously-treated,,"Disease free survival, relapse free survival, regression free survival, recurrence free survival",1836.0,921.0,915.0,Placebo,,,,,,,,,,,,,,,,,,,,,,,,0.68,0.50-0.91,0.0091,,,,,88.0,80.0,0.58,0.46-0.74,<0.0001,,,,COSO28394862,2022Oct18,COSO28394862,breast,NS,NS,NS,carcinoma,NS,NS,NS
795.0,BRCA1,BRCA1_unspecified or BRCA2_unspecified,,,,breast / carcinoma / NS,1.0,Approved FDA,Olaparib,Required,"Active, not recruiting",NCT02032823,OlympiA,PCD,2020Mar27,Yes,Yes,EFS 3y 93 v 89%,7.0,https://www.accessdata.fda.gov/drugsatfda_docs/label/2022/208558s023lbl.pdf,Previously-treated,,"Disease free survival, relapse free survival, regression free survival, recurrence free survival",1836.0,921.0,915.0,Placebo,,,,,,,,,,,,,,,,,,,,,,,,0.68,0.50-0.91,0.0091,,,,,88.0,80.0,0.58,0.46-0.74,<0.0001,,,,COSO28394862,2022Oct18,COSO28394862,breast,NS,NS,NS,carcinoma,NS,NS,NS
796.0,BRCA1,BRCA1_unspecified or BRCA2_unspecified,,,,breast / carcinoma / NS,1.0,Approved FDA,Olaparib,Required,"Active, not recruiting",NCT02032823,OlympiA,PCD,2020Mar27,Yes,Yes,EFS 3y 93 v 89%,7.0,https://www.accessdata.fda.gov/drugsatfda_docs/label/2022/208558s023lbl.pdf,Previously-treated,,"Disease free survival, relapse free survival, regression free survival, recurrence free survival",1836.0,921.0,915.0,Placebo,,,,,,,,,,,,,,,,,,,,,,,,0.68,0.50-0.91,0.0091,,,,,88.0,80.0,0.58,0.46-0.74,<0.0001,,,,COSO28394862,2022Oct18,COSO28394862,breast,NS,NS,NS,carcinoma,NS,NS,NS
797.0,BRCA1,BRCA1_unspecified or BRCA2_unspecified,,,,breast / carcinoma / NS,1.0,Approved FDA,Olaparib,Required,"Active, not recruiting",NCT02032823,OlympiA,PCD,2020Mar27,Yes,Yes,EFS 3y 93 v 89%,7.0,https://www.accessdata.fda.gov/drugsatfda_docs/label/2022/208558s023lbl.pdf,Previously-treated,,"Disease free survival, relapse free survival, regression free survival, recurrence free survival",1836.0,921.0,915.0,Placebo,,,,,,,,,,,,,,,,,,,,,,,,0.68,0.50-0.91,0.0091,,,,,88.0,80.0,0.58,0.46-0.74,<0.0001,,,,COSO28394862,2022Oct18,COSO28394862,breast,NS,NS,NS,carcinoma,NS,NS,NS
798.0,BRCA1,BRCA1_unspecified or BRCA2_unspecified,,,,breast / carcinoma / NS,1.0,Approved FDA,Olaparib,Required,"Active, not recruiting",NCT02032823,OlympiA,PCD,2020Mar27,Yes,Yes,EFS 3y 93 v 89%,7.0,https://www.accessdata.fda.gov/drugsatfda_docs/label/2022/208558s023lbl.pdf,Previously-treated,,"Disease free survival, relapse free survival, regression free survival, recurrence free survival",1836.0,921.0,915.0,Placebo,,,,,,,,,,,,,,,,,,,,,,,,0.68,0.50-0.91,0.0091,,,,,88.0,80.0,0.58,0.46-0.74,<0.0001,,,,COSO28394862,2022Oct18,COSO28394862,breast,NS,NS,NS,carcinoma,NS,NS,NS
799.0,BRCA1,BRCA1_unspecified or BRCA2_unspecified,,,,breast / carcinoma / NS,1.0,Approved FDA,Olaparib,Required,"Active, not recruiting",NCT02032823,OlympiA,PCD,2020Mar27,Yes,Yes,EFS 3y 93 v 89%,7.0,https://www.accessdata.fda.gov/drugsatfda_docs/label/2022/208558s023lbl.pdf,Previously-treated,,"Disease free survival, relapse free survival, regression free survival, recurrence free survival",1836.0,921.0,915.0,Placebo,,,,,,,,,,,,,,,,,,,,,,,,0.68,0.50-0.91,0.0091,,,,,88.0,80.0,0.58,0.46-0.74,<0.0001,,,,COSO28394862,2022Oct18,COSO28394862,breast,NS,NS,NS,carcinoma,NS,NS,NS
800.0,BRCA1,BRCA1_unspecified or BRCA2_unspecified,,,,breast / carcinoma / NS,1.0,Approved FDA,Olaparib,Required,"Active, not recruiting",NCT02032823,OlympiA,PCD,2020Mar27,Yes,Yes,EFS 3y 93 v 89%,7.0,https://www.accessdata.fda.gov/drugsatfda_docs/label/2022/208558s023lbl.pdf,Previously-treated,,"Disease free survival, relapse free survival, regression free survival, recurrence free survival",1836.0,921.0,915.0,Placebo,,,,,,,,,,,,,,,,,,,,,,,,0.68,0.50-0.91,0.0091,,,,,88.0,80.0,0.58,0.46-0.74,<0.0001,,,,COSO28394862,2022Oct18,COSO28394862,breast,NS,NS,NS,carcinoma,NS,NS,NS
801.0,BRCA1,BRCA1_unspecified or BRCA2_unspecified,,,,breast / carcinoma / NS,1.0,Approved FDA,Olaparib,Required,"Active, not recruiting",NCT02032823,OlympiA,PCD,2020Mar27,Yes,Yes,EFS 3y 93 v 89%,7.0,https://www.accessdata.fda.gov/drugsatfda_docs/label/2022/208558s023lbl.pdf,Previously-treated,,"Disease free survival, relapse free survival, regression free survival, recurrence free survival",1836.0,921.0,915.0,Placebo,,,,,,,,,,,,,,,,,,,,,,,,0.68,0.50-0.91,0.0091,,,,,88.0,80.0,0.58,0.46-0.74,<0.0001,,,,COSO28394862,2022Oct18,COSO28394862,breast,NS,NS,NS,carcinoma,NS,NS,NS
802.0,BRCA1,BRCA1_unspecified or BRCA2_unspecified,,,,breast / carcinoma / NS,1.0,Approved FDA,Olaparib,Required,"Active, not recruiting",NCT02032823,OlympiA,PCD,2020Mar27,Yes,Yes,EFS 3y 93 v 89%,7.0,https://www.accessdata.fda.gov/drugsatfda_docs/label/2022/208558s023lbl.pdf,Previously-treated,,"Disease free survival, relapse free survival, regression free survival, recurrence free survival",1836.0,921.0,915.0,Placebo,,,,,,,,,,,,,,,,,,,,,,,,0.68,0.50-0.91,0.0091,,,,,88.0,80.0,0.58,0.46-0.74,<0.0001,,,,COSO28394862,2022Oct18,COSO28394862,breast,NS,NS,NS,carcinoma,NS,NS,NS
803.0,BRCA1,BRCA1_unspecified or BRCA2_unspecified,,,,breast / carcinoma / NS,1.0,Approved FDA,Olaparib,Required,"Active, not recruiting",NCT02032823,OlympiA,PCD,2020Mar27,Yes,Yes,EFS 3y 93 v 89%,7.0,https://www.accessdata.fda.gov/drugsatfda_docs/label/2022/208558s023lbl.pdf,Previously-treated,,"Disease free survival, relapse free survival, regression free survival, recurrence free survival",1836.0,921.0,915.0,Placebo,,,,,,,,,,,,,,,,,,,,,,,,0.68,0.50-0.91,0.0091,,,,,88.0,80.0,0.58,0.46-0.74,<0.0001,,,,COSO28394862,2022Oct18,COSO28394862,breast,NS,NS,NS,carcinoma,NS,NS,NS
804.0,BRCA1,BRCA1_unspecified or BRCA2_unspecified,,,,breast / carcinoma / NS,1.0,Approved FDA,Olaparib,Required,"Active, not recruiting",NCT02032823,OlympiA,PCD,2020Mar27,Yes,Yes,EFS 3y 93 v 89%,7.0,https://www.accessdata.fda.gov/drugsatfda_docs/label/2022/208558s023lbl.pdf,Previously-treated,,"Disease free survival, relapse free survival, regression free survival, recurrence free survival",1836.0,921.0,915.0,Placebo,,,,,,,,,,,,,,,,,,,,,,,,0.68,0.50-0.91,0.0091,,,,,88.0,80.0,0.58,0.46-0.74,<0.0001,,,,COSO28394862,2022Oct18,COSO28394862,breast,NS,NS,NS,carcinoma,NS,NS,NS
805.0,BRCA1,BRCA1_unspecified or BRCA2_unspecified,,,,breast / carcinoma / NS,1.0,Approved FDA,Olaparib,Required,"Active, not recruiting",NCT02032823,OlympiA,PCD,2020Mar27,Yes,Yes,EFS 3y 93 v 89%,7.0,https://www.accessdata.fda.gov/drugsatfda_docs/label/2022/208558s023lbl.pdf,Previously-treated,,"Disease free survival, relapse free survival, regression free survival, recurrence free survival",1836.0,921.0,915.0,Placebo,,,,,,,,,,,,,,,,,,,,,,,,0.68,0.50-0.91,0.0091,,,,,88.0,80.0,0.58,0.46-0.74,<0.0001,,,,COSO28394862,2022Oct18,COSO28394862,breast,NS,NS,NS,carcinoma,NS,NS,NS
1469.0,BRCA1,BRCA1_unspecified or BRCA2_unspecified,,,,breast / carcinoma / NS,1.0,Phase 2,Olaparib,,Not yet recruiting,NCT05332561,COGNITION-GUIDE Arm 4,ECD,2029Apr01,Yes,No,,4.0,NCT05332561,,,"Disease free survival, relapse free survival, regression free survival, recurrence free survival",240.0,240.0,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,COSO28394862,2022Apr25,COSO28394862,breast,NS,NS,NS,carcinoma,NS,NS,NS
1470.0,BRCA1,BRCA1_unspecified or BRCA2_unspecified,,,,breast / carcinoma / NS,1.0,Phase 2,Olaparib,,Not yet recruiting,NCT05332561,COGNITION-GUIDE Arm 4,ECD,2029Apr01,Yes,No,,4.0,NCT05332561,,,"Disease free survival, relapse free survival, regression free survival, recurrence free survival",240.0,240.0,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,COSO28394862,2022Apr25,COSO28394862,breast,NS,NS,NS,carcinoma,NS,NS,NS
1471.0,BRCA1,BRCA1_unspecified or BRCA2_unspecified,,,,breast / carcinoma / NS,1.0,Phase 2,Olaparib,,Not yet recruiting,NCT05332561,COGNITION-GUIDE Arm 4,ECD,2029Apr01,Yes,No,,4.0,NCT05332561,,,"Disease free survival, relapse free survival, regression free survival, recurrence free survival",240.0,240.0,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,COSO28394862,2022Apr25,COSO28394862,breast,NS,NS,NS,carcinoma,NS,NS,NS
1472.0,BRCA1,BRCA1_unspecified or BRCA2_unspecified,,,,breast / carcinoma / NS,1.0,Phase 2,Olaparib,,Not yet recruiting,NCT05332561,COGNITION-GUIDE Arm 4,ECD,2029Apr01,Yes,No,,4.0,NCT05332561,,,"Disease free survival, relapse free survival, regression free survival, recurrence free survival",240.0,240.0,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,COSO28394862,2022Apr25,COSO28394862,breast,NS,NS,NS,carcinoma,NS,NS,NS
1473.0,BRCA1,BRCA1_unspecified or BRCA2_unspecified,,,,breast / carcinoma / NS,1.0,Phase 2,Olaparib,,Not yet recruiting,NCT05332561,COGNITION-GUIDE Arm 4,ECD,2029Apr01,Yes,No,,4.0,NCT05332561,,,"Disease free survival, relapse free survival, regression free survival, recurrence free survival",240.0,240.0,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,COSO28394862,2022Apr25,COSO28394862,breast,NS,NS,NS,carcinoma,NS,NS,NS
1474.0,BRCA1,BRCA1_unspecified or BRCA2_unspecified,,,,breast / carcinoma / NS,1.0,Phase 2,Olaparib,,Not yet recruiting,NCT05332561,COGNITION-GUIDE Arm 4,ECD,2029Apr01,Yes,No,,4.0,NCT05332561,,,"Disease free survival, relapse free survival, regression free survival, recurrence free survival",240.0,240.0,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,COSO28394862,2022Apr25,COSO28394862,breast,NS,NS,NS,carcinoma,NS,NS,NS
1475.0,BRCA1,BRCA1_unspecified or BRCA2_unspecified,,,,breast / carcinoma / NS,1.0,Phase 2,Olaparib,,Not yet recruiting,NCT05332561,COGNITION-GUIDE Arm 4,ECD,2029Apr01,Yes,No,,4.0,NCT05332561,,,"Disease free survival, relapse free survival, regression free survival, recurrence free survival",240.0,240.0,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,COSO28394862,2022Apr25,COSO28394862,breast,NS,NS,NS,carcinoma,NS,NS,NS
1476.0,BRCA1,BRCA1_unspecified or BRCA2_unspecified,,,,breast / carcinoma / NS,1.0,Phase 2,Olaparib,,Not yet recruiting,NCT05332561,COGNITION-GUIDE Arm 4,ECD,2029Apr01,Yes,No,,4.0,NCT05332561,,,"Disease free survival, relapse free survival, regression free survival, recurrence free survival",240.0,240.0,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,COSO28394862,2022Apr25,COSO28394862,breast,NS,NS,NS,carcinoma,NS,NS,NS
1477.0,BRCA1,BRCA1_unspecified or BRCA2_unspecified,,,,breast / carcinoma / NS,1.0,Phase 2,Olaparib,,Not yet recruiting,NCT05332561,COGNITION-GUIDE Arm 4,ECD,2029Apr01,Yes,No,,4.0,NCT05332561,,,"Disease free survival, relapse free survival, regression free survival, recurrence free survival",240.0,240.0,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,COSO28394862,2022Apr25,COSO28394862,breast,NS,NS,NS,carcinoma,NS,NS,NS
1478.0,BRCA1,BRCA1_unspecified or BRCA2_unspecified,,,,breast / carcinoma / NS,1.0,Phase 2,Olaparib,,Not yet recruiting,NCT05332561,COGNITION-GUIDE Arm 4,ECD,2029Apr01,Yes,No,,4.0,NCT05332561,,,"Disease free survival, relapse free survival, regression free survival, recurrence free survival",240.0,240.0,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,COSO28394862,2022Apr25,COSO28394862,breast,NS,NS,NS,carcinoma,NS,NS,NS
1479.0,BRCA1,BRCA1_unspecified or BRCA2_unspecified,,,,breast / carcinoma / NS,1.0,Phase 2,Olaparib,,Not yet recruiting,NCT05332561,COGNITION-GUIDE Arm 4,ECD,2029Apr01,Yes,No,,4.0,NCT05332561,,,"Disease free survival, relapse free survival, regression free survival, recurrence free survival",240.0,240.0,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,COSO28394862,2022Apr25,COSO28394862,breast,NS,NS,NS,carcinoma,NS,NS,NS
1480.0,BRCA1,BRCA1_unspecified or BRCA2_unspecified,,,,breast / carcinoma / NS,1.0,Phase 2,Olaparib,,Not yet recruiting,NCT05332561,COGNITION-GUIDE Arm 4,ECD,2029Apr01,Yes,No,,4.0,NCT05332561,,,"Disease free survival, relapse free survival, regression free survival, recurrence free survival",240.0,240.0,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,COSO28394862,2022Apr25,COSO28394862,breast,NS,NS,NS,carcinoma,NS,NS,NS
1481.0,BRCA1,BRCA1_unspecified or BRCA2_unspecified,,,,breast / carcinoma / NS,1.0,Phase 2,Olaparib,,Not yet recruiting,NCT05332561,COGNITION-GUIDE Arm 4,ECD,2029Apr01,Yes,No,,4.0,NCT05332561,,,"Disease free survival, relapse free survival, regression free survival, recurrence free survival",240.0,240.0,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,COSO28394862,2022Apr25,COSO28394862,breast,NS,NS,NS,carcinoma,NS,NS,NS
1482.0,BRCA1,BRCA1_unspecified or BRCA2_unspecified,,,,breast / carcinoma / NS,1.0,Phase 2,Olaparib,,Recruiting,NCT05498155,OlympiaN Cohort A,ECD,2024May17,Yes,No,,4.0,NCT05498155,,,"Complete response, Pathological complete response",80.0,80.0,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,COSO28394862,2022Nov28,COSO28394862,breast,NS,NS,NS,carcinoma,NS,NS,NS
1483.0,BRCA1,BRCA1_unspecified or BRCA2_unspecified,,,,breast / carcinoma / NS,1.0,Phase 2,Olaparib,,Recruiting,NCT05498155,OlympiaN Cohort A,ECD,2024May17,Yes,No,,4.0,NCT05498155,,,"Complete response, Pathological complete response",80.0,80.0,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,COSO28394862,2022Nov28,COSO28394862,breast,NS,NS,NS,carcinoma,NS,NS,NS
1484.0,BRCA1,BRCA1_unspecified or BRCA2_unspecified,,,,breast / carcinoma / NS,1.0,Phase 2,Olaparib,,Recruiting,NCT05498155,OlympiaN Cohort A,ECD,2024May17,Yes,No,,4.0,NCT05498155,,,"Complete response, Pathological complete response",80.0,80.0,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,COSO28394862,2022Nov28,COSO28394862,breast,NS,NS,NS,carcinoma,NS,NS,NS
1485.0,BRCA1,BRCA1_unspecified or BRCA2_unspecified,,,,breast / carcinoma / NS,1.0,Phase 2,Olaparib,,Recruiting,NCT05498155,OlympiaN Cohort A,ECD,2024May17,Yes,No,,4.0,NCT05498155,,,"Complete response, Pathological complete response",80.0,80.0,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,COSO28394862,2022Nov28,COSO28394862,breast,NS,NS,NS,carcinoma,NS,NS,NS
1486.0,BRCA1,BRCA1_unspecified or BRCA2_unspecified,,,,breast / carcinoma / NS,1.0,Phase 2,Olaparib,,Recruiting,NCT05498155,OlympiaN Cohort A,ECD,2024May17,Yes,No,,4.0,NCT05498155,,,"Complete response, Pathological complete response",80.0,80.0,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,COSO28394862,2022Nov28,COSO28394862,breast,NS,NS,NS,carcinoma,NS,NS,NS
1487.0,BRCA1,BRCA1_unspecified or BRCA2_unspecified,,,,breast / carcinoma / NS,1.0,Phase 2,Olaparib,,Recruiting,NCT05498155,OlympiaN Cohort A,ECD,2024May17,Yes,No,,4.0,NCT05498155,,,"Complete response, Pathological complete response",80.0,80.0,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,COSO28394862,2022Nov28,COSO28394862,breast,NS,NS,NS,carcinoma,NS,NS,NS
1488.0,BRCA1,BRCA1_unspecified or BRCA2_unspecified,,,,breast / carcinoma / NS,1.0,Phase 2,Olaparib,,Recruiting,NCT05498155,OlympiaN Cohort A,ECD,2024May17,Yes,No,,4.0,NCT05498155,,,"Complete response, Pathological complete response",80.0,80.0,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,COSO28394862,2022Nov28,COSO28394862,breast,NS,NS,NS,carcinoma,NS,NS,NS
1489.0,BRCA1,BRCA1_unspecified or BRCA2_unspecified,,,,breast / carcinoma / NS,1.0,Phase 2,Olaparib,,Recruiting,NCT05498155,OlympiaN Cohort A,ECD,2024May17,Yes,No,,4.0,NCT05498155,,,"Complete response, Pathological complete response",80.0,80.0,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,COSO28394862,2022Nov28,COSO28394862,breast,NS,NS,NS,carcinoma,NS,NS,NS
1490.0,BRCA1,BRCA1_unspecified or BRCA2_unspecified,,,,breast / carcinoma / NS,1.0,Phase 2,Olaparib,,Recruiting,NCT05498155,OlympiaN Cohort A,ECD,2024May17,Yes,No,,4.0,NCT05498155,,,"Complete response, Pathological complete response",80.0,80.0,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,COSO28394862,2022Nov28,COSO28394862,breast,NS,NS,NS,carcinoma,NS,NS,NS
1491.0,BRCA1,BRCA1_unspecified or BRCA2_unspecified,,,,breast / carcinoma / NS,1.0,Phase 2,Olaparib,,Recruiting,NCT05498155,OlympiaN Cohort A,ECD,2024May17,Yes,No,,4.0,NCT05498155,,,"Complete response, Pathological complete response",80.0,80.0,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,COSO28394862,2022Nov28,COSO28394862,breast,NS,NS,NS,carcinoma,NS,NS,NS
1492.0,BRCA1,BRCA1_unspecified or BRCA2_unspecified,,,,breast / carcinoma / NS,1.0,Phase 2,Olaparib,,Recruiting,NCT05498155,OlympiaN Cohort A,ECD,2024May17,Yes,No,,4.0,NCT05498155,,,"Complete response, Pathological complete response",80.0,80.0,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,COSO28394862,2022Nov28,COSO28394862,breast,NS,NS,NS,carcinoma,NS,NS,NS
1493.0,BRCA1,BRCA1_unspecified or BRCA2_unspecified,,,,breast / carcinoma / NS,1.0,Phase 2,Olaparib,,Recruiting,NCT05498155,OlympiaN Cohort A,ECD,2024May17,Yes,No,,4.0,NCT05498155,,,"Complete response, Pathological complete response",80.0,80.0,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,COSO28394862,2022Nov28,COSO28394862,breast,NS,NS,NS,carcinoma,NS,NS,NS
1494.0,BRCA1,BRCA1_unspecified or BRCA2_unspecified,,,,breast / carcinoma / NS,1.0,Phase 2,Olaparib,,Recruiting,NCT05498155,OlympiaN Cohort A,ECD,2024May17,Yes,No,,4.0,NCT05498155,,,"Complete response, Pathological complete response",80.0,80.0,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,COSO28394862,2022Nov28,COSO28394862,breast,NS,NS,NS,carcinoma,NS,NS,NS
1495.0,BRCA1,BRCA1_unspecified or BRCA2_unspecified,,,,breast / carcinoma / NS,1.0,Phase 2,Olaparib,,Unknown,NCT02681562,OLTRE,ECD,2018Jan01,Yes,No,,4.0,NCT02681562,,,Unknown,45.0,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,COSO28394862,2022May03,COSO28394862,breast,NS,NS,NS,carcinoma,NS,NS,NS
1496.0,BRCA1,BRCA1_unspecified or BRCA2_unspecified,,,,breast / carcinoma / NS,1.0,Phase 2,Olaparib,,Unknown,NCT02681562,OLTRE,ECD,2018Jan01,Yes,No,,4.0,NCT02681562,,,Unknown,45.0,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,COSO28394862,2022May03,COSO28394862,breast,NS,NS,NS,carcinoma,NS,NS,NS
1497.0,BRCA1,BRCA1_unspecified or BRCA2_unspecified,,,,breast / carcinoma / NS,1.0,Phase 2,Olaparib,,Unknown,NCT02681562,OLTRE,ECD,2018Jan01,Yes,No,,4.0,NCT02681562,,,Unknown,45.0,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,COSO28394862,2022May03,COSO28394862,breast,NS,NS,NS,carcinoma,NS,NS,NS
1498.0,BRCA1,BRCA1_unspecified or BRCA2_unspecified,,,,breast / carcinoma / NS,1.0,Phase 2,Olaparib,,Unknown,NCT02681562,OLTRE,ECD,2018Jan01,Yes,No,,4.0,NCT02681562,,,Unknown,45.0,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,COSO28394862,2022May03,COSO28394862,breast,NS,NS,NS,carcinoma,NS,NS,NS
1499.0,BRCA1,BRCA1_unspecified or BRCA2_unspecified,,,,breast / carcinoma / NS,1.0,Phase 2,Olaparib,,Unknown,NCT02681562,OLTRE,ECD,2018Jan01,Yes,No,,4.0,NCT02681562,,,Unknown,45.0,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,COSO28394862,2022May03,COSO28394862,breast,NS,NS,NS,carcinoma,NS,NS,NS
1500.0,BRCA1,BRCA1_unspecified or BRCA2_unspecified,,,,breast / carcinoma / NS,1.0,Phase 2,Olaparib,,Unknown,NCT02681562,OLTRE,ECD,2018Jan01,Yes,No,,4.0,NCT02681562,,,Unknown,45.0,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,COSO28394862,2022May03,COSO28394862,breast,NS,NS,NS,carcinoma,NS,NS,NS
1501.0,BRCA1,BRCA1_unspecified or BRCA2_unspecified,,,,breast / carcinoma / NS,1.0,Phase 2,Olaparib,,Unknown,NCT02681562,OLTRE,ECD,2018Jan01,Yes,No,,4.0,NCT02681562,,,Unknown,45.0,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,COSO28394862,2022May03,COSO28394862,breast,NS,NS,NS,carcinoma,NS,NS,NS
1502.0,BRCA1,BRCA1_unspecified or BRCA2_unspecified,,,,breast / carcinoma / NS,1.0,Phase 2,Olaparib,,Unknown,NCT02681562,OLTRE,ECD,2018Jan01,Yes,No,,4.0,NCT02681562,,,Unknown,45.0,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,COSO28394862,2022May03,COSO28394862,breast,NS,NS,NS,carcinoma,NS,NS,NS
1503.0,BRCA1,BRCA1_unspecified or BRCA2_unspecified,,,,breast / carcinoma / NS,1.0,Phase 2,Olaparib,,Unknown,NCT02681562,OLTRE,ECD,2018Jan01,Yes,No,,4.0,NCT02681562,,,Unknown,45.0,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,COSO28394862,2022May03,COSO28394862,breast,NS,NS,NS,carcinoma,NS,NS,NS
1504.0,BRCA1,BRCA1_unspecified or BRCA2_unspecified,,,,breast / carcinoma / NS,1.0,Phase 2,Olaparib,,Unknown,NCT02681562,OLTRE,ECD,2018Jan01,Yes,No,,4.0,NCT02681562,,,Unknown,45.0,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,COSO28394862,2022May03,COSO28394862,breast,NS,NS,NS,carcinoma,NS,NS,NS
1505.0,BRCA1,BRCA1_unspecified or BRCA2_unspecified,,,,breast / carcinoma / NS,1.0,Phase 2,Olaparib,,Unknown,NCT02681562,OLTRE,ECD,2018Jan01,Yes,No,,4.0,NCT02681562,,,Unknown,45.0,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,COSO28394862,2022May03,COSO28394862,breast,NS,NS,NS,carcinoma,NS,NS,NS
1506.0,BRCA1,BRCA1_unspecified or BRCA2_unspecified,,,,breast / carcinoma / NS,1.0,Phase 2,Olaparib,,Unknown,NCT02681562,OLTRE,ECD,2018Jan01,Yes,No,,4.0,NCT02681562,,,Unknown,45.0,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,COSO28394862,2022May03,COSO28394862,breast,NS,NS,NS,carcinoma,NS,NS,NS
1507.0,BRCA1,BRCA1_unspecified or BRCA2_unspecified,,,,breast / carcinoma / NS,1.0,Phase 2,Olaparib,,Unknown,NCT02681562,OLTRE,ECD,2018Jan01,Yes,No,,4.0,NCT02681562,,,Unknown,45.0,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,COSO28394862,2022May03,COSO28394862,breast,NS,NS,NS,carcinoma,NS,NS,NS
1508.0,BRCA1,BRCA1_unspecified or BRCA2_unspecified,,,,breast / carcinoma / NS,1.0,Phase 2,Olaparib,,Withdrawn,NCT01661868,,PCD,2012Aug01,Yes,Yes,Drug unavailable,4.0,NCT01661868,,,Response rate,0.0,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,COSO28394862,2022Feb21,COSO28394862,breast,NS,NS,NS,carcinoma,NS,NS,NS
1509.0,BRCA1,BRCA1_unspecified or BRCA2_unspecified,,,,breast / carcinoma / NS,1.0,Phase 2,Olaparib,,Withdrawn,NCT01661868,,PCD,2012Aug01,Yes,Yes,Drug unavailable,4.0,NCT01661868,,,Response rate,0.0,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,COSO28394862,2022Feb21,COSO28394862,breast,NS,NS,NS,carcinoma,NS,NS,NS
1510.0,BRCA1,BRCA1_unspecified or BRCA2_unspecified,,,,breast / carcinoma / NS,1.0,Phase 2,Olaparib,,Withdrawn,NCT01661868,,PCD,2012Aug01,Yes,Yes,Drug unavailable,4.0,NCT01661868,,,Response rate,0.0,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,COSO28394862,2022Feb21,COSO28394862,breast,NS,NS,NS,carcinoma,NS,NS,NS
1511.0,BRCA1,BRCA1_unspecified or BRCA2_unspecified,,,,breast / carcinoma / NS,1.0,Phase 2,Olaparib,,Withdrawn,NCT01661868,,PCD,2012Aug01,Yes,Yes,Drug unavailable,4.0,NCT01661868,,,Response rate,0.0,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,COSO28394862,2022Feb21,COSO28394862,breast,NS,NS,NS,carcinoma,NS,NS,NS
1512.0,BRCA1,BRCA1_unspecified or BRCA2_unspecified,,,,breast / carcinoma / NS,1.0,Phase 2,Olaparib,,Withdrawn,NCT01661868,,PCD,2012Aug01,Yes,Yes,Drug unavailable,4.0,NCT01661868,,,Response rate,0.0,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,COSO28394862,2022Feb21,COSO28394862,breast,NS,NS,NS,carcinoma,NS,NS,NS
1513.0,BRCA1,BRCA1_unspecified or BRCA2_unspecified,,,,breast / carcinoma / NS,1.0,Phase 2,Olaparib,,Withdrawn,NCT01661868,,PCD,2012Aug01,Yes,Yes,Drug unavailable,4.0,NCT01661868,,,Response rate,0.0,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,COSO28394862,2022Feb21,COSO28394862,breast,NS,NS,NS,carcinoma,NS,NS,NS
1514.0,BRCA1,BRCA1_unspecified or BRCA2_unspecified,,,,breast / carcinoma / NS,1.0,Phase 2,Olaparib,,Withdrawn,NCT01661868,,PCD,2012Aug01,Yes,Yes,Drug unavailable,4.0,NCT01661868,,,Response rate,0.0,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,COSO28394862,2022Feb21,COSO28394862,breast,NS,NS,NS,carcinoma,NS,NS,NS
1515.0,BRCA1,BRCA1_unspecified or BRCA2_unspecified,,,,breast / carcinoma / NS,1.0,Phase 2,Olaparib,,Withdrawn,NCT01661868,,PCD,2012Aug01,Yes,Yes,Drug unavailable,4.0,NCT01661868,,,Response rate,0.0,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,COSO28394862,2022Feb21,COSO28394862,breast,NS,NS,NS,carcinoma,NS,NS,NS
1516.0,BRCA1,BRCA1_unspecified or BRCA2_unspecified,,,,breast / carcinoma / NS,1.0,Phase 2,Olaparib,,Withdrawn,NCT01661868,,PCD,2012Aug01,Yes,Yes,Drug unavailable,4.0,NCT01661868,,,Response rate,0.0,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,COSO28394862,2022Feb21,COSO28394862,breast,NS,NS,NS,carcinoma,NS,NS,NS
1517.0,BRCA1,BRCA1_unspecified or BRCA2_unspecified,,,,breast / carcinoma / NS,1.0,Phase 2,Olaparib,,Withdrawn,NCT01661868,,PCD,2012Aug01,Yes,Yes,Drug unavailable,4.0,NCT01661868,,,Response rate,0.0,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,COSO28394862,2022Feb21,COSO28394862,breast,NS,NS,NS,carcinoma,NS,NS,NS
1518.0,BRCA1,BRCA1_unspecified or BRCA2_unspecified,,,,breast / carcinoma / NS,1.0,Phase 2,Olaparib,,Withdrawn,NCT01661868,,PCD,2012Aug01,Yes,Yes,Drug unavailable,4.0,NCT01661868,,,Response rate,0.0,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,COSO28394862,2022Feb21,COSO28394862,breast,NS,NS,NS,carcinoma,NS,NS,NS
1519.0,BRCA1,BRCA1_unspecified or BRCA2_unspecified,,,,breast / carcinoma / NS,1.0,Phase 2,Olaparib,,Withdrawn,NCT01661868,,PCD,2012Aug01,Yes,Yes,Drug unavailable,4.0,NCT01661868,,,Response rate,0.0,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,COSO28394862,2022Feb21,COSO28394862,breast,NS,NS,NS,carcinoma,NS,NS,NS
1520.0,BRCA1,BRCA1_unspecified or BRCA2_unspecified,,,,breast / carcinoma / NS,1.0,Phase 2,Olaparib,,Withdrawn,NCT01661868,,PCD,2012Aug01,Yes,Yes,Drug unavailable,4.0,NCT01661868,,,Response rate,0.0,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,COSO28394862,2022Feb21,COSO28394862,breast,NS,NS,NS,carcinoma,NS,NS,NS
1521.0,BRCA1,BRCA1_unspecified or BRCA2_unspecified,,,,breast / carcinoma / NS,1.0,Phase 2,Olaparib,,"Active, not recruiting",NCT02849496,,ECD,2023Aug31,No,No,,4.0,NCT02849496,,,Progression free survival,81.0,81.0,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,COSO28394862,2022Nov28,COSO28394862,breast,NS,NS,NS,carcinoma,NS,NS,NS
1522.0,BRCA1,BRCA1_unspecified or BRCA2_unspecified,,,,breast / carcinoma / NS,1.0,Phase 2,Olaparib,,"Active, not recruiting",NCT02849496,,ECD,2023Aug31,No,No,,4.0,NCT02849496,,,Progression free survival,81.0,81.0,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,COSO28394862,2022Nov28,COSO28394862,breast,NS,NS,NS,carcinoma,NS,NS,NS
1523.0,BRCA1,BRCA1_unspecified or BRCA2_unspecified,,,,breast / carcinoma / NS,1.0,Phase 2,Olaparib,,"Active, not recruiting",NCT02849496,,ECD,2023Aug31,No,No,,4.0,NCT02849496,,,Progression free survival,81.0,81.0,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,COSO28394862,2022Nov28,COSO28394862,breast,NS,NS,NS,carcinoma,NS,NS,NS
1524.0,BRCA1,BRCA1_unspecified or BRCA2_unspecified,,,,breast / carcinoma / NS,1.0,Phase 2,Olaparib,,"Active, not recruiting",NCT02849496,,ECD,2023Aug31,No,No,,4.0,NCT02849496,,,Progression free survival,81.0,81.0,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,COSO28394862,2022Nov28,COSO28394862,breast,NS,NS,NS,carcinoma,NS,NS,NS
1525.0,BRCA1,BRCA1_unspecified or BRCA2_unspecified,,,,breast / carcinoma / NS,1.0,Phase 2,Olaparib,,"Active, not recruiting",NCT02849496,,ECD,2023Aug31,No,No,,4.0,NCT02849496,,,Progression free survival,81.0,81.0,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,COSO28394862,2022Nov28,COSO28394862,breast,NS,NS,NS,carcinoma,NS,NS,NS
1526.0,BRCA1,BRCA1_unspecified or BRCA2_unspecified,,,,breast / carcinoma / NS,1.0,Phase 2,Olaparib,,"Active, not recruiting",NCT02849496,,ECD,2023Aug31,No,No,,4.0,NCT02849496,,,Progression free survival,81.0,81.0,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,COSO28394862,2022Nov28,COSO28394862,breast,NS,NS,NS,carcinoma,NS,NS,NS
1527.0,BRCA1,BRCA1_unspecified or BRCA2_unspecified,,,,breast / carcinoma / NS,1.0,Phase 2,Olaparib,,"Active, not recruiting",NCT02849496,,ECD,2023Aug31,No,No,,4.0,NCT02849496,,,Progression free survival,81.0,81.0,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,COSO28394862,2022Nov28,COSO28394862,breast,NS,NS,NS,carcinoma,NS,NS,NS
1528.0,BRCA1,BRCA1_unspecified or BRCA2_unspecified,,,,breast / carcinoma / NS,1.0,Phase 2,Olaparib,,"Active, not recruiting",NCT02849496,,ECD,2023Aug31,No,No,,4.0,NCT02849496,,,Progression free survival,81.0,81.0,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,COSO28394862,2022Nov28,COSO28394862,breast,NS,NS,NS,carcinoma,NS,NS,NS
1529.0,BRCA1,BRCA1_unspecified or BRCA2_unspecified,,,,breast / carcinoma / NS,1.0,Phase 2,Olaparib,,"Active, not recruiting",NCT02849496,,ECD,2023Aug31,No,No,,4.0,NCT02849496,,,Progression free survival,81.0,81.0,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,COSO28394862,2022Nov28,COSO28394862,breast,NS,NS,NS,carcinoma,NS,NS,NS
1530.0,BRCA1,BRCA1_unspecified or BRCA2_unspecified,,,,breast / carcinoma / NS,1.0,Phase 2,Olaparib,,"Active, not recruiting",NCT02849496,,ECD,2023Aug31,No,No,,4.0,NCT02849496,,,Progression free survival,81.0,81.0,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,COSO28394862,2022Nov28,COSO28394862,breast,NS,NS,NS,carcinoma,NS,NS,NS
1531.0,BRCA1,BRCA1_unspecified or BRCA2_unspecified,,,,breast / carcinoma / NS,1.0,Phase 2,Olaparib,,"Active, not recruiting",NCT02849496,,ECD,2023Aug31,No,No,,4.0,NCT02849496,,,Progression free survival,81.0,81.0,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,COSO28394862,2022Nov28,COSO28394862,breast,NS,NS,NS,carcinoma,NS,NS,NS
1532.0,BRCA1,BRCA1_unspecified or BRCA2_unspecified,,,,breast / carcinoma / NS,1.0,Phase 2,Olaparib,,"Active, not recruiting",NCT02849496,,ECD,2023Aug31,No,No,,4.0,NCT02849496,,,Progression free survival,81.0,81.0,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,COSO28394862,2022Nov28,COSO28394862,breast,NS,NS,NS,carcinoma,NS,NS,NS
1533.0,BRCA1,BRCA1_unspecified or BRCA2_unspecified,,,,breast / carcinoma / NS,1.0,Phase 2,Olaparib,,"Active, not recruiting",NCT02849496,,ECD,2023Aug31,No,No,,4.0,NCT02849496,,,Progression free survival,81.0,81.0,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,COSO28394862,2022Nov28,COSO28394862,breast,NS,NS,NS,carcinoma,NS,NS,NS
1534.0,BRCA1,BRCA1_unspecified or BRCA2_unspecified,,,,breast / carcinoma / NS,1.0,Phase 3,Olaparib,,Completed,NCT03286842,LUCY,PCD,2021Oct08,Yes,Yes,,1.0,34087573,,,,256.0,256.0,,,,,,,,,,,8.11,,,6.93?8.67,,,,,,,,,,,,,,,,,,,,,,,,,,,COSO28394862,2022May03,COSO28394862,breast,NS,NS,NS,carcinoma,NS,NS,NS
1535.0,BRCA1,BRCA1_unspecified or BRCA2_unspecified,,,,breast / carcinoma / NS,1.0,Phase 3,Olaparib,,Completed,NCT03286842,LUCY,PCD,2021Oct08,Yes,Yes,,1.0,34087573,,,,256.0,256.0,,,,,,,,,,,8.11,,,6.93?8.67,,,,,,,,,,,,,,,,,,,,,,,,,,,COSO28394862,2022May03,COSO28394862,breast,NS,NS,NS,carcinoma,NS,NS,NS
1536.0,BRCA1,BRCA1_unspecified or BRCA2_unspecified,,,,breast / carcinoma / NS,1.0,Phase 3,Olaparib,,Completed,NCT03286842,LUCY,PCD,2021Oct08,Yes,Yes,,1.0,34087573,,,,256.0,256.0,,,,,,,,,,,8.11,,,6.93?8.67,,,,,,,,,,,,,,,,,,,,,,,,,,,COSO28394862,2022May03,COSO28394862,breast,NS,NS,NS,carcinoma,NS,NS,NS
1537.0,BRCA1,BRCA1_unspecified or BRCA2_unspecified,,,,breast / carcinoma / NS,1.0,Phase 3,Olaparib,,Completed,NCT03286842,LUCY,PCD,2021Oct08,Yes,Yes,,1.0,34087573,,,,256.0,256.0,,,,,,,,,,,8.11,,,6.93?8.67,,,,,,,,,,,,,,,,,,,,,,,,,,,COSO28394862,2022May03,COSO28394862,breast,NS,NS,NS,carcinoma,NS,NS,NS
1538.0,BRCA1,BRCA1_unspecified or BRCA2_unspecified,,,,breast / carcinoma / NS,1.0,Phase 3,Olaparib,,Completed,NCT03286842,LUCY,PCD,2021Oct08,Yes,Yes,,1.0,34087573,,,,256.0,256.0,,,,,,,,,,,8.11,,,6.93?8.67,,,,,,,,,,,,,,,,,,,,,,,,,,,COSO28394862,2022May03,COSO28394862,breast,NS,NS,NS,carcinoma,NS,NS,NS
1539.0,BRCA1,BRCA1_unspecified or BRCA2_unspecified,,,,breast / carcinoma / NS,1.0,Phase 3,Olaparib,,Completed,NCT03286842,LUCY,PCD,2021Oct08,Yes,Yes,,1.0,34087573,,,,256.0,256.0,,,,,,,,,,,8.11,,,6.93?8.67,,,,,,,,,,,,,,,,,,,,,,,,,,,COSO28394862,2022May03,COSO28394862,breast,NS,NS,NS,carcinoma,NS,NS,NS
1540.0,BRCA1,BRCA1_unspecified or BRCA2_unspecified,,,,breast / carcinoma / NS,1.0,Phase 3,Olaparib,,Completed,NCT03286842,LUCY,PCD,2021Oct08,Yes,Yes,,1.0,34087573,,,,256.0,256.0,,,,,,,,,,,8.11,,,6.93?8.67,,,,,,,,,,,,,,,,,,,,,,,,,,,COSO28394862,2022May03,COSO28394862,breast,NS,NS,NS,carcinoma,NS,NS,NS
1541.0,BRCA1,BRCA1_unspecified or BRCA2_unspecified,,,,breast / carcinoma / NS,1.0,Phase 3,Olaparib,,Completed,NCT03286842,LUCY,PCD,2021Oct08,Yes,Yes,,1.0,34087573,,,,256.0,256.0,,,,,,,,,,,8.11,,,6.93?8.67,,,,,,,,,,,,,,,,,,,,,,,,,,,COSO28394862,2022May03,COSO28394862,breast,NS,NS,NS,carcinoma,NS,NS,NS
1542.0,BRCA1,BRCA1_unspecified or BRCA2_unspecified,,,,breast / carcinoma / NS,1.0,Phase 3,Olaparib,,Completed,NCT03286842,LUCY,PCD,2021Oct08,Yes,Yes,,1.0,34087573,,,,256.0,256.0,,,,,,,,,,,8.11,,,6.93?8.67,,,,,,,,,,,,,,,,,,,,,,,,,,,COSO28394862,2022May03,COSO28394862,breast,NS,NS,NS,carcinoma,NS,NS,NS
1543.0,BRCA1,BRCA1_unspecified or BRCA2_unspecified,,,,breast / carcinoma / NS,1.0,Phase 3,Olaparib,,Completed,NCT03286842,LUCY,PCD,2021Oct08,Yes,Yes,,1.0,34087573,,,,256.0,256.0,,,,,,,,,,,8.11,,,6.93?8.67,,,,,,,,,,,,,,,,,,,,,,,,,,,COSO28394862,2022May03,COSO28394862,breast,NS,NS,NS,carcinoma,NS,NS,NS
1544.0,BRCA1,BRCA1_unspecified or BRCA2_unspecified,,,,breast / carcinoma / NS,1.0,Phase 3,Olaparib,,Completed,NCT03286842,LUCY,PCD,2021Oct08,Yes,Yes,,1.0,34087573,,,,256.0,256.0,,,,,,,,,,,8.11,,,6.93?8.67,,,,,,,,,,,,,,,,,,,,,,,,,,,COSO28394862,2022May03,COSO28394862,breast,NS,NS,NS,carcinoma,NS,NS,NS
1545.0,BRCA1,BRCA1_unspecified or BRCA2_unspecified,,,,breast / carcinoma / NS,1.0,Phase 3,Olaparib,,Completed,NCT03286842,LUCY,PCD,2021Oct08,Yes,Yes,,1.0,34087573,,,,256.0,256.0,,,,,,,,,,,8.11,,,6.93?8.67,,,,,,,,,,,,,,,,,,,,,,,,,,,COSO28394862,2022May03,COSO28394862,breast,NS,NS,NS,carcinoma,NS,NS,NS
1546.0,BRCA1,BRCA1_unspecified or BRCA2_unspecified,,,,breast / carcinoma / NS,1.0,Phase 3,Olaparib,,Completed,NCT03286842,LUCY,PCD,2021Oct08,Yes,Yes,,1.0,34087573,,,,256.0,256.0,,,,,,,,,,,8.11,,,6.93?8.67,,,,,,,,,,,,,,,,,,,,,,,,,,,COSO28394862,2022May03,COSO28394862,breast,NS,NS,NS,carcinoma,NS,NS,NS
1651.0,BRCA1,BRCA1_unspecified or BRCA2_unspecified,,,,breast / carcinoma / NS,1.0,Phase 4,Olaparib,,Completed,NCT04330040,SOLI,PCD,2022Sep30,Yes,No,,4.0,NCT04330040,Previously-treated,,Maximum tolerated dose/toxicity,162.0,162.0,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,COSO28394862,2022Nov28,COSO28394862,breast,NS,NS,NS,carcinoma,NS,NS,NS
1652.0,BRCA1,BRCA1_unspecified or BRCA2_unspecified,,,,breast / carcinoma / NS,1.0,Phase 4,Olaparib,,Completed,NCT04330040,SOLI,PCD,2022Sep30,Yes,No,,4.0,NCT04330040,Previously-treated,,Maximum tolerated dose/toxicity,162.0,162.0,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,COSO28394862,2022Nov28,COSO28394862,breast,NS,NS,NS,carcinoma,NS,NS,NS
1653.0,BRCA1,BRCA1_unspecified or BRCA2_unspecified,,,,breast / carcinoma / NS,1.0,Phase 4,Olaparib,,Completed,NCT04330040,SOLI,PCD,2022Sep30,Yes,No,,4.0,NCT04330040,Previously-treated,,Maximum tolerated dose/toxicity,162.0,162.0,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,COSO28394862,2022Nov28,COSO28394862,breast,NS,NS,NS,carcinoma,NS,NS,NS
1654.0,BRCA1,BRCA1_unspecified or BRCA2_unspecified,,,,breast / carcinoma / NS,1.0,Phase 4,Olaparib,,Completed,NCT04330040,SOLI,PCD,2022Sep30,Yes,No,,4.0,NCT04330040,Previously-treated,,Maximum tolerated dose/toxicity,162.0,162.0,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,COSO28394862,2022Nov28,COSO28394862,breast,NS,NS,NS,carcinoma,NS,NS,NS
1655.0,BRCA1,BRCA1_unspecified or BRCA2_unspecified,,,,breast / carcinoma / NS,1.0,Phase 4,Olaparib,,Completed,NCT04330040,SOLI,PCD,2022Sep30,Yes,No,,4.0,NCT04330040,Previously-treated,,Maximum tolerated dose/toxicity,162.0,162.0,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,COSO28394862,2022Nov28,COSO28394862,breast,NS,NS,NS,carcinoma,NS,NS,NS
1656.0,BRCA1,BRCA1_unspecified or BRCA2_unspecified,,,,breast / carcinoma / NS,1.0,Phase 4,Olaparib,,Completed,NCT04330040,SOLI,PCD,2022Sep30,Yes,No,,4.0,NCT04330040,Previously-treated,,Maximum tolerated dose/toxicity,162.0,162.0,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,COSO28394862,2022Nov28,COSO28394862,breast,NS,NS,NS,carcinoma,NS,NS,NS
1657.0,BRCA1,BRCA1_unspecified or BRCA2_unspecified,,,,breast / carcinoma / NS,1.0,Phase 4,Olaparib,,Completed,NCT04330040,SOLI,PCD,2022Sep30,Yes,No,,4.0,NCT04330040,Previously-treated,,Maximum tolerated dose/toxicity,162.0,162.0,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,COSO28394862,2022Nov28,COSO28394862,breast,NS,NS,NS,carcinoma,NS,NS,NS
1658.0,BRCA1,BRCA1_unspecified or BRCA2_unspecified,,,,breast / carcinoma / NS,1.0,Phase 4,Olaparib,,Completed,NCT04330040,SOLI,PCD,2022Sep30,Yes,No,,4.0,NCT04330040,Previously-treated,,Maximum tolerated dose/toxicity,162.0,162.0,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,COSO28394862,2022Nov28,COSO28394862,breast,NS,NS,NS,carcinoma,NS,NS,NS
1659.0,BRCA1,BRCA1_unspecified or BRCA2_unspecified,,,,breast / carcinoma / NS,1.0,Phase 4,Olaparib,,Completed,NCT04330040,SOLI,PCD,2022Sep30,Yes,No,,4.0,NCT04330040,Previously-treated,,Maximum tolerated dose/toxicity,162.0,162.0,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,COSO28394862,2022Nov28,COSO28394862,breast,NS,NS,NS,carcinoma,NS,NS,NS
1660.0,BRCA1,BRCA1_unspecified or BRCA2_unspecified,,,,breast / carcinoma / NS,1.0,Phase 4,Olaparib,,Completed,NCT04330040,SOLI,PCD,2022Sep30,Yes,No,,4.0,NCT04330040,Previously-treated,,Maximum tolerated dose/toxicity,162.0,162.0,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,COSO28394862,2022Nov28,COSO28394862,breast,NS,NS,NS,carcinoma,NS,NS,NS
1661.0,BRCA1,BRCA1_unspecified or BRCA2_unspecified,,,,breast / carcinoma / NS,1.0,Phase 4,Olaparib,,Completed,NCT04330040,SOLI,PCD,2022Sep30,Yes,No,,4.0,NCT04330040,Previously-treated,,Maximum tolerated dose/toxicity,162.0,162.0,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,COSO28394862,2022Nov28,COSO28394862,breast,NS,NS,NS,carcinoma,NS,NS,NS
1662.0,BRCA1,BRCA1_unspecified or BRCA2_unspecified,,,,breast / carcinoma / NS,1.0,Phase 4,Olaparib,,Completed,NCT04330040,SOLI,PCD,2022Sep30,Yes,No,,4.0,NCT04330040,Previously-treated,,Maximum tolerated dose/toxicity,162.0,162.0,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,COSO28394862,2022Nov28,COSO28394862,breast,NS,NS,NS,carcinoma,NS,NS,NS
1663.0,BRCA1,BRCA1_unspecified or BRCA2_unspecified,,,,breast / carcinoma / NS,1.0,Phase 4,Olaparib,,Completed,NCT04330040,SOLI,PCD,2022Sep30,Yes,No,,4.0,NCT04330040,Previously-treated,,Maximum tolerated dose/toxicity,162.0,162.0,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,COSO28394862,2022Nov28,COSO28394862,breast,NS,NS,NS,carcinoma,NS,NS,NS
1742.0,BRCA2,BRCA2_unspecified,,,,breast / carcinoma / NS,3.0,Phase 2,Olaparib,,Completed,NCT00679783,,PCD,2010Mar26,Yes,Yes,,1.0,21862407,Previously-treated,,Overall Response Rate,5.0,5.0,,,0.0,,,,,,,,,,,,,,,,,,,,,,,,,,,0.0,0.0,3.0,,,,,,,,,COSO28394862,2022Nov28,COSO28394862,breast,NS,NS,NS,carcinoma,NS,NS,NS
1743.0,BRCA2,BRCA2_unspecified,,,,breast / carcinoma / NS,3.0,Phase 2,Olaparib,,Completed,NCT00679783,,PCD,2010Mar26,Yes,Yes,,1.0,21862407,Previously-treated,,Overall Response Rate,5.0,5.0,,,0.0,,,,,,,,,,,,,,,,,,,,,,,,,,,0.0,0.0,3.0,,,,,,,,,COSO28394862,2022Nov28,COSO28394862,breast,NS,NS,NS,carcinoma,NS,NS,NS
1744.0,BRCA2,BRCA2_unspecified,,,,breast / carcinoma / NS,3.0,Phase 2,Olaparib,,Completed,NCT00679783,,PCD,2010Mar26,Yes,Yes,,1.0,21862407,Previously-treated,,Overall Response Rate,5.0,5.0,,,0.0,,,,,,,,,,,,,,,,,,,,,,,,,,,0.0,0.0,3.0,,,,,,,,,COSO28394862,2022Nov28,COSO28394862,breast,NS,NS,NS,carcinoma,NS,NS,NS
1745.0,BRCA2,BRCA2_unspecified,,,,breast / carcinoma / NS,3.0,Phase 2,Olaparib,,Completed,NCT00679783,,PCD,2010Mar26,Yes,Yes,,1.0,21862407,Previously-treated,,Overall Response Rate,5.0,5.0,,,0.0,,,,,,,,,,,,,,,,,,,,,,,,,,,0.0,0.0,3.0,,,,,,,,,COSO28394862,2022Nov28,COSO28394862,breast,NS,NS,NS,carcinoma,NS,NS,NS
1746.0,BRCA2,BRCA2_unspecified,,,,breast / carcinoma / NS,3.0,Phase 2,Olaparib,,Completed,NCT00679783,,PCD,2010Mar26,Yes,Yes,,1.0,21862407,Previously-treated,,Overall Response Rate,5.0,5.0,,,0.0,,,,,,,,,,,,,,,,,,,,,,,,,,,0.0,0.0,3.0,,,,,,,,,COSO28394862,2022Nov28,COSO28394862,breast,NS,NS,NS,carcinoma,NS,NS,NS
1747.0,BRCA2,BRCA2_unspecified,,,,breast / carcinoma / NS,3.0,Phase 2,Olaparib,,Completed,NCT00679783,,PCD,2010Mar26,Yes,Yes,,1.0,21862407,Previously-treated,,Overall Response Rate,5.0,5.0,,,0.0,,,,,,,,,,,,,,,,,,,,,,,,,,,0.0,0.0,3.0,,,,,,,,,COSO28394862,2022Nov28,COSO28394862,breast,NS,NS,NS,carcinoma,NS,NS,NS
1748.0,BRCA2,BRCA2_unspecified,,,,breast / carcinoma / NS,3.0,Phase 2,Olaparib,,Completed,NCT00679783,,PCD,2010Mar26,Yes,Yes,,1.0,21862407,Previously-treated,,Overall Response Rate,5.0,5.0,,,0.0,,,,,,,,,,,,,,,,,,,,,,,,,,,0.0,0.0,3.0,,,,,,,,,COSO28394862,2022Nov28,COSO28394862,breast,NS,NS,NS,carcinoma,NS,NS,NS
1749.0,BRCA2,BRCA2_unspecified,,,,breast / carcinoma / NS,3.0,Phase 2,Olaparib,,Completed,NCT00679783,,PCD,2010Mar26,Yes,Yes,,1.0,21862407,Previously-treated,,Overall Response Rate,5.0,5.0,,,0.0,,,,,,,,,,,,,,,,,,,,,,,,,,,0.0,0.0,3.0,,,,,,,,,COSO28394862,2022Nov28,COSO28394862,breast,NS,NS,NS,carcinoma,NS,NS,NS
1750.0,BRCA2,BRCA2_unspecified,,,,breast / carcinoma / NS,3.0,Phase 2,Olaparib,,Completed,NCT00679783,,PCD,2010Mar26,Yes,Yes,,1.0,21862407,Previously-treated,,Overall Response Rate,5.0,5.0,,,0.0,,,,,,,,,,,,,,,,,,,,,,,,,,,0.0,0.0,3.0,,,,,,,,,COSO28394862,2022Nov28,COSO28394862,breast,NS,NS,NS,carcinoma,NS,NS,NS
1751.0,BRCA2,BRCA2_unspecified,,,,breast / carcinoma / NS,3.0,Phase 2,Olaparib,,Completed,NCT00679783,,PCD,2010Mar26,Yes,Yes,,1.0,21862407,Previously-treated,,Overall Response Rate,5.0,5.0,,,0.0,,,,,,,,,,,,,,,,,,,,,,,,,,,0.0,0.0,3.0,,,,,,,,,COSO28394862,2022Nov28,COSO28394862,breast,NS,NS,NS,carcinoma,NS,NS,NS
1752.0,BRCA2,BRCA2_unspecified,,,,breast / carcinoma / NS,3.0,Phase 2,Olaparib,,Completed,NCT00679783,,PCD,2010Mar26,Yes,Yes,,1.0,21862407,Previously-treated,,Overall Response Rate,5.0,5.0,,,0.0,,,,,,,,,,,,,,,,,,,,,,,,,,,0.0,0.0,3.0,,,,,,,,,COSO28394862,2022Nov28,COSO28394862,breast,NS,NS,NS,carcinoma,NS,NS,NS
1753.0,BRCA2,BRCA2_unspecified,,,,breast / carcinoma / NS,3.0,Phase 2,Olaparib,,Completed,NCT00679783,,PCD,2010Mar26,Yes,Yes,,1.0,21862407,Previously-treated,,Overall Response Rate,5.0,5.0,,,0.0,,,,,,,,,,,,,,,,,,,,,,,,,,,0.0,0.0,3.0,,,,,,,,,COSO28394862,2022Nov28,COSO28394862,breast,NS,NS,NS,carcinoma,NS,NS,NS
1754.0,BRCA2,BRCA2_unspecified,,,,breast / carcinoma / NS,3.0,Phase 2,Olaparib,,Completed,NCT00679783,,PCD,2010Mar26,Yes,Yes,,1.0,21862407,Previously-treated,,Overall Response Rate,5.0,5.0,,,0.0,,,,,,,,,,,,,,,,,,,,,,,,,,,0.0,0.0,3.0,,,,,,,,,COSO28394862,2022Nov28,COSO28394862,breast,NS,NS,NS,carcinoma,NS,NS,NS
16601.0,FGFR1,FGFR1_unspecified,,,,breast / carcinoma / NS,3.0,Phase 2,Sunitinib,,Recruiting,NCT02693535,TAPUR,ECD,2024Dec31,Expression confirmed,Yes,,2.0,10.1158/1538-7445.AM2021-CT173,Previously-treated,,"Disease control rate, Clinical benefit rate",27.0,27.0,,,7.0,,1-24,,,,,,,,,,,,,,,,29.0,,,,,,,,,0.0,2.0,5.0,,,,,,,,,COSO28394862,2022Nov28,COSO28394862,breast,NS,NS,NS,carcinoma,NS,NS,NS
16602.0,FGFR1,FGFR1_unspecified,,,,breast / carcinoma / NS,3.0,Phase 2,Sunitinib,,Recruiting,NCT02693535,TAPUR,ECD,2024Dec31,Expression confirmed,Yes,,2.0,10.1158/1538-7445.AM2021-CT173,Previously-treated,,"Disease control rate, Clinical benefit rate",27.0,27.0,,,7.0,,1-24,,,,,,,,,,,,,,,,29.0,,,,,,,,,0.0,2.0,5.0,,,,,,,,,COSO28394862,2022Nov28,COSO28394862,breast,NS,NS,NS,carcinoma,NS,NS,NS
16603.0,FGFR1,FGFR1_unspecified,,,,breast / carcinoma / NS,3.0,Phase 2,Sunitinib,,Recruiting,NCT02693535,TAPUR,ECD,2024Dec31,Expression confirmed,Yes,,2.0,10.1158/1538-7445.AM2021-CT173,Previously-treated,,"Disease control rate, Clinical benefit rate",27.0,27.0,,,7.0,,1-24,,,,,,,,,,,,,,,,29.0,,,,,,,,,0.0,2.0,5.0,,,,,,,,,COSO28394862,2022Nov28,COSO28394862,breast,NS,NS,NS,carcinoma,NS,NS,NS
16604.0,FGFR1,FGFR1_unspecified,,,,breast / carcinoma / NS,3.0,Phase 2,Sunitinib,,Recruiting,NCT02693535,TAPUR,ECD,2024Dec31,Expression confirmed,Yes,,2.0,10.1158/1538-7445.AM2021-CT173,Previously-treated,,"Disease control rate, Clinical benefit rate",27.0,27.0,,,7.0,,1-24,,,,,,,,,,,,,,,,29.0,,,,,,,,,0.0,2.0,5.0,,,,,,,,,COSO28394862,2022Nov28,COSO28394862,breast,NS,NS,NS,carcinoma,NS,NS,NS
16605.0,FGFR1,FGFR1_unspecified,,,,breast / carcinoma / NS,3.0,Phase 2,Sunitinib,,Recruiting,NCT02693535,TAPUR,ECD,2024Dec31,Expression confirmed,Yes,,2.0,10.1158/1538-7445.AM2021-CT173,Previously-treated,,"Disease control rate, Clinical benefit rate",27.0,27.0,,,7.0,,1-24,,,,,,,,,,,,,,,,29.0,,,,,,,,,0.0,2.0,5.0,,,,,,,,,COSO28394862,2022Nov28,COSO28394862,breast,NS,NS,NS,carcinoma,NS,NS,NS
16606.0,FGFR1,FGFR1_unspecified,,,,breast / carcinoma / NS,3.0,Phase 2,Sunitinib,,Recruiting,NCT02693535,TAPUR,ECD,2024Dec31,Expression confirmed,Yes,,2.0,10.1158/1538-7445.AM2021-CT173,Previously-treated,,"Disease control rate, Clinical benefit rate",27.0,27.0,,,7.0,,1-24,,,,,,,,,,,,,,,,29.0,,,,,,,,,0.0,2.0,5.0,,,,,,,,,COSO28394862,2022Nov28,COSO28394862,breast,NS,NS,NS,carcinoma,NS,NS,NS
16607.0,FGFR1,FGFR1_unspecified,,,,breast / carcinoma / NS,3.0,Phase 2,Sunitinib,,Recruiting,NCT02693535,TAPUR,ECD,2024Dec31,Expression confirmed,Yes,,2.0,10.1158/1538-7445.AM2021-CT173,Previously-treated,,"Disease control rate, Clinical benefit rate",27.0,27.0,,,7.0,,1-24,,,,,,,,,,,,,,,,29.0,,,,,,,,,0.0,2.0,5.0,,,,,,,,,COSO28394862,2022Nov28,COSO28394862,breast,NS,NS,NS,carcinoma,NS,NS,NS
16608.0,FGFR1,FGFR1_unspecified,,,,breast / carcinoma / NS,3.0,Phase 2,Sunitinib,,Recruiting,NCT02693535,TAPUR,ECD,2024Dec31,Expression confirmed,Yes,,2.0,10.1158/1538-7445.AM2021-CT173,Previously-treated,,"Disease control rate, Clinical benefit rate",27.0,27.0,,,7.0,,1-24,,,,,,,,,,,,,,,,29.0,,,,,,,,,0.0,2.0,5.0,,,,,,,,,COSO28394862,2022Nov28,COSO28394862,breast,NS,NS,NS,carcinoma,NS,NS,NS
16609.0,FGFR1,FGFR1_unspecified,,,,breast / carcinoma / NS,3.0,Phase 2,Sunitinib,,Recruiting,NCT02693535,TAPUR,ECD,2024Dec31,Expression confirmed,Yes,,2.0,10.1158/1538-7445.AM2021-CT173,Previously-treated,,"Disease control rate, Clinical benefit rate",27.0,27.0,,,7.0,,1-24,,,,,,,,,,,,,,,,29.0,,,,,,,,,0.0,2.0,5.0,,,,,,,,,COSO28394862,2022Nov28,COSO28394862,breast,NS,NS,NS,carcinoma,NS,NS,NS
16610.0,FGFR1,FGFR1_unspecified,,,,breast / carcinoma / NS,3.0,Phase 2,Sunitinib,,Recruiting,NCT02693535,TAPUR,ECD,2024Dec31,Expression confirmed,Yes,,2.0,10.1158/1538-7445.AM2021-CT173,Previously-treated,,"Disease control rate, Clinical benefit rate",27.0,27.0,,,7.0,,1-24,,,,,,,,,,,,,,,,29.0,,,,,,,,,0.0,2.0,5.0,,,,,,,,,COSO28394862,2022Nov28,COSO28394862,breast,NS,NS,NS,carcinoma,NS,NS,NS
16611.0,FGFR1,FGFR1_unspecified,,,,breast / carcinoma / NS,3.0,Phase 2,Sunitinib,,Recruiting,NCT02693535,TAPUR,ECD,2024Dec31,Expression confirmed,Yes,,2.0,10.1158/1538-7445.AM2021-CT173,Previously-treated,,"Disease control rate, Clinical benefit rate",27.0,27.0,,,7.0,,1-24,,,,,,,,,,,,,,,,29.0,,,,,,,,,0.0,2.0,5.0,,,,,,,,,COSO28394862,2022Nov28,COSO28394862,breast,NS,NS,NS,carcinoma,NS,NS,NS
16612.0,FGFR1,FGFR1_unspecified,,,,breast / carcinoma / NS,3.0,Phase 2,Sunitinib,,Recruiting,NCT02693535,TAPUR,ECD,2024Dec31,Expression confirmed,Yes,,2.0,10.1158/1538-7445.AM2021-CT173,Previously-treated,,"Disease control rate, Clinical benefit rate",27.0,27.0,,,7.0,,1-24,,,,,,,,,,,,,,,,29.0,,,,,,,,,0.0,2.0,5.0,,,,,,,,,COSO28394862,2022Nov28,COSO28394862,breast,NS,NS,NS,carcinoma,NS,NS,NS
16613.0,FGFR1,FGFR1_unspecified,,,,breast / carcinoma / NS,3.0,Phase 2,Sunitinib,,Recruiting,NCT02693535,TAPUR,ECD,2024Dec31,Expression confirmed,Yes,,2.0,10.1158/1538-7445.AM2021-CT173,Previously-treated,,"Disease control rate, Clinical benefit rate",27.0,27.0,,,7.0,,1-24,,,,,,,,,,,,,,,,29.0,,,,,,,,,0.0,2.0,5.0,,,,,,,,,COSO28394862,2022Nov28,COSO28394862,breast,NS,NS,NS,carcinoma,NS,NS,NS
2860.0,ERBB2,ERBB2_unspecified,,,,breast / carcinoma / NS,2.0,Approved FDA,Trastuzumab,Required,Unknown,,Study 6,,,Overexpression,Yes,,7.0,https://www.accessdata.fda.gov/drugsatfda_docs/label/2018/103792s5345lbl.pdf,Previously-treated,,Overall Response Rate,222.0,222.0,,,14.0,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,COSO28394862,2023Jan17,COSO28394862,breast,NS,NS,NS,carcinoma,NS,NS,NS
2861.0,ERBB2,ERBB2_unspecified,,,,breast / carcinoma / NS,2.0,Approved FDA,Trastuzumab,Required,Unknown,,Study 6,,,Overexpression,Yes,,7.0,https://www.accessdata.fda.gov/drugsatfda_docs/label/2018/103792s5345lbl.pdf,Previously-treated,,Overall Response Rate,222.0,222.0,,,14.0,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,COSO28394862,2023Jan17,COSO28394862,breast,NS,NS,NS,carcinoma,NS,NS,NS
2862.0,ERBB2,ERBB2_unspecified,,,,breast / carcinoma / NS,2.0,Approved FDA,Trastuzumab,Required,Unknown,,Study 6,,,Overexpression,Yes,,7.0,https://www.accessdata.fda.gov/drugsatfda_docs/label/2018/103792s5345lbl.pdf,Previously-treated,,Overall Response Rate,222.0,222.0,,,14.0,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,COSO28394862,2023Jan17,COSO28394862,breast,NS,NS,NS,carcinoma,NS,NS,NS
2863.0,ERBB2,ERBB2_unspecified,,,,breast / carcinoma / NS,2.0,Approved FDA,Trastuzumab,Required,Unknown,,Study 6,,,Overexpression,Yes,,7.0,https://www.accessdata.fda.gov/drugsatfda_docs/label/2018/103792s5345lbl.pdf,Previously-treated,,Overall Response Rate,222.0,222.0,,,14.0,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,COSO28394862,2023Jan17,COSO28394862,breast,NS,NS,NS,carcinoma,NS,NS,NS
2864.0,ERBB2,ERBB2_unspecified,,,,breast / carcinoma / NS,2.0,Approved FDA,Trastuzumab,Required,Unknown,,Study 6,,,Overexpression,Yes,,7.0,https://www.accessdata.fda.gov/drugsatfda_docs/label/2018/103792s5345lbl.pdf,Previously-treated,,Overall Response Rate,222.0,222.0,,,14.0,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,COSO28394862,2023Jan17,COSO28394862,breast,NS,NS,NS,carcinoma,NS,NS,NS
2865.0,ERBB2,ERBB2_unspecified,,,,breast / carcinoma / NS,2.0,Approved FDA,Trastuzumab,Required,Unknown,,Study 6,,,Overexpression,Yes,,7.0,https://www.accessdata.fda.gov/drugsatfda_docs/label/2018/103792s5345lbl.pdf,Previously-treated,,Overall Response Rate,222.0,222.0,,,14.0,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,COSO28394862,2023Jan17,COSO28394862,breast,NS,NS,NS,carcinoma,NS,NS,NS
2866.0,ERBB2,ERBB2_unspecified,,,,breast / carcinoma / NS,2.0,Approved FDA,Trastuzumab,Required,Unknown,,Study 6,,,Overexpression,Yes,,7.0,https://www.accessdata.fda.gov/drugsatfda_docs/label/2018/103792s5345lbl.pdf,Previously-treated,,Overall Response Rate,222.0,222.0,,,14.0,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,COSO28394862,2023Jan17,COSO28394862,breast,NS,NS,NS,carcinoma,NS,NS,NS
2867.0,ERBB2,ERBB2_unspecified,,,,breast / carcinoma / NS,2.0,Approved FDA,Trastuzumab,Required,Unknown,,Study 6,,,Overexpression,Yes,,7.0,https://www.accessdata.fda.gov/drugsatfda_docs/label/2018/103792s5345lbl.pdf,Previously-treated,,Overall Response Rate,222.0,222.0,,,14.0,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,COSO28394862,2023Jan17,COSO28394862,breast,NS,NS,NS,carcinoma,NS,NS,NS
2868.0,ERBB2,ERBB2_unspecified,,,,breast / carcinoma / NS,2.0,Approved FDA,Trastuzumab,Required,Unknown,,Study 6,,,Overexpression,Yes,,7.0,https://www.accessdata.fda.gov/drugsatfda_docs/label/2018/103792s5345lbl.pdf,Previously-treated,,Overall Response Rate,222.0,222.0,,,14.0,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,COSO28394862,2023Jan17,COSO28394862,breast,NS,NS,NS,carcinoma,NS,NS,NS
2869.0,ERBB2,ERBB2_unspecified,,,,breast / carcinoma / NS,2.0,Approved FDA,Trastuzumab,Required,Unknown,,Study 6,,,Overexpression,Yes,,7.0,https://www.accessdata.fda.gov/drugsatfda_docs/label/2018/103792s5345lbl.pdf,Previously-treated,,Overall Response Rate,222.0,222.0,,,14.0,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,COSO28394862,2023Jan17,COSO28394862,breast,NS,NS,NS,carcinoma,NS,NS,NS
2870.0,ERBB2,ERBB2_unspecified,,,,breast / carcinoma / NS,2.0,Approved FDA,Trastuzumab,Required,Unknown,,Study 6,,,Overexpression,Yes,,7.0,https://www.accessdata.fda.gov/drugsatfda_docs/label/2018/103792s5345lbl.pdf,Previously-treated,,Overall Response Rate,222.0,222.0,,,14.0,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,COSO28394862,2023Jan17,COSO28394862,breast,NS,NS,NS,carcinoma,NS,NS,NS
2871.0,ERBB2,ERBB2_unspecified,,,,breast / carcinoma / NS,2.0,Approved FDA,Trastuzumab,Required,Unknown,,Study 6,,,Overexpression,Yes,,7.0,https://www.accessdata.fda.gov/drugsatfda_docs/label/2018/103792s5345lbl.pdf,Previously-treated,,Overall Response Rate,222.0,222.0,,,14.0,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,COSO28394862,2023Jan17,COSO28394862,breast,NS,NS,NS,carcinoma,NS,NS,NS
2872.0,ERBB2,ERBB2_unspecified,,,,breast / carcinoma / NS,2.0,Approved FDA,Trastuzumab,Required,Unknown,,Study 6,,,Overexpression,Yes,,7.0,https://www.accessdata.fda.gov/drugsatfda_docs/label/2018/103792s5345lbl.pdf,Previously-treated,,Overall Response Rate,222.0,222.0,,,14.0,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,COSO28394862,2023Jan17,COSO28394862,breast,NS,NS,NS,carcinoma,NS,NS,NS
2873.0,ERBB2,ERBB2_unspecified,,,,breast / carcinoma / NS,2.0,Approved FDA,Trastuzumab,Required,Completed,NCT00045032,HERA (Study 3),PCD,2005Mar01,Overexpression,Yes,,1.0,21354370,,,"Disease free survival, relapse free survival, regression free survival, recurrence free survival",3401.0,1703.0,1698.0,Observation,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,78.6,72.2,0.76,0.66-0.87,<0.0001,,,,COSO28394862,2023Jan17,COSO28394862,breast,NS,NS,NS,carcinoma,NS,NS,NS
2874.0,ERBB2,ERBB2_unspecified,,,,breast / carcinoma / NS,2.0,Approved FDA,Trastuzumab,Required,Completed,NCT00045032,HERA (Study 3),PCD,2005Mar01,Overexpression,Yes,,1.0,21354370,,,"Disease free survival, relapse free survival, regression free survival, recurrence free survival",3401.0,1703.0,1698.0,Observation,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,78.6,72.2,0.76,0.66-0.87,<0.0001,,,,COSO28394862,2023Jan17,COSO28394862,breast,NS,NS,NS,carcinoma,NS,NS,NS
2875.0,ERBB2,ERBB2_unspecified,,,,breast / carcinoma / NS,2.0,Approved FDA,Trastuzumab,Required,Completed,NCT00045032,HERA (Study 3),PCD,2005Mar01,Overexpression,Yes,,1.0,21354370,,,"Disease free survival, relapse free survival, regression free survival, recurrence free survival",3401.0,1703.0,1698.0,Observation,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,78.6,72.2,0.76,0.66-0.87,<0.0001,,,,COSO28394862,2023Jan17,COSO28394862,breast,NS,NS,NS,carcinoma,NS,NS,NS
2876.0,ERBB2,ERBB2_unspecified,,,,breast / carcinoma / NS,2.0,Approved FDA,Trastuzumab,Required,Completed,NCT00045032,HERA (Study 3),PCD,2005Mar01,Overexpression,Yes,,1.0,21354370,,,"Disease free survival, relapse free survival, regression free survival, recurrence free survival",3401.0,1703.0,1698.0,Observation,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,78.6,72.2,0.76,0.66-0.87,<0.0001,,,,COSO28394862,2023Jan17,COSO28394862,breast,NS,NS,NS,carcinoma,NS,NS,NS
2877.0,ERBB2,ERBB2_unspecified,,,,breast / carcinoma / NS,2.0,Approved FDA,Trastuzumab,Required,Completed,NCT00045032,HERA (Study 3),PCD,2005Mar01,Overexpression,Yes,,1.0,21354370,,,"Disease free survival, relapse free survival, regression free survival, recurrence free survival",3401.0,1703.0,1698.0,Observation,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,78.6,72.2,0.76,0.66-0.87,<0.0001,,,,COSO28394862,2023Jan17,COSO28394862,breast,NS,NS,NS,carcinoma,NS,NS,NS
2878.0,ERBB2,ERBB2_unspecified,,,,breast / carcinoma / NS,2.0,Approved FDA,Trastuzumab,Required,Completed,NCT00045032,HERA (Study 3),PCD,2005Mar01,Overexpression,Yes,,1.0,21354370,,,"Disease free survival, relapse free survival, regression free survival, recurrence free survival",3401.0,1703.0,1698.0,Observation,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,78.6,72.2,0.76,0.66-0.87,<0.0001,,,,COSO28394862,2023Jan17,COSO28394862,breast,NS,NS,NS,carcinoma,NS,NS,NS
2879.0,ERBB2,ERBB2_unspecified,,,,breast / carcinoma / NS,2.0,Approved FDA,Trastuzumab,Required,Completed,NCT00045032,HERA (Study 3),PCD,2005Mar01,Overexpression,Yes,,1.0,21354370,,,"Disease free survival, relapse free survival, regression free survival, recurrence free survival",3401.0,1703.0,1698.0,Observation,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,78.6,72.2,0.76,0.66-0.87,<0.0001,,,,COSO28394862,2023Jan17,COSO28394862,breast,NS,NS,NS,carcinoma,NS,NS,NS
2880.0,ERBB2,ERBB2_unspecified,,,,breast / carcinoma / NS,2.0,Approved FDA,Trastuzumab,Required,Completed,NCT00045032,HERA (Study 3),PCD,2005Mar01,Overexpression,Yes,,1.0,21354370,,,"Disease free survival, relapse free survival, regression free survival, recurrence free survival",3401.0,1703.0,1698.0,Observation,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,78.6,72.2,0.76,0.66-0.87,<0.0001,,,,COSO28394862,2023Jan17,COSO28394862,breast,NS,NS,NS,carcinoma,NS,NS,NS
2881.0,ERBB2,ERBB2_unspecified,,,,breast / carcinoma / NS,2.0,Approved FDA,Trastuzumab,Required,Completed,NCT00045032,HERA (Study 3),PCD,2005Mar01,Overexpression,Yes,,1.0,21354370,,,"Disease free survival, relapse free survival, regression free survival, recurrence free survival",3401.0,1703.0,1698.0,Observation,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,78.6,72.2,0.76,0.66-0.87,<0.0001,,,,COSO28394862,2023Jan17,COSO28394862,breast,NS,NS,NS,carcinoma,NS,NS,NS
2882.0,ERBB2,ERBB2_unspecified,,,,breast / carcinoma / NS,2.0,Approved FDA,Trastuzumab,Required,Completed,NCT00045032,HERA (Study 3),PCD,2005Mar01,Overexpression,Yes,,1.0,21354370,,,"Disease free survival, relapse free survival, regression free survival, recurrence free survival",3401.0,1703.0,1698.0,Observation,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,78.6,72.2,0.76,0.66-0.87,<0.0001,,,,COSO28394862,2023Jan17,COSO28394862,breast,NS,NS,NS,carcinoma,NS,NS,NS
2883.0,ERBB2,ERBB2_unspecified,,,,breast / carcinoma / NS,2.0,Approved FDA,Trastuzumab,Required,Completed,NCT00045032,HERA (Study 3),PCD,2005Mar01,Overexpression,Yes,,1.0,21354370,,,"Disease free survival, relapse free survival, regression free survival, recurrence free survival",3401.0,1703.0,1698.0,Observation,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,78.6,72.2,0.76,0.66-0.87,<0.0001,,,,COSO28394862,2023Jan17,COSO28394862,breast,NS,NS,NS,carcinoma,NS,NS,NS
2884.0,ERBB2,ERBB2_unspecified,,,,breast / carcinoma / NS,2.0,Approved FDA,Trastuzumab,Required,Completed,NCT00045032,HERA (Study 3),PCD,2005Mar01,Overexpression,Yes,,1.0,21354370,,,"Disease free survival, relapse free survival, regression free survival, recurrence free survival",3401.0,1703.0,1698.0,Observation,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,78.6,72.2,0.76,0.66-0.87,<0.0001,,,,COSO28394862,2023Jan17,COSO28394862,breast,NS,NS,NS,carcinoma,NS,NS,NS
2885.0,ERBB2,ERBB2_unspecified,,,,breast / carcinoma / NS,2.0,Approved FDA,Trastuzumab,Required,Completed,NCT00045032,HERA (Study 3),PCD,2005Mar01,Overexpression,Yes,,1.0,21354370,,,"Disease free survival, relapse free survival, regression free survival, recurrence free survival",3401.0,1703.0,1698.0,Observation,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,78.6,72.2,0.76,0.66-0.87,<0.0001,,,,COSO28394862,2023Jan17,COSO28394862,breast,NS,NS,NS,carcinoma,NS,NS,NS
5031.0,ERBB2,ERBB2_unspecified,,,,breast / carcinoma / NS,2.0,Phase 1,Trastuzumab,,Terminated,NCT02571530,,PCD,2021Jun01,Yes,Yes,Slow accrual,4.0,NCT02571530,,,Maximum tolerated dose/toxicity,2.0,2.0,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,COSO28394862,2022Oct17,COSO28394862,breast,NS,NS,NS,carcinoma,NS,NS,NS
5032.0,ERBB2,ERBB2_unspecified,,,,breast / carcinoma / NS,2.0,Phase 1,Trastuzumab,,Terminated,NCT02571530,,PCD,2021Jun01,Yes,Yes,Slow accrual,4.0,NCT02571530,,,Maximum tolerated dose/toxicity,2.0,2.0,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,COSO28394862,2022Oct17,COSO28394862,breast,NS,NS,NS,carcinoma,NS,NS,NS
5033.0,ERBB2,ERBB2_unspecified,,,,breast / carcinoma / NS,2.0,Phase 1,Trastuzumab,,Terminated,NCT02571530,,PCD,2021Jun01,Yes,Yes,Slow accrual,4.0,NCT02571530,,,Maximum tolerated dose/toxicity,2.0,2.0,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,COSO28394862,2022Oct17,COSO28394862,breast,NS,NS,NS,carcinoma,NS,NS,NS
5034.0,ERBB2,ERBB2_unspecified,,,,breast / carcinoma / NS,2.0,Phase 1,Trastuzumab,,Terminated,NCT02571530,,PCD,2021Jun01,Yes,Yes,Slow accrual,4.0,NCT02571530,,,Maximum tolerated dose/toxicity,2.0,2.0,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,COSO28394862,2022Oct17,COSO28394862,breast,NS,NS,NS,carcinoma,NS,NS,NS
5035.0,ERBB2,ERBB2_unspecified,,,,breast / carcinoma / NS,2.0,Phase 1,Trastuzumab,,Terminated,NCT02571530,,PCD,2021Jun01,Yes,Yes,Slow accrual,4.0,NCT02571530,,,Maximum tolerated dose/toxicity,2.0,2.0,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,COSO28394862,2022Oct17,COSO28394862,breast,NS,NS,NS,carcinoma,NS,NS,NS
5036.0,ERBB2,ERBB2_unspecified,,,,breast / carcinoma / NS,2.0,Phase 1,Trastuzumab,,Terminated,NCT02571530,,PCD,2021Jun01,Yes,Yes,Slow accrual,4.0,NCT02571530,,,Maximum tolerated dose/toxicity,2.0,2.0,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,COSO28394862,2022Oct17,COSO28394862,breast,NS,NS,NS,carcinoma,NS,NS,NS
5037.0,ERBB2,ERBB2_unspecified,,,,breast / carcinoma / NS,2.0,Phase 1,Trastuzumab,,Terminated,NCT02571530,,PCD,2021Jun01,Yes,Yes,Slow accrual,4.0,NCT02571530,,,Maximum tolerated dose/toxicity,2.0,2.0,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,COSO28394862,2022Oct17,COSO28394862,breast,NS,NS,NS,carcinoma,NS,NS,NS
5038.0,ERBB2,ERBB2_unspecified,,,,breast / carcinoma / NS,2.0,Phase 1,Trastuzumab,,Terminated,NCT02571530,,PCD,2021Jun01,Yes,Yes,Slow accrual,4.0,NCT02571530,,,Maximum tolerated dose/toxicity,2.0,2.0,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,COSO28394862,2022Oct17,COSO28394862,breast,NS,NS,NS,carcinoma,NS,NS,NS
5039.0,ERBB2,ERBB2_unspecified,,,,breast / carcinoma / NS,2.0,Phase 1,Trastuzumab,,Terminated,NCT02571530,,PCD,2021Jun01,Yes,Yes,Slow accrual,4.0,NCT02571530,,,Maximum tolerated dose/toxicity,2.0,2.0,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,COSO28394862,2022Oct17,COSO28394862,breast,NS,NS,NS,carcinoma,NS,NS,NS
5040.0,ERBB2,ERBB2_unspecified,,,,breast / carcinoma / NS,2.0,Phase 1,Trastuzumab,,Terminated,NCT02571530,,PCD,2021Jun01,Yes,Yes,Slow accrual,4.0,NCT02571530,,,Maximum tolerated dose/toxicity,2.0,2.0,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,COSO28394862,2022Oct17,COSO28394862,breast,NS,NS,NS,carcinoma,NS,NS,NS
5041.0,ERBB2,ERBB2_unspecified,,,,breast / carcinoma / NS,2.0,Phase 1,Trastuzumab,,Terminated,NCT02571530,,PCD,2021Jun01,Yes,Yes,Slow accrual,4.0,NCT02571530,,,Maximum tolerated dose/toxicity,2.0,2.0,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,COSO28394862,2022Oct17,COSO28394862,breast,NS,NS,NS,carcinoma,NS,NS,NS
5042.0,ERBB2,ERBB2_unspecified,,,,breast / carcinoma / NS,2.0,Phase 1,Trastuzumab,,Terminated,NCT02571530,,PCD,2021Jun01,Yes,Yes,Slow accrual,4.0,NCT02571530,,,Maximum tolerated dose/toxicity,2.0,2.0,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,COSO28394862,2022Oct17,COSO28394862,breast,NS,NS,NS,carcinoma,NS,NS,NS
5043.0,ERBB2,ERBB2_unspecified,,,,breast / carcinoma / NS,2.0,Phase 1,Trastuzumab,,Terminated,NCT02571530,,PCD,2021Jun01,Yes,Yes,Slow accrual,4.0,NCT02571530,,,Maximum tolerated dose/toxicity,2.0,2.0,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,COSO28394862,2022Oct17,COSO28394862,breast,NS,NS,NS,carcinoma,NS,NS,NS
12688.0,ERBB2,ERBB2_unspecified,,,,breast / carcinoma / NS,2.0,Phase 2,Trastuzumab,,Completed,NCT01373710,HIT,PCD,2018Apr01,Overexpression,Yes,,1.0,29635147,,,Progression free survival,14.0,14.0,,,,,,,,,,,,,,,,,,,,,,,,7.3,,,,,,,3.0,7.0,,,,,,,,,COSO28394862,2022Nov28,COSO28394862,breast,NS,NS,NS,carcinoma,NS,NS,NS
12689.0,ERBB2,ERBB2_unspecified,,,,breast / carcinoma / NS,2.0,Phase 2,Trastuzumab,,Completed,NCT01373710,HIT,PCD,2018Apr01,Overexpression,Yes,,1.0,29635147,,,Progression free survival,14.0,14.0,,,,,,,,,,,,,,,,,,,,,,,,7.3,,,,,,,3.0,7.0,,,,,,,,,COSO28394862,2022Nov28,COSO28394862,breast,NS,NS,NS,carcinoma,NS,NS,NS
12690.0,ERBB2,ERBB2_unspecified,,,,breast / carcinoma / NS,2.0,Phase 2,Trastuzumab,,Completed,NCT01373710,HIT,PCD,2018Apr01,Overexpression,Yes,,1.0,29635147,,,Progression free survival,14.0,14.0,,,,,,,,,,,,,,,,,,,,,,,,7.3,,,,,,,3.0,7.0,,,,,,,,,COSO28394862,2022Nov28,COSO28394862,breast,NS,NS,NS,carcinoma,NS,NS,NS
12691.0,ERBB2,ERBB2_unspecified,,,,breast / carcinoma / NS,2.0,Phase 2,Trastuzumab,,Completed,NCT01373710,HIT,PCD,2018Apr01,Overexpression,Yes,,1.0,29635147,,,Progression free survival,14.0,14.0,,,,,,,,,,,,,,,,,,,,,,,,7.3,,,,,,,3.0,7.0,,,,,,,,,COSO28394862,2022Nov28,COSO28394862,breast,NS,NS,NS,carcinoma,NS,NS,NS
12692.0,ERBB2,ERBB2_unspecified,,,,breast / carcinoma / NS,2.0,Phase 2,Trastuzumab,,Completed,NCT01373710,HIT,PCD,2018Apr01,Overexpression,Yes,,1.0,29635147,,,Progression free survival,14.0,14.0,,,,,,,,,,,,,,,,,,,,,,,,7.3,,,,,,,3.0,7.0,,,,,,,,,COSO28394862,2022Nov28,COSO28394862,breast,NS,NS,NS,carcinoma,NS,NS,NS
12693.0,ERBB2,ERBB2_unspecified,,,,breast / carcinoma / NS,2.0,Phase 2,Trastuzumab,,Completed,NCT01373710,HIT,PCD,2018Apr01,Overexpression,Yes,,1.0,29635147,,,Progression free survival,14.0,14.0,,,,,,,,,,,,,,,,,,,,,,,,7.3,,,,,,,3.0,7.0,,,,,,,,,COSO28394862,2022Nov28,COSO28394862,breast,NS,NS,NS,carcinoma,NS,NS,NS
12694.0,ERBB2,ERBB2_unspecified,,,,breast / carcinoma / NS,2.0,Phase 2,Trastuzumab,,Completed,NCT01373710,HIT,PCD,2018Apr01,Overexpression,Yes,,1.0,29635147,,,Progression free survival,14.0,14.0,,,,,,,,,,,,,,,,,,,,,,,,7.3,,,,,,,3.0,7.0,,,,,,,,,COSO28394862,2022Nov28,COSO28394862,breast,NS,NS,NS,carcinoma,NS,NS,NS
12695.0,ERBB2,ERBB2_unspecified,,,,breast / carcinoma / NS,2.0,Phase 2,Trastuzumab,,Completed,NCT01373710,HIT,PCD,2018Apr01,Overexpression,Yes,,1.0,29635147,,,Progression free survival,14.0,14.0,,,,,,,,,,,,,,,,,,,,,,,,7.3,,,,,,,3.0,7.0,,,,,,,,,COSO28394862,2022Nov28,COSO28394862,breast,NS,NS,NS,carcinoma,NS,NS,NS
12696.0,ERBB2,ERBB2_unspecified,,,,breast / carcinoma / NS,2.0,Phase 2,Trastuzumab,,Completed,NCT01373710,HIT,PCD,2018Apr01,Overexpression,Yes,,1.0,29635147,,,Progression free survival,14.0,14.0,,,,,,,,,,,,,,,,,,,,,,,,7.3,,,,,,,3.0,7.0,,,,,,,,,COSO28394862,2022Nov28,COSO28394862,breast,NS,NS,NS,carcinoma,NS,NS,NS
12697.0,ERBB2,ERBB2_unspecified,,,,breast / carcinoma / NS,2.0,Phase 2,Trastuzumab,,Completed,NCT01373710,HIT,PCD,2018Apr01,Overexpression,Yes,,1.0,29635147,,,Progression free survival,14.0,14.0,,,,,,,,,,,,,,,,,,,,,,,,7.3,,,,,,,3.0,7.0,,,,,,,,,COSO28394862,2022Nov28,COSO28394862,breast,NS,NS,NS,carcinoma,NS,NS,NS
12698.0,ERBB2,ERBB2_unspecified,,,,breast / carcinoma / NS,2.0,Phase 2,Trastuzumab,,Completed,NCT01373710,HIT,PCD,2018Apr01,Overexpression,Yes,,1.0,29635147,,,Progression free survival,14.0,14.0,,,,,,,,,,,,,,,,,,,,,,,,7.3,,,,,,,3.0,7.0,,,,,,,,,COSO28394862,2022Nov28,COSO28394862,breast,NS,NS,NS,carcinoma,NS,NS,NS
12699.0,ERBB2,ERBB2_unspecified,,,,breast / carcinoma / NS,2.0,Phase 2,Trastuzumab,,Completed,NCT01373710,HIT,PCD,2018Apr01,Overexpression,Yes,,1.0,29635147,,,Progression free survival,14.0,14.0,,,,,,,,,,,,,,,,,,,,,,,,7.3,,,,,,,3.0,7.0,,,,,,,,,COSO28394862,2022Nov28,COSO28394862,breast,NS,NS,NS,carcinoma,NS,NS,NS
12700.0,ERBB2,ERBB2_unspecified,,,,breast / carcinoma / NS,2.0,Phase 2,Trastuzumab,,Completed,NCT01373710,HIT,PCD,2018Apr01,Overexpression,Yes,,1.0,29635147,,,Progression free survival,14.0,14.0,,,,,,,,,,,,,,,,,,,,,,,,7.3,,,,,,,3.0,7.0,,,,,,,,,COSO28394862,2022Nov28,COSO28394862,breast,NS,NS,NS,carcinoma,NS,NS,NS
12701.0,ERBB2,ERBB2_unspecified,,,,breast / carcinoma / NS,2.0,Phase 2,Trastuzumab,,Completed,NCT01325207,,PCD,2016Jun20,Expression confirmed,Yes,,4.0,NCT01325207,,,Response rate,26.0,26.0,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,0.0,5.0,13.0,,,,,,,,,COSO28394862,2022Nov28,COSO28394862,breast,NS,NS,NS,carcinoma,NS,NS,NS
12702.0,ERBB2,ERBB2_unspecified,,,,breast / carcinoma / NS,2.0,Phase 2,Trastuzumab,,Completed,NCT01325207,,PCD,2016Jun20,Expression confirmed,Yes,,4.0,NCT01325207,,,Response rate,26.0,26.0,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,0.0,5.0,13.0,,,,,,,,,COSO28394862,2022Nov28,COSO28394862,breast,NS,NS,NS,carcinoma,NS,NS,NS
12703.0,ERBB2,ERBB2_unspecified,,,,breast / carcinoma / NS,2.0,Phase 2,Trastuzumab,,Completed,NCT01325207,,PCD,2016Jun20,Expression confirmed,Yes,,4.0,NCT01325207,,,Response rate,26.0,26.0,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,0.0,5.0,13.0,,,,,,,,,COSO28394862,2022Nov28,COSO28394862,breast,NS,NS,NS,carcinoma,NS,NS,NS
12704.0,ERBB2,ERBB2_unspecified,,,,breast / carcinoma / NS,2.0,Phase 2,Trastuzumab,,Completed,NCT01325207,,PCD,2016Jun20,Expression confirmed,Yes,,4.0,NCT01325207,,,Response rate,26.0,26.0,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,0.0,5.0,13.0,,,,,,,,,COSO28394862,2022Nov28,COSO28394862,breast,NS,NS,NS,carcinoma,NS,NS,NS
12705.0,ERBB2,ERBB2_unspecified,,,,breast / carcinoma / NS,2.0,Phase 2,Trastuzumab,,Completed,NCT01325207,,PCD,2016Jun20,Expression confirmed,Yes,,4.0,NCT01325207,,,Response rate,26.0,26.0,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,0.0,5.0,13.0,,,,,,,,,COSO28394862,2022Nov28,COSO28394862,breast,NS,NS,NS,carcinoma,NS,NS,NS
12706.0,ERBB2,ERBB2_unspecified,,,,breast / carcinoma / NS,2.0,Phase 2,Trastuzumab,,Completed,NCT01325207,,PCD,2016Jun20,Expression confirmed,Yes,,4.0,NCT01325207,,,Response rate,26.0,26.0,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,0.0,5.0,13.0,,,,,,,,,COSO28394862,2022Nov28,COSO28394862,breast,NS,NS,NS,carcinoma,NS,NS,NS
12707.0,ERBB2,ERBB2_unspecified,,,,breast / carcinoma / NS,2.0,Phase 2,Trastuzumab,,Completed,NCT01325207,,PCD,2016Jun20,Expression confirmed,Yes,,4.0,NCT01325207,,,Response rate,26.0,26.0,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,0.0,5.0,13.0,,,,,,,,,COSO28394862,2022Nov28,COSO28394862,breast,NS,NS,NS,carcinoma,NS,NS,NS
12708.0,ERBB2,ERBB2_unspecified,,,,breast / carcinoma / NS,2.0,Phase 2,Trastuzumab,,Completed,NCT01325207,,PCD,2016Jun20,Expression confirmed,Yes,,4.0,NCT01325207,,,Response rate,26.0,26.0,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,0.0,5.0,13.0,,,,,,,,,COSO28394862,2022Nov28,COSO28394862,breast,NS,NS,NS,carcinoma,NS,NS,NS
12709.0,ERBB2,ERBB2_unspecified,,,,breast / carcinoma / NS,2.0,Phase 2,Trastuzumab,,Completed,NCT01325207,,PCD,2016Jun20,Expression confirmed,Yes,,4.0,NCT01325207,,,Response rate,26.0,26.0,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,0.0,5.0,13.0,,,,,,,,,COSO28394862,2022Nov28,COSO28394862,breast,NS,NS,NS,carcinoma,NS,NS,NS
12710.0,ERBB2,ERBB2_unspecified,,,,breast / carcinoma / NS,2.0,Phase 2,Trastuzumab,,Completed,NCT01325207,,PCD,2016Jun20,Expression confirmed,Yes,,4.0,NCT01325207,,,Response rate,26.0,26.0,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,0.0,5.0,13.0,,,,,,,,,COSO28394862,2022Nov28,COSO28394862,breast,NS,NS,NS,carcinoma,NS,NS,NS
12711.0,ERBB2,ERBB2_unspecified,,,,breast / carcinoma / NS,2.0,Phase 2,Trastuzumab,,Completed,NCT01325207,,PCD,2016Jun20,Expression confirmed,Yes,,4.0,NCT01325207,,,Response rate,26.0,26.0,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,0.0,5.0,13.0,,,,,,,,,COSO28394862,2022Nov28,COSO28394862,breast,NS,NS,NS,carcinoma,NS,NS,NS
12712.0,ERBB2,ERBB2_unspecified,,,,breast / carcinoma / NS,2.0,Phase 2,Trastuzumab,,Completed,NCT01325207,,PCD,2016Jun20,Expression confirmed,Yes,,4.0,NCT01325207,,,Response rate,26.0,26.0,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,0.0,5.0,13.0,,,,,,,,,COSO28394862,2022Nov28,COSO28394862,breast,NS,NS,NS,carcinoma,NS,NS,NS
12713.0,ERBB2,ERBB2_unspecified,,,,breast / carcinoma / NS,2.0,Phase 2,Trastuzumab,,Completed,NCT01325207,,PCD,2016Jun20,Expression confirmed,Yes,,4.0,NCT01325207,,,Response rate,26.0,26.0,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,0.0,5.0,13.0,,,,,,,,,COSO28394862,2022Nov28,COSO28394862,breast,NS,NS,NS,carcinoma,NS,NS,NS
12714.0,ERBB2,ERBB2_unspecified,,,,breast / carcinoma / NS,2.0,Phase 2,Trastuzumab,,Completed,NCT00826267,,PCD,2011Aug01,Expression confirmed,Yes,,4.0,NCT00826267,Untreated,,Overall Response Rate,11.0,11.0,,,36.4,,10.9-69.2,,,,,,,,,,,,,,,,100.0,,,,,,,,,,,,,,,,,,,,COSO28394862,2022Nov28,COSO28394862,breast,NS,NS,NS,carcinoma,NS,NS,NS
12715.0,ERBB2,ERBB2_unspecified,,,,breast / carcinoma / NS,2.0,Phase 2,Trastuzumab,,Completed,NCT00826267,,PCD,2011Aug01,Expression confirmed,Yes,,4.0,NCT00826267,Untreated,,Overall Response Rate,11.0,11.0,,,36.4,,10.9-69.2,,,,,,,,,,,,,,,,100.0,,,,,,,,,,,,,,,,,,,,COSO28394862,2022Nov28,COSO28394862,breast,NS,NS,NS,carcinoma,NS,NS,NS
12716.0,ERBB2,ERBB2_unspecified,,,,breast / carcinoma / NS,2.0,Phase 2,Trastuzumab,,Completed,NCT00826267,,PCD,2011Aug01,Expression confirmed,Yes,,4.0,NCT00826267,Untreated,,Overall Response Rate,11.0,11.0,,,36.4,,10.9-69.2,,,,,,,,,,,,,,,,100.0,,,,,,,,,,,,,,,,,,,,COSO28394862,2022Nov28,COSO28394862,breast,NS,NS,NS,carcinoma,NS,NS,NS
12717.0,ERBB2,ERBB2_unspecified,,,,breast / carcinoma / NS,2.0,Phase 2,Trastuzumab,,Completed,NCT00826267,,PCD,2011Aug01,Expression confirmed,Yes,,4.0,NCT00826267,Untreated,,Overall Response Rate,11.0,11.0,,,36.4,,10.9-69.2,,,,,,,,,,,,,,,,100.0,,,,,,,,,,,,,,,,,,,,COSO28394862,2022Nov28,COSO28394862,breast,NS,NS,NS,carcinoma,NS,NS,NS
12718.0,ERBB2,ERBB2_unspecified,,,,breast / carcinoma / NS,2.0,Phase 2,Trastuzumab,,Completed,NCT00826267,,PCD,2011Aug01,Expression confirmed,Yes,,4.0,NCT00826267,Untreated,,Overall Response Rate,11.0,11.0,,,36.4,,10.9-69.2,,,,,,,,,,,,,,,,100.0,,,,,,,,,,,,,,,,,,,,COSO28394862,2022Nov28,COSO28394862,breast,NS,NS,NS,carcinoma,NS,NS,NS
12719.0,ERBB2,ERBB2_unspecified,,,,breast / carcinoma / NS,2.0,Phase 2,Trastuzumab,,Completed,NCT00826267,,PCD,2011Aug01,Expression confirmed,Yes,,4.0,NCT00826267,Untreated,,Overall Response Rate,11.0,11.0,,,36.4,,10.9-69.2,,,,,,,,,,,,,,,,100.0,,,,,,,,,,,,,,,,,,,,COSO28394862,2022Nov28,COSO28394862,breast,NS,NS,NS,carcinoma,NS,NS,NS
12720.0,ERBB2,ERBB2_unspecified,,,,breast / carcinoma / NS,2.0,Phase 2,Trastuzumab,,Completed,NCT00826267,,PCD,2011Aug01,Expression confirmed,Yes,,4.0,NCT00826267,Untreated,,Overall Response Rate,11.0,11.0,,,36.4,,10.9-69.2,,,,,,,,,,,,,,,,100.0,,,,,,,,,,,,,,,,,,,,COSO28394862,2022Nov28,COSO28394862,breast,NS,NS,NS,carcinoma,NS,NS,NS
12721.0,ERBB2,ERBB2_unspecified,,,,breast / carcinoma / NS,2.0,Phase 2,Trastuzumab,,Completed,NCT00826267,,PCD,2011Aug01,Expression confirmed,Yes,,4.0,NCT00826267,Untreated,,Overall Response Rate,11.0,11.0,,,36.4,,10.9-69.2,,,,,,,,,,,,,,,,100.0,,,,,,,,,,,,,,,,,,,,COSO28394862,2022Nov28,COSO28394862,breast,NS,NS,NS,carcinoma,NS,NS,NS
12722.0,ERBB2,ERBB2_unspecified,,,,breast / carcinoma / NS,2.0,Phase 2,Trastuzumab,,Completed,NCT00826267,,PCD,2011Aug01,Expression confirmed,Yes,,4.0,NCT00826267,Untreated,,Overall Response Rate,11.0,11.0,,,36.4,,10.9-69.2,,,,,,,,,,,,,,,,100.0,,,,,,,,,,,,,,,,,,,,COSO28394862,2022Nov28,COSO28394862,breast,NS,NS,NS,carcinoma,NS,NS,NS
12723.0,ERBB2,ERBB2_unspecified,,,,breast / carcinoma / NS,2.0,Phase 2,Trastuzumab,,Completed,NCT00826267,,PCD,2011Aug01,Expression confirmed,Yes,,4.0,NCT00826267,Untreated,,Overall Response Rate,11.0,11.0,,,36.4,,10.9-69.2,,,,,,,,,,,,,,,,100.0,,,,,,,,,,,,,,,,,,,,COSO28394862,2022Nov28,COSO28394862,breast,NS,NS,NS,carcinoma,NS,NS,NS
12724.0,ERBB2,ERBB2_unspecified,,,,breast / carcinoma / NS,2.0,Phase 2,Trastuzumab,,Completed,NCT00826267,,PCD,2011Aug01,Expression confirmed,Yes,,4.0,NCT00826267,Untreated,,Overall Response Rate,11.0,11.0,,,36.4,,10.9-69.2,,,,,,,,,,,,,,,,100.0,,,,,,,,,,,,,,,,,,,,COSO28394862,2022Nov28,COSO28394862,breast,NS,NS,NS,carcinoma,NS,NS,NS
12725.0,ERBB2,ERBB2_unspecified,,,,breast / carcinoma / NS,2.0,Phase 2,Trastuzumab,,Completed,NCT00826267,,PCD,2011Aug01,Expression confirmed,Yes,,4.0,NCT00826267,Untreated,,Overall Response Rate,11.0,11.0,,,36.4,,10.9-69.2,,,,,,,,,,,,,,,,100.0,,,,,,,,,,,,,,,,,,,,COSO28394862,2022Nov28,COSO28394862,breast,NS,NS,NS,carcinoma,NS,NS,NS
12726.0,ERBB2,ERBB2_unspecified,,,,breast / carcinoma / NS,2.0,Phase 2,Trastuzumab,,Completed,NCT00826267,,PCD,2011Aug01,Expression confirmed,Yes,,4.0,NCT00826267,Untreated,,Overall Response Rate,11.0,11.0,,,36.4,,10.9-69.2,,,,,,,,,,,,,,,,100.0,,,,,,,,,,,,,,,,,,,,COSO28394862,2022Nov28,COSO28394862,breast,NS,NS,NS,carcinoma,NS,NS,NS
12727.0,ERBB2,ERBB2_unspecified,,,,breast / carcinoma / NS,2.0,Phase 2,Trastuzumab,,Completed,NCT00796978,,PCD,2018Jan12,Expression confirmed,Yes,"SAE 14.3%, DFS 5yr 86.4%",4.0,NCT00796978,,Geriatric,Maximum tolerated dose/toxicity,55.0,55.0,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,COSO28394862,2022Nov28,COSO28394862,breast,NS,NS,NS,carcinoma,NS,NS,NS
12728.0,ERBB2,ERBB2_unspecified,,,,breast / carcinoma / NS,2.0,Phase 2,Trastuzumab,,Completed,NCT00796978,,PCD,2018Jan12,Expression confirmed,Yes,"SAE 14.3%, DFS 5yr 86.4%",4.0,NCT00796978,,Geriatric,Maximum tolerated dose/toxicity,55.0,55.0,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,COSO28394862,2022Nov28,COSO28394862,breast,NS,NS,NS,carcinoma,NS,NS,NS
12729.0,ERBB2,ERBB2_unspecified,,,,breast / carcinoma / NS,2.0,Phase 2,Trastuzumab,,Completed,NCT00796978,,PCD,2018Jan12,Expression confirmed,Yes,"SAE 14.3%, DFS 5yr 86.4%",4.0,NCT00796978,,Geriatric,Maximum tolerated dose/toxicity,55.0,55.0,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,COSO28394862,2022Nov28,COSO28394862,breast,NS,NS,NS,carcinoma,NS,NS,NS
12730.0,ERBB2,ERBB2_unspecified,,,,breast / carcinoma / NS,2.0,Phase 2,Trastuzumab,,Completed,NCT00796978,,PCD,2018Jan12,Expression confirmed,Yes,"SAE 14.3%, DFS 5yr 86.4%",4.0,NCT00796978,,Geriatric,Maximum tolerated dose/toxicity,55.0,55.0,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,COSO28394862,2022Nov28,COSO28394862,breast,NS,NS,NS,carcinoma,NS,NS,NS
12731.0,ERBB2,ERBB2_unspecified,,,,breast / carcinoma / NS,2.0,Phase 2,Trastuzumab,,Completed,NCT00796978,,PCD,2018Jan12,Expression confirmed,Yes,"SAE 14.3%, DFS 5yr 86.4%",4.0,NCT00796978,,Geriatric,Maximum tolerated dose/toxicity,55.0,55.0,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,COSO28394862,2022Nov28,COSO28394862,breast,NS,NS,NS,carcinoma,NS,NS,NS
12732.0,ERBB2,ERBB2_unspecified,,,,breast / carcinoma / NS,2.0,Phase 2,Trastuzumab,,Completed,NCT00796978,,PCD,2018Jan12,Expression confirmed,Yes,"SAE 14.3%, DFS 5yr 86.4%",4.0,NCT00796978,,Geriatric,Maximum tolerated dose/toxicity,55.0,55.0,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,COSO28394862,2022Nov28,COSO28394862,breast,NS,NS,NS,carcinoma,NS,NS,NS
12733.0,ERBB2,ERBB2_unspecified,,,,breast / carcinoma / NS,2.0,Phase 2,Trastuzumab,,Completed,NCT00796978,,PCD,2018Jan12,Expression confirmed,Yes,"SAE 14.3%, DFS 5yr 86.4%",4.0,NCT00796978,,Geriatric,Maximum tolerated dose/toxicity,55.0,55.0,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,COSO28394862,2022Nov28,COSO28394862,breast,NS,NS,NS,carcinoma,NS,NS,NS
12734.0,ERBB2,ERBB2_unspecified,,,,breast / carcinoma / NS,2.0,Phase 2,Trastuzumab,,Completed,NCT00796978,,PCD,2018Jan12,Expression confirmed,Yes,"SAE 14.3%, DFS 5yr 86.4%",4.0,NCT00796978,,Geriatric,Maximum tolerated dose/toxicity,55.0,55.0,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,COSO28394862,2022Nov28,COSO28394862,breast,NS,NS,NS,carcinoma,NS,NS,NS
12735.0,ERBB2,ERBB2_unspecified,,,,breast / carcinoma / NS,2.0,Phase 2,Trastuzumab,,Completed,NCT00796978,,PCD,2018Jan12,Expression confirmed,Yes,"SAE 14.3%, DFS 5yr 86.4%",4.0,NCT00796978,,Geriatric,Maximum tolerated dose/toxicity,55.0,55.0,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,COSO28394862,2022Nov28,COSO28394862,breast,NS,NS,NS,carcinoma,NS,NS,NS
12736.0,ERBB2,ERBB2_unspecified,,,,breast / carcinoma / NS,2.0,Phase 2,Trastuzumab,,Completed,NCT00796978,,PCD,2018Jan12,Expression confirmed,Yes,"SAE 14.3%, DFS 5yr 86.4%",4.0,NCT00796978,,Geriatric,Maximum tolerated dose/toxicity,55.0,55.0,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,COSO28394862,2022Nov28,COSO28394862,breast,NS,NS,NS,carcinoma,NS,NS,NS
12737.0,ERBB2,ERBB2_unspecified,,,,breast / carcinoma / NS,2.0,Phase 2,Trastuzumab,,Completed,NCT00796978,,PCD,2018Jan12,Expression confirmed,Yes,"SAE 14.3%, DFS 5yr 86.4%",4.0,NCT00796978,,Geriatric,Maximum tolerated dose/toxicity,55.0,55.0,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,COSO28394862,2022Nov28,COSO28394862,breast,NS,NS,NS,carcinoma,NS,NS,NS
12738.0,ERBB2,ERBB2_unspecified,,,,breast / carcinoma / NS,2.0,Phase 2,Trastuzumab,,Completed,NCT00796978,,PCD,2018Jan12,Expression confirmed,Yes,"SAE 14.3%, DFS 5yr 86.4%",4.0,NCT00796978,,Geriatric,Maximum tolerated dose/toxicity,55.0,55.0,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,COSO28394862,2022Nov28,COSO28394862,breast,NS,NS,NS,carcinoma,NS,NS,NS
12739.0,ERBB2,ERBB2_unspecified,,,,breast / carcinoma / NS,2.0,Phase 2,Trastuzumab,,Completed,NCT00796978,,PCD,2018Jan12,Expression confirmed,Yes,"SAE 14.3%, DFS 5yr 86.4%",4.0,NCT00796978,,Geriatric,Maximum tolerated dose/toxicity,55.0,55.0,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,COSO28394862,2022Nov28,COSO28394862,breast,NS,NS,NS,carcinoma,NS,NS,NS
12740.0,ERBB2,ERBB2_unspecified,,,,breast / carcinoma / NS,2.0,Phase 2,Trastuzumab,,Terminated,NCT00427427,,,,Overexpression,Yes,Slow accrual,4.0,NCT00427427,,,Maximum tolerated dose/toxicity,75.0,75.0,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,COSO28394862,2021Dec08,COSO28394862,breast,NS,NS,NS,carcinoma,NS,NS,NS
12741.0,ERBB2,ERBB2_unspecified,,,,breast / carcinoma / NS,2.0,Phase 2,Trastuzumab,,Terminated,NCT00427427,,,,Overexpression,Yes,Slow accrual,4.0,NCT00427427,,,Maximum tolerated dose/toxicity,75.0,75.0,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,COSO28394862,2021Dec08,COSO28394862,breast,NS,NS,NS,carcinoma,NS,NS,NS
12742.0,ERBB2,ERBB2_unspecified,,,,breast / carcinoma / NS,2.0,Phase 2,Trastuzumab,,Terminated,NCT00427427,,,,Overexpression,Yes,Slow accrual,4.0,NCT00427427,,,Maximum tolerated dose/toxicity,75.0,75.0,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,COSO28394862,2021Dec08,COSO28394862,breast,NS,NS,NS,carcinoma,NS,NS,NS
12743.0,ERBB2,ERBB2_unspecified,,,,breast / carcinoma / NS,2.0,Phase 2,Trastuzumab,,Terminated,NCT00427427,,,,Overexpression,Yes,Slow accrual,4.0,NCT00427427,,,Maximum tolerated dose/toxicity,75.0,75.0,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,COSO28394862,2021Dec08,COSO28394862,breast,NS,NS,NS,carcinoma,NS,NS,NS
12744.0,ERBB2,ERBB2_unspecified,,,,breast / carcinoma / NS,2.0,Phase 2,Trastuzumab,,Terminated,NCT00427427,,,,Overexpression,Yes,Slow accrual,4.0,NCT00427427,,,Maximum tolerated dose/toxicity,75.0,75.0,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,COSO28394862,2021Dec08,COSO28394862,breast,NS,NS,NS,carcinoma,NS,NS,NS
12745.0,ERBB2,ERBB2_unspecified,,,,breast / carcinoma / NS,2.0,Phase 2,Trastuzumab,,Terminated,NCT00427427,,,,Overexpression,Yes,Slow accrual,4.0,NCT00427427,,,Maximum tolerated dose/toxicity,75.0,75.0,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,COSO28394862,2021Dec08,COSO28394862,breast,NS,NS,NS,carcinoma,NS,NS,NS
12746.0,ERBB2,ERBB2_unspecified,,,,breast / carcinoma / NS,2.0,Phase 2,Trastuzumab,,Terminated,NCT00427427,,,,Overexpression,Yes,Slow accrual,4.0,NCT00427427,,,Maximum tolerated dose/toxicity,75.0,75.0,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,COSO28394862,2021Dec08,COSO28394862,breast,NS,NS,NS,carcinoma,NS,NS,NS
12747.0,ERBB2,ERBB2_unspecified,,,,breast / carcinoma / NS,2.0,Phase 2,Trastuzumab,,Terminated,NCT00427427,,,,Overexpression,Yes,Slow accrual,4.0,NCT00427427,,,Maximum tolerated dose/toxicity,75.0,75.0,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,COSO28394862,2021Dec08,COSO28394862,breast,NS,NS,NS,carcinoma,NS,NS,NS
12748.0,ERBB2,ERBB2_unspecified,,,,breast / carcinoma / NS,2.0,Phase 2,Trastuzumab,,Terminated,NCT00427427,,,,Overexpression,Yes,Slow accrual,4.0,NCT00427427,,,Maximum tolerated dose/toxicity,75.0,75.0,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,COSO28394862,2021Dec08,COSO28394862,breast,NS,NS,NS,carcinoma,NS,NS,NS
12749.0,ERBB2,ERBB2_unspecified,,,,breast / carcinoma / NS,2.0,Phase 2,Trastuzumab,,Terminated,NCT00427427,,,,Overexpression,Yes,Slow accrual,4.0,NCT00427427,,,Maximum tolerated dose/toxicity,75.0,75.0,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,COSO28394862,2021Dec08,COSO28394862,breast,NS,NS,NS,carcinoma,NS,NS,NS
12750.0,ERBB2,ERBB2_unspecified,,,,breast / carcinoma / NS,2.0,Phase 2,Trastuzumab,,Terminated,NCT00427427,,,,Overexpression,Yes,Slow accrual,4.0,NCT00427427,,,Maximum tolerated dose/toxicity,75.0,75.0,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,COSO28394862,2021Dec08,COSO28394862,breast,NS,NS,NS,carcinoma,NS,NS,NS
12751.0,ERBB2,ERBB2_unspecified,,,,breast / carcinoma / NS,2.0,Phase 2,Trastuzumab,,Terminated,NCT00427427,,,,Overexpression,Yes,Slow accrual,4.0,NCT00427427,,,Maximum tolerated dose/toxicity,75.0,75.0,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,COSO28394862,2021Dec08,COSO28394862,breast,NS,NS,NS,carcinoma,NS,NS,NS
12752.0,ERBB2,ERBB2_unspecified,,,,breast / carcinoma / NS,2.0,Phase 2,Trastuzumab,,Terminated,NCT00427427,,,,Overexpression,Yes,Slow accrual,4.0,NCT00427427,,,Maximum tolerated dose/toxicity,75.0,75.0,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,COSO28394862,2021Dec08,COSO28394862,breast,NS,NS,NS,carcinoma,NS,NS,NS
12753.0,ERBB2,ERBB2_unspecified,,,,breast / carcinoma / NS,2.0,Phase 2,Trastuzumab,,Terminated,NCT00133796,,PCD,2005Sep01,Overexpression,No,,4.0,NCT00133796,,,Clinical activity,40.0,40.0,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,COSO28394862,2021Dec08,COSO28394862,breast,NS,NS,NS,carcinoma,NS,NS,NS
12754.0,ERBB2,ERBB2_unspecified,,,,breast / carcinoma / NS,2.0,Phase 2,Trastuzumab,,Terminated,NCT00133796,,PCD,2005Sep01,Overexpression,No,,4.0,NCT00133796,,,Clinical activity,40.0,40.0,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,COSO28394862,2021Dec08,COSO28394862,breast,NS,NS,NS,carcinoma,NS,NS,NS
12755.0,ERBB2,ERBB2_unspecified,,,,breast / carcinoma / NS,2.0,Phase 2,Trastuzumab,,Terminated,NCT00133796,,PCD,2005Sep01,Overexpression,No,,4.0,NCT00133796,,,Clinical activity,40.0,40.0,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,COSO28394862,2021Dec08,COSO28394862,breast,NS,NS,NS,carcinoma,NS,NS,NS
12756.0,ERBB2,ERBB2_unspecified,,,,breast / carcinoma / NS,2.0,Phase 2,Trastuzumab,,Terminated,NCT00133796,,PCD,2005Sep01,Overexpression,No,,4.0,NCT00133796,,,Clinical activity,40.0,40.0,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,COSO28394862,2021Dec08,COSO28394862,breast,NS,NS,NS,carcinoma,NS,NS,NS
12757.0,ERBB2,ERBB2_unspecified,,,,breast / carcinoma / NS,2.0,Phase 2,Trastuzumab,,Terminated,NCT00133796,,PCD,2005Sep01,Overexpression,No,,4.0,NCT00133796,,,Clinical activity,40.0,40.0,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,COSO28394862,2021Dec08,COSO28394862,breast,NS,NS,NS,carcinoma,NS,NS,NS
12758.0,ERBB2,ERBB2_unspecified,,,,breast / carcinoma / NS,2.0,Phase 2,Trastuzumab,,Terminated,NCT00133796,,PCD,2005Sep01,Overexpression,No,,4.0,NCT00133796,,,Clinical activity,40.0,40.0,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,COSO28394862,2021Dec08,COSO28394862,breast,NS,NS,NS,carcinoma,NS,NS,NS
12759.0,ERBB2,ERBB2_unspecified,,,,breast / carcinoma / NS,2.0,Phase 2,Trastuzumab,,Terminated,NCT00133796,,PCD,2005Sep01,Overexpression,No,,4.0,NCT00133796,,,Clinical activity,40.0,40.0,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,COSO28394862,2021Dec08,COSO28394862,breast,NS,NS,NS,carcinoma,NS,NS,NS
12760.0,ERBB2,ERBB2_unspecified,,,,breast / carcinoma / NS,2.0,Phase 2,Trastuzumab,,Terminated,NCT00133796,,PCD,2005Sep01,Overexpression,No,,4.0,NCT00133796,,,Clinical activity,40.0,40.0,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,COSO28394862,2021Dec08,COSO28394862,breast,NS,NS,NS,carcinoma,NS,NS,NS
12761.0,ERBB2,ERBB2_unspecified,,,,breast / carcinoma / NS,2.0,Phase 2,Trastuzumab,,Terminated,NCT00133796,,PCD,2005Sep01,Overexpression,No,,4.0,NCT00133796,,,Clinical activity,40.0,40.0,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,COSO28394862,2021Dec08,COSO28394862,breast,NS,NS,NS,carcinoma,NS,NS,NS
12762.0,ERBB2,ERBB2_unspecified,,,,breast / carcinoma / NS,2.0,Phase 2,Trastuzumab,,Terminated,NCT00133796,,PCD,2005Sep01,Overexpression,No,,4.0,NCT00133796,,,Clinical activity,40.0,40.0,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,COSO28394862,2021Dec08,COSO28394862,breast,NS,NS,NS,carcinoma,NS,NS,NS
12763.0,ERBB2,ERBB2_unspecified,,,,breast / carcinoma / NS,2.0,Phase 2,Trastuzumab,,Terminated,NCT00133796,,PCD,2005Sep01,Overexpression,No,,4.0,NCT00133796,,,Clinical activity,40.0,40.0,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,COSO28394862,2021Dec08,COSO28394862,breast,NS,NS,NS,carcinoma,NS,NS,NS
12764.0,ERBB2,ERBB2_unspecified,,,,breast / carcinoma / NS,2.0,Phase 2,Trastuzumab,,Terminated,NCT00133796,,PCD,2005Sep01,Overexpression,No,,4.0,NCT00133796,,,Clinical activity,40.0,40.0,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,COSO28394862,2021Dec08,COSO28394862,breast,NS,NS,NS,carcinoma,NS,NS,NS
12765.0,ERBB2,ERBB2_unspecified,,,,breast / carcinoma / NS,2.0,Phase 2,Trastuzumab,,Terminated,NCT00133796,,PCD,2005Sep01,Overexpression,No,,4.0,NCT00133796,,,Clinical activity,40.0,40.0,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,COSO28394862,2021Dec08,COSO28394862,breast,NS,NS,NS,carcinoma,NS,NS,NS
15496.0,ERBB2,ERBB2_unspecified,,,,breast / carcinoma / NS,2.0,Phase 3,Trastuzumab,,Completed,NCT02040935,HOMERUS,PCD,2018Sep14,Expression confirmed,Yes,SAE 8%,3.0,https://oncologypro.esmo.org/meeting-resources/esmo-virtual-congress-2020/safety-and-tolerability-of-subcutaneous-trastuzumab-h-sc-self-administered-at-home-via-single-use-injection-device-sid-in-patients-pts-with-h,Previously-treated,,Maximum tolerated dose/toxicity,125.0,125.0,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,COSO28394862,2022Nov28,COSO28394862,breast,NS,NS,NS,carcinoma,NS,NS,NS
15497.0,ERBB2,ERBB2_unspecified,,,,breast / carcinoma / NS,2.0,Phase 3,Trastuzumab,,Completed,NCT02040935,HOMERUS,PCD,2018Sep14,Expression confirmed,Yes,SAE 8%,3.0,https://oncologypro.esmo.org/meeting-resources/esmo-virtual-congress-2020/safety-and-tolerability-of-subcutaneous-trastuzumab-h-sc-self-administered-at-home-via-single-use-injection-device-sid-in-patients-pts-with-h,Previously-treated,,Maximum tolerated dose/toxicity,125.0,125.0,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,COSO28394862,2022Nov28,COSO28394862,breast,NS,NS,NS,carcinoma,NS,NS,NS
15498.0,ERBB2,ERBB2_unspecified,,,,breast / carcinoma / NS,2.0,Phase 3,Trastuzumab,,Completed,NCT02040935,HOMERUS,PCD,2018Sep14,Expression confirmed,Yes,SAE 8%,3.0,https://oncologypro.esmo.org/meeting-resources/esmo-virtual-congress-2020/safety-and-tolerability-of-subcutaneous-trastuzumab-h-sc-self-administered-at-home-via-single-use-injection-device-sid-in-patients-pts-with-h,Previously-treated,,Maximum tolerated dose/toxicity,125.0,125.0,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,COSO28394862,2022Nov28,COSO28394862,breast,NS,NS,NS,carcinoma,NS,NS,NS
15499.0,ERBB2,ERBB2_unspecified,,,,breast / carcinoma / NS,2.0,Phase 3,Trastuzumab,,Completed,NCT02040935,HOMERUS,PCD,2018Sep14,Expression confirmed,Yes,SAE 8%,3.0,https://oncologypro.esmo.org/meeting-resources/esmo-virtual-congress-2020/safety-and-tolerability-of-subcutaneous-trastuzumab-h-sc-self-administered-at-home-via-single-use-injection-device-sid-in-patients-pts-with-h,Previously-treated,,Maximum tolerated dose/toxicity,125.0,125.0,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,COSO28394862,2022Nov28,COSO28394862,breast,NS,NS,NS,carcinoma,NS,NS,NS
15500.0,ERBB2,ERBB2_unspecified,,,,breast / carcinoma / NS,2.0,Phase 3,Trastuzumab,,Completed,NCT02040935,HOMERUS,PCD,2018Sep14,Expression confirmed,Yes,SAE 8%,3.0,https://oncologypro.esmo.org/meeting-resources/esmo-virtual-congress-2020/safety-and-tolerability-of-subcutaneous-trastuzumab-h-sc-self-administered-at-home-via-single-use-injection-device-sid-in-patients-pts-with-h,Previously-treated,,Maximum tolerated dose/toxicity,125.0,125.0,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,COSO28394862,2022Nov28,COSO28394862,breast,NS,NS,NS,carcinoma,NS,NS,NS
15501.0,ERBB2,ERBB2_unspecified,,,,breast / carcinoma / NS,2.0,Phase 3,Trastuzumab,,Completed,NCT02040935,HOMERUS,PCD,2018Sep14,Expression confirmed,Yes,SAE 8%,3.0,https://oncologypro.esmo.org/meeting-resources/esmo-virtual-congress-2020/safety-and-tolerability-of-subcutaneous-trastuzumab-h-sc-self-administered-at-home-via-single-use-injection-device-sid-in-patients-pts-with-h,Previously-treated,,Maximum tolerated dose/toxicity,125.0,125.0,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,COSO28394862,2022Nov28,COSO28394862,breast,NS,NS,NS,carcinoma,NS,NS,NS
15502.0,ERBB2,ERBB2_unspecified,,,,breast / carcinoma / NS,2.0,Phase 3,Trastuzumab,,Completed,NCT02040935,HOMERUS,PCD,2018Sep14,Expression confirmed,Yes,SAE 8%,3.0,https://oncologypro.esmo.org/meeting-resources/esmo-virtual-congress-2020/safety-and-tolerability-of-subcutaneous-trastuzumab-h-sc-self-administered-at-home-via-single-use-injection-device-sid-in-patients-pts-with-h,Previously-treated,,Maximum tolerated dose/toxicity,125.0,125.0,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,COSO28394862,2022Nov28,COSO28394862,breast,NS,NS,NS,carcinoma,NS,NS,NS
15503.0,ERBB2,ERBB2_unspecified,,,,breast / carcinoma / NS,2.0,Phase 3,Trastuzumab,,Completed,NCT02040935,HOMERUS,PCD,2018Sep14,Expression confirmed,Yes,SAE 8%,3.0,https://oncologypro.esmo.org/meeting-resources/esmo-virtual-congress-2020/safety-and-tolerability-of-subcutaneous-trastuzumab-h-sc-self-administered-at-home-via-single-use-injection-device-sid-in-patients-pts-with-h,Previously-treated,,Maximum tolerated dose/toxicity,125.0,125.0,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,COSO28394862,2022Nov28,COSO28394862,breast,NS,NS,NS,carcinoma,NS,NS,NS
15504.0,ERBB2,ERBB2_unspecified,,,,breast / carcinoma / NS,2.0,Phase 3,Trastuzumab,,Completed,NCT02040935,HOMERUS,PCD,2018Sep14,Expression confirmed,Yes,SAE 8%,3.0,https://oncologypro.esmo.org/meeting-resources/esmo-virtual-congress-2020/safety-and-tolerability-of-subcutaneous-trastuzumab-h-sc-self-administered-at-home-via-single-use-injection-device-sid-in-patients-pts-with-h,Previously-treated,,Maximum tolerated dose/toxicity,125.0,125.0,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,COSO28394862,2022Nov28,COSO28394862,breast,NS,NS,NS,carcinoma,NS,NS,NS
15505.0,ERBB2,ERBB2_unspecified,,,,breast / carcinoma / NS,2.0,Phase 3,Trastuzumab,,Completed,NCT02040935,HOMERUS,PCD,2018Sep14,Expression confirmed,Yes,SAE 8%,3.0,https://oncologypro.esmo.org/meeting-resources/esmo-virtual-congress-2020/safety-and-tolerability-of-subcutaneous-trastuzumab-h-sc-self-administered-at-home-via-single-use-injection-device-sid-in-patients-pts-with-h,Previously-treated,,Maximum tolerated dose/toxicity,125.0,125.0,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,COSO28394862,2022Nov28,COSO28394862,breast,NS,NS,NS,carcinoma,NS,NS,NS
15506.0,ERBB2,ERBB2_unspecified,,,,breast / carcinoma / NS,2.0,Phase 3,Trastuzumab,,Completed,NCT02040935,HOMERUS,PCD,2018Sep14,Expression confirmed,Yes,SAE 8%,3.0,https://oncologypro.esmo.org/meeting-resources/esmo-virtual-congress-2020/safety-and-tolerability-of-subcutaneous-trastuzumab-h-sc-self-administered-at-home-via-single-use-injection-device-sid-in-patients-pts-with-h,Previously-treated,,Maximum tolerated dose/toxicity,125.0,125.0,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,COSO28394862,2022Nov28,COSO28394862,breast,NS,NS,NS,carcinoma,NS,NS,NS
15507.0,ERBB2,ERBB2_unspecified,,,,breast / carcinoma / NS,2.0,Phase 3,Trastuzumab,,Completed,NCT02040935,HOMERUS,PCD,2018Sep14,Expression confirmed,Yes,SAE 8%,3.0,https://oncologypro.esmo.org/meeting-resources/esmo-virtual-congress-2020/safety-and-tolerability-of-subcutaneous-trastuzumab-h-sc-self-administered-at-home-via-single-use-injection-device-sid-in-patients-pts-with-h,Previously-treated,,Maximum tolerated dose/toxicity,125.0,125.0,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,COSO28394862,2022Nov28,COSO28394862,breast,NS,NS,NS,carcinoma,NS,NS,NS
15508.0,ERBB2,ERBB2_unspecified,,,,breast / carcinoma / NS,2.0,Phase 3,Trastuzumab,,Completed,NCT02040935,HOMERUS,PCD,2018Sep14,Expression confirmed,Yes,SAE 8%,3.0,https://oncologypro.esmo.org/meeting-resources/esmo-virtual-congress-2020/safety-and-tolerability-of-subcutaneous-trastuzumab-h-sc-self-administered-at-home-via-single-use-injection-device-sid-in-patients-pts-with-h,Previously-treated,,Maximum tolerated dose/toxicity,125.0,125.0,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,COSO28394862,2022Nov28,COSO28394862,breast,NS,NS,NS,carcinoma,NS,NS,NS
15509.0,ERBB2,ERBB2_unspecified,,,,breast / carcinoma / NS,2.0,Phase 3,Trastuzumab,,Completed,NCT02721641,,PCD,2015Feb01,Overexpression,Yes,SAE 15.94%,4.0,NCT02721641,Previously-treated,,Maximum tolerated dose/toxicity,69.0,69.0,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,COSO28394862,2022Nov28,COSO28394862,breast,NS,NS,NS,carcinoma,NS,NS,NS
15510.0,ERBB2,ERBB2_unspecified,,,,breast / carcinoma / NS,2.0,Phase 3,Trastuzumab,,Completed,NCT02721641,,PCD,2015Feb01,Overexpression,Yes,SAE 15.94%,4.0,NCT02721641,Previously-treated,,Maximum tolerated dose/toxicity,69.0,69.0,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,COSO28394862,2022Nov28,COSO28394862,breast,NS,NS,NS,carcinoma,NS,NS,NS
15511.0,ERBB2,ERBB2_unspecified,,,,breast / carcinoma / NS,2.0,Phase 3,Trastuzumab,,Completed,NCT02721641,,PCD,2015Feb01,Overexpression,Yes,SAE 15.94%,4.0,NCT02721641,Previously-treated,,Maximum tolerated dose/toxicity,69.0,69.0,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,COSO28394862,2022Nov28,COSO28394862,breast,NS,NS,NS,carcinoma,NS,NS,NS
15512.0,ERBB2,ERBB2_unspecified,,,,breast / carcinoma / NS,2.0,Phase 3,Trastuzumab,,Completed,NCT02721641,,PCD,2015Feb01,Overexpression,Yes,SAE 15.94%,4.0,NCT02721641,Previously-treated,,Maximum tolerated dose/toxicity,69.0,69.0,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,COSO28394862,2022Nov28,COSO28394862,breast,NS,NS,NS,carcinoma,NS,NS,NS
15513.0,ERBB2,ERBB2_unspecified,,,,breast / carcinoma / NS,2.0,Phase 3,Trastuzumab,,Completed,NCT02721641,,PCD,2015Feb01,Overexpression,Yes,SAE 15.94%,4.0,NCT02721641,Previously-treated,,Maximum tolerated dose/toxicity,69.0,69.0,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,COSO28394862,2022Nov28,COSO28394862,breast,NS,NS,NS,carcinoma,NS,NS,NS
15514.0,ERBB2,ERBB2_unspecified,,,,breast / carcinoma / NS,2.0,Phase 3,Trastuzumab,,Completed,NCT02721641,,PCD,2015Feb01,Overexpression,Yes,SAE 15.94%,4.0,NCT02721641,Previously-treated,,Maximum tolerated dose/toxicity,69.0,69.0,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,COSO28394862,2022Nov28,COSO28394862,breast,NS,NS,NS,carcinoma,NS,NS,NS
15515.0,ERBB2,ERBB2_unspecified,,,,breast / carcinoma / NS,2.0,Phase 3,Trastuzumab,,Completed,NCT02721641,,PCD,2015Feb01,Overexpression,Yes,SAE 15.94%,4.0,NCT02721641,Previously-treated,,Maximum tolerated dose/toxicity,69.0,69.0,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,COSO28394862,2022Nov28,COSO28394862,breast,NS,NS,NS,carcinoma,NS,NS,NS
15516.0,ERBB2,ERBB2_unspecified,,,,breast / carcinoma / NS,2.0,Phase 3,Trastuzumab,,Completed,NCT02721641,,PCD,2015Feb01,Overexpression,Yes,SAE 15.94%,4.0,NCT02721641,Previously-treated,,Maximum tolerated dose/toxicity,69.0,69.0,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,COSO28394862,2022Nov28,COSO28394862,breast,NS,NS,NS,carcinoma,NS,NS,NS
15517.0,ERBB2,ERBB2_unspecified,,,,breast / carcinoma / NS,2.0,Phase 3,Trastuzumab,,Completed,NCT02721641,,PCD,2015Feb01,Overexpression,Yes,SAE 15.94%,4.0,NCT02721641,Previously-treated,,Maximum tolerated dose/toxicity,69.0,69.0,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,COSO28394862,2022Nov28,COSO28394862,breast,NS,NS,NS,carcinoma,NS,NS,NS
15518.0,ERBB2,ERBB2_unspecified,,,,breast / carcinoma / NS,2.0,Phase 3,Trastuzumab,,Completed,NCT02721641,,PCD,2015Feb01,Overexpression,Yes,SAE 15.94%,4.0,NCT02721641,Previously-treated,,Maximum tolerated dose/toxicity,69.0,69.0,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,COSO28394862,2022Nov28,COSO28394862,breast,NS,NS,NS,carcinoma,NS,NS,NS
15519.0,ERBB2,ERBB2_unspecified,,,,breast / carcinoma / NS,2.0,Phase 3,Trastuzumab,,Completed,NCT02721641,,PCD,2015Feb01,Overexpression,Yes,SAE 15.94%,4.0,NCT02721641,Previously-treated,,Maximum tolerated dose/toxicity,69.0,69.0,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,COSO28394862,2022Nov28,COSO28394862,breast,NS,NS,NS,carcinoma,NS,NS,NS
15520.0,ERBB2,ERBB2_unspecified,,,,breast / carcinoma / NS,2.0,Phase 3,Trastuzumab,,Completed,NCT02721641,,PCD,2015Feb01,Overexpression,Yes,SAE 15.94%,4.0,NCT02721641,Previously-treated,,Maximum tolerated dose/toxicity,69.0,69.0,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,COSO28394862,2022Nov28,COSO28394862,breast,NS,NS,NS,carcinoma,NS,NS,NS
15521.0,ERBB2,ERBB2_unspecified,,,,breast / carcinoma / NS,2.0,Phase 3,Trastuzumab,,Completed,NCT02721641,,PCD,2015Feb01,Overexpression,Yes,SAE 15.94%,4.0,NCT02721641,Previously-treated,,Maximum tolerated dose/toxicity,69.0,69.0,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,COSO28394862,2022Nov28,COSO28394862,breast,NS,NS,NS,carcinoma,NS,NS,NS
15522.0,ERBB2,ERBB2_unspecified,,,,breast / carcinoma / NS,2.0,Phase 3,Trastuzumab,,Recruiting,NCT01785420,,ECD,2025Apr01,Overexpression,No,,4.0,NCT01785420,,,"Disease free survival, relapse free survival, regression free survival, recurrence free survival",1100.0,,,Placebo,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,COSO28394862,2021Dec09,COSO28394862,breast,NS,NS,NS,carcinoma,NS,NS,NS
15523.0,ERBB2,ERBB2_unspecified,,,,breast / carcinoma / NS,2.0,Phase 3,Trastuzumab,,Recruiting,NCT01785420,,ECD,2025Apr01,Overexpression,No,,4.0,NCT01785420,,,"Disease free survival, relapse free survival, regression free survival, recurrence free survival",1100.0,,,Placebo,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,COSO28394862,2021Dec09,COSO28394862,breast,NS,NS,NS,carcinoma,NS,NS,NS
15524.0,ERBB2,ERBB2_unspecified,,,,breast / carcinoma / NS,2.0,Phase 3,Trastuzumab,,Recruiting,NCT01785420,,ECD,2025Apr01,Overexpression,No,,4.0,NCT01785420,,,"Disease free survival, relapse free survival, regression free survival, recurrence free survival",1100.0,,,Placebo,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,COSO28394862,2021Dec09,COSO28394862,breast,NS,NS,NS,carcinoma,NS,NS,NS
15525.0,ERBB2,ERBB2_unspecified,,,,breast / carcinoma / NS,2.0,Phase 3,Trastuzumab,,Recruiting,NCT01785420,,ECD,2025Apr01,Overexpression,No,,4.0,NCT01785420,,,"Disease free survival, relapse free survival, regression free survival, recurrence free survival",1100.0,,,Placebo,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,COSO28394862,2021Dec09,COSO28394862,breast,NS,NS,NS,carcinoma,NS,NS,NS
15526.0,ERBB2,ERBB2_unspecified,,,,breast / carcinoma / NS,2.0,Phase 3,Trastuzumab,,Recruiting,NCT01785420,,ECD,2025Apr01,Overexpression,No,,4.0,NCT01785420,,,"Disease free survival, relapse free survival, regression free survival, recurrence free survival",1100.0,,,Placebo,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,COSO28394862,2021Dec09,COSO28394862,breast,NS,NS,NS,carcinoma,NS,NS,NS
15527.0,ERBB2,ERBB2_unspecified,,,,breast / carcinoma / NS,2.0,Phase 3,Trastuzumab,,Recruiting,NCT01785420,,ECD,2025Apr01,Overexpression,No,,4.0,NCT01785420,,,"Disease free survival, relapse free survival, regression free survival, recurrence free survival",1100.0,,,Placebo,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,COSO28394862,2021Dec09,COSO28394862,breast,NS,NS,NS,carcinoma,NS,NS,NS
15528.0,ERBB2,ERBB2_unspecified,,,,breast / carcinoma / NS,2.0,Phase 3,Trastuzumab,,Recruiting,NCT01785420,,ECD,2025Apr01,Overexpression,No,,4.0,NCT01785420,,,"Disease free survival, relapse free survival, regression free survival, recurrence free survival",1100.0,,,Placebo,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,COSO28394862,2021Dec09,COSO28394862,breast,NS,NS,NS,carcinoma,NS,NS,NS
15529.0,ERBB2,ERBB2_unspecified,,,,breast / carcinoma / NS,2.0,Phase 3,Trastuzumab,,Recruiting,NCT01785420,,ECD,2025Apr01,Overexpression,No,,4.0,NCT01785420,,,"Disease free survival, relapse free survival, regression free survival, recurrence free survival",1100.0,,,Placebo,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,COSO28394862,2021Dec09,COSO28394862,breast,NS,NS,NS,carcinoma,NS,NS,NS
15530.0,ERBB2,ERBB2_unspecified,,,,breast / carcinoma / NS,2.0,Phase 3,Trastuzumab,,Recruiting,NCT01785420,,ECD,2025Apr01,Overexpression,No,,4.0,NCT01785420,,,"Disease free survival, relapse free survival, regression free survival, recurrence free survival",1100.0,,,Placebo,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,COSO28394862,2021Dec09,COSO28394862,breast,NS,NS,NS,carcinoma,NS,NS,NS
15531.0,ERBB2,ERBB2_unspecified,,,,breast / carcinoma / NS,2.0,Phase 3,Trastuzumab,,Recruiting,NCT01785420,,ECD,2025Apr01,Overexpression,No,,4.0,NCT01785420,,,"Disease free survival, relapse free survival, regression free survival, recurrence free survival",1100.0,,,Placebo,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,COSO28394862,2021Dec09,COSO28394862,breast,NS,NS,NS,carcinoma,NS,NS,NS
15532.0,ERBB2,ERBB2_unspecified,,,,breast / carcinoma / NS,2.0,Phase 3,Trastuzumab,,Recruiting,NCT01785420,,ECD,2025Apr01,Overexpression,No,,4.0,NCT01785420,,,"Disease free survival, relapse free survival, regression free survival, recurrence free survival",1100.0,,,Placebo,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,COSO28394862,2021Dec09,COSO28394862,breast,NS,NS,NS,carcinoma,NS,NS,NS
15533.0,ERBB2,ERBB2_unspecified,,,,breast / carcinoma / NS,2.0,Phase 3,Trastuzumab,,Recruiting,NCT01785420,,ECD,2025Apr01,Overexpression,No,,4.0,NCT01785420,,,"Disease free survival, relapse free survival, regression free survival, recurrence free survival",1100.0,,,Placebo,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,COSO28394862,2021Dec09,COSO28394862,breast,NS,NS,NS,carcinoma,NS,NS,NS
15534.0,ERBB2,ERBB2_unspecified,,,,breast / carcinoma / NS,2.0,Phase 3,Trastuzumab,,Recruiting,NCT01785420,,ECD,2025Apr01,Overexpression,No,,4.0,NCT01785420,,,"Disease free survival, relapse free survival, regression free survival, recurrence free survival",1100.0,,,Placebo,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,COSO28394862,2021Dec09,COSO28394862,breast,NS,NS,NS,carcinoma,NS,NS,NS
15691.0,ERBB2,ERBB2_unspecified,,,,breast / carcinoma / NS,2.0,Phase 4,Trastuzumab,,Recruiting,NCT04928261,,ECD,2023Sep01,Expression confirmed,No,,4.0,NCT04928261,Previously-treated,,Response rate,50.0,50.0,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,COSO28394862,2022Jan18,COSO28394862,breast,NS,NS,NS,carcinoma,NS,NS,NS
15692.0,ERBB2,ERBB2_unspecified,,,,breast / carcinoma / NS,2.0,Phase 4,Trastuzumab,,Recruiting,NCT04928261,,ECD,2023Sep01,Expression confirmed,No,,4.0,NCT04928261,Previously-treated,,Response rate,50.0,50.0,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,COSO28394862,2022Jan18,COSO28394862,breast,NS,NS,NS,carcinoma,NS,NS,NS
15693.0,ERBB2,ERBB2_unspecified,,,,breast / carcinoma / NS,2.0,Phase 4,Trastuzumab,,Recruiting,NCT04928261,,ECD,2023Sep01,Expression confirmed,No,,4.0,NCT04928261,Previously-treated,,Response rate,50.0,50.0,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,COSO28394862,2022Jan18,COSO28394862,breast,NS,NS,NS,carcinoma,NS,NS,NS
15694.0,ERBB2,ERBB2_unspecified,,,,breast / carcinoma / NS,2.0,Phase 4,Trastuzumab,,Recruiting,NCT04928261,,ECD,2023Sep01,Expression confirmed,No,,4.0,NCT04928261,Previously-treated,,Response rate,50.0,50.0,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,COSO28394862,2022Jan18,COSO28394862,breast,NS,NS,NS,carcinoma,NS,NS,NS
15695.0,ERBB2,ERBB2_unspecified,,,,breast / carcinoma / NS,2.0,Phase 4,Trastuzumab,,Recruiting,NCT04928261,,ECD,2023Sep01,Expression confirmed,No,,4.0,NCT04928261,Previously-treated,,Response rate,50.0,50.0,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,COSO28394862,2022Jan18,COSO28394862,breast,NS,NS,NS,carcinoma,NS,NS,NS
15696.0,ERBB2,ERBB2_unspecified,,,,breast / carcinoma / NS,2.0,Phase 4,Trastuzumab,,Recruiting,NCT04928261,,ECD,2023Sep01,Expression confirmed,No,,4.0,NCT04928261,Previously-treated,,Response rate,50.0,50.0,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,COSO28394862,2022Jan18,COSO28394862,breast,NS,NS,NS,carcinoma,NS,NS,NS
15697.0,ERBB2,ERBB2_unspecified,,,,breast / carcinoma / NS,2.0,Phase 4,Trastuzumab,,Recruiting,NCT04928261,,ECD,2023Sep01,Expression confirmed,No,,4.0,NCT04928261,Previously-treated,,Response rate,50.0,50.0,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,COSO28394862,2022Jan18,COSO28394862,breast,NS,NS,NS,carcinoma,NS,NS,NS
15698.0,ERBB2,ERBB2_unspecified,,,,breast / carcinoma / NS,2.0,Phase 4,Trastuzumab,,Recruiting,NCT04928261,,ECD,2023Sep01,Expression confirmed,No,,4.0,NCT04928261,Previously-treated,,Response rate,50.0,50.0,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,COSO28394862,2022Jan18,COSO28394862,breast,NS,NS,NS,carcinoma,NS,NS,NS
15699.0,ERBB2,ERBB2_unspecified,,,,breast / carcinoma / NS,2.0,Phase 4,Trastuzumab,,Recruiting,NCT04928261,,ECD,2023Sep01,Expression confirmed,No,,4.0,NCT04928261,Previously-treated,,Response rate,50.0,50.0,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,COSO28394862,2022Jan18,COSO28394862,breast,NS,NS,NS,carcinoma,NS,NS,NS
15700.0,ERBB2,ERBB2_unspecified,,,,breast / carcinoma / NS,2.0,Phase 4,Trastuzumab,,Recruiting,NCT04928261,,ECD,2023Sep01,Expression confirmed,No,,4.0,NCT04928261,Previously-treated,,Response rate,50.0,50.0,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,COSO28394862,2022Jan18,COSO28394862,breast,NS,NS,NS,carcinoma,NS,NS,NS
15701.0,ERBB2,ERBB2_unspecified,,,,breast / carcinoma / NS,2.0,Phase 4,Trastuzumab,,Recruiting,NCT04928261,,ECD,2023Sep01,Expression confirmed,No,,4.0,NCT04928261,Previously-treated,,Response rate,50.0,50.0,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,COSO28394862,2022Jan18,COSO28394862,breast,NS,NS,NS,carcinoma,NS,NS,NS
15702.0,ERBB2,ERBB2_unspecified,,,,breast / carcinoma / NS,2.0,Phase 4,Trastuzumab,,Recruiting,NCT04928261,,ECD,2023Sep01,Expression confirmed,No,,4.0,NCT04928261,Previously-treated,,Response rate,50.0,50.0,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,COSO28394862,2022Jan18,COSO28394862,breast,NS,NS,NS,carcinoma,NS,NS,NS
15703.0,ERBB2,ERBB2_unspecified,,,,breast / carcinoma / NS,2.0,Phase 4,Trastuzumab,,Recruiting,NCT04928261,,ECD,2023Sep01,Expression confirmed,No,,4.0,NCT04928261,Previously-treated,,Response rate,50.0,50.0,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,COSO28394862,2022Jan18,COSO28394862,breast,NS,NS,NS,carcinoma,NS,NS,NS
18070.0,PIK3CA,PIK3CA_unspecified,,,,breast / carcinoma / NS,1.0,Phase 3,Trastuzumab,,Completed,NCT00829166,EMILIA,PCD,2012Jul01,Yes,Yes,,1.0,26920887,Previously-treated,,"OS, PFS",79.0,40.0,39.0,Capecitabine + Lapatinib,,,,,,,,,10.9,4.3,0.45,0.25-0.82,,,,,,,,,,,,,,,,,,,,,,,,,,,COSO28394862,2021Dec08,COSO28394862,breast,NS,NS,NS,carcinoma,NS,NS,NS
18071.0,PIK3CA,PIK3CA_unspecified,,,,breast / carcinoma / NS,1.0,Phase 3,Trastuzumab,,Completed,NCT00829166,EMILIA,PCD,2012Jul01,Yes,Yes,,1.0,26920887,Previously-treated,,"OS, PFS",79.0,40.0,39.0,Capecitabine + Lapatinib,,,,,,,,,10.9,4.3,0.45,0.25-0.82,,,,,,,,,,,,,,,,,,,,,,,,,,,COSO28394862,2021Dec08,COSO28394862,breast,NS,NS,NS,carcinoma,NS,NS,NS
18072.0,PIK3CA,PIK3CA_unspecified,,,,breast / carcinoma / NS,1.0,Phase 3,Trastuzumab,,Completed,NCT00829166,EMILIA,PCD,2012Jul01,Yes,Yes,,1.0,26920887,Previously-treated,,"OS, PFS",79.0,40.0,39.0,Capecitabine + Lapatinib,,,,,,,,,10.9,4.3,0.45,0.25-0.82,,,,,,,,,,,,,,,,,,,,,,,,,,,COSO28394862,2021Dec08,COSO28394862,breast,NS,NS,NS,carcinoma,NS,NS,NS
18073.0,PIK3CA,PIK3CA_unspecified,,,,breast / carcinoma / NS,1.0,Phase 3,Trastuzumab,,Completed,NCT00829166,EMILIA,PCD,2012Jul01,Yes,Yes,,1.0,26920887,Previously-treated,,"OS, PFS",79.0,40.0,39.0,Capecitabine + Lapatinib,,,,,,,,,10.9,4.3,0.45,0.25-0.82,,,,,,,,,,,,,,,,,,,,,,,,,,,COSO28394862,2021Dec08,COSO28394862,breast,NS,NS,NS,carcinoma,NS,NS,NS
18074.0,PIK3CA,PIK3CA_unspecified,,,,breast / carcinoma / NS,1.0,Phase 3,Trastuzumab,,Completed,NCT00829166,EMILIA,PCD,2012Jul01,Yes,Yes,,1.0,26920887,Previously-treated,,"OS, PFS",79.0,40.0,39.0,Capecitabine + Lapatinib,,,,,,,,,10.9,4.3,0.45,0.25-0.82,,,,,,,,,,,,,,,,,,,,,,,,,,,COSO28394862,2021Dec08,COSO28394862,breast,NS,NS,NS,carcinoma,NS,NS,NS
18075.0,PIK3CA,PIK3CA_unspecified,,,,breast / carcinoma / NS,1.0,Phase 3,Trastuzumab,,Completed,NCT00829166,EMILIA,PCD,2012Jul01,Yes,Yes,,1.0,26920887,Previously-treated,,"OS, PFS",79.0,40.0,39.0,Capecitabine + Lapatinib,,,,,,,,,10.9,4.3,0.45,0.25-0.82,,,,,,,,,,,,,,,,,,,,,,,,,,,COSO28394862,2021Dec08,COSO28394862,breast,NS,NS,NS,carcinoma,NS,NS,NS
18076.0,PIK3CA,PIK3CA_unspecified,,,,breast / carcinoma / NS,1.0,Phase 3,Trastuzumab,,Completed,NCT00829166,EMILIA,PCD,2012Jul01,Yes,Yes,,1.0,26920887,Previously-treated,,"OS, PFS",79.0,40.0,39.0,Capecitabine + Lapatinib,,,,,,,,,10.9,4.3,0.45,0.25-0.82,,,,,,,,,,,,,,,,,,,,,,,,,,,COSO28394862,2021Dec08,COSO28394862,breast,NS,NS,NS,carcinoma,NS,NS,NS
18077.0,PIK3CA,PIK3CA_unspecified,,,,breast / carcinoma / NS,1.0,Phase 3,Trastuzumab,,Completed,NCT00829166,EMILIA,PCD,2012Jul01,Yes,Yes,,1.0,26920887,Previously-treated,,"OS, PFS",79.0,40.0,39.0,Capecitabine + Lapatinib,,,,,,,,,10.9,4.3,0.45,0.25-0.82,,,,,,,,,,,,,,,,,,,,,,,,,,,COSO28394862,2021Dec08,COSO28394862,breast,NS,NS,NS,carcinoma,NS,NS,NS
18078.0,PIK3CA,PIK3CA_unspecified,,,,breast / carcinoma / NS,1.0,Phase 3,Trastuzumab,,Completed,NCT00829166,EMILIA,PCD,2012Jul01,Yes,Yes,,1.0,26920887,Previously-treated,,"OS, PFS",79.0,40.0,39.0,Capecitabine + Lapatinib,,,,,,,,,10.9,4.3,0.45,0.25-0.82,,,,,,,,,,,,,,,,,,,,,,,,,,,COSO28394862,2021Dec08,COSO28394862,breast,NS,NS,NS,carcinoma,NS,NS,NS
18079.0,PIK3CA,PIK3CA_unspecified,,,,breast / carcinoma / NS,1.0,Phase 3,Trastuzumab,,Completed,NCT00829166,EMILIA,PCD,2012Jul01,Yes,Yes,,1.0,26920887,Previously-treated,,"OS, PFS",79.0,40.0,39.0,Capecitabine + Lapatinib,,,,,,,,,10.9,4.3,0.45,0.25-0.82,,,,,,,,,,,,,,,,,,,,,,,,,,,COSO28394862,2021Dec08,COSO28394862,breast,NS,NS,NS,carcinoma,NS,NS,NS
18080.0,PIK3CA,PIK3CA_unspecified,,,,breast / carcinoma / NS,1.0,Phase 3,Trastuzumab,,Completed,NCT00829166,EMILIA,PCD,2012Jul01,Yes,Yes,,1.0,26920887,Previously-treated,,"OS, PFS",79.0,40.0,39.0,Capecitabine + Lapatinib,,,,,,,,,10.9,4.3,0.45,0.25-0.82,,,,,,,,,,,,,,,,,,,,,,,,,,,COSO28394862,2021Dec08,COSO28394862,breast,NS,NS,NS,carcinoma,NS,NS,NS
18081.0,PIK3CA,PIK3CA_unspecified,,,,breast / carcinoma / NS,1.0,Phase 3,Trastuzumab,,Completed,NCT00829166,EMILIA,PCD,2012Jul01,Yes,Yes,,1.0,26920887,Previously-treated,,"OS, PFS",79.0,40.0,39.0,Capecitabine + Lapatinib,,,,,,,,,10.9,4.3,0.45,0.25-0.82,,,,,,,,,,,,,,,,,,,,,,,,,,,COSO28394862,2021Dec08,COSO28394862,breast,NS,NS,NS,carcinoma,NS,NS,NS
18082.0,PIK3CA,PIK3CA_unspecified,,,,breast / carcinoma / NS,1.0,Phase 3,Trastuzumab,,Completed,NCT00829166,EMILIA,PCD,2012Jul01,Yes,Yes,,1.0,26920887,Previously-treated,,"OS, PFS",79.0,40.0,39.0,Capecitabine + Lapatinib,,,,,,,,,10.9,4.3,0.45,0.25-0.82,,,,,,,,,,,,,,,,,,,,,,,,,,,COSO28394862,2021Dec08,COSO28394862,breast,NS,NS,NS,carcinoma,NS,NS,NS
18161.0,PIK3CA,PIK3CA_unspecified,,,,breast / carcinoma / NS,1.0,Retrospective/Meta-analysis,Trastuzumab,,Unknown,,,,,Comparison with wt,Yes,pCR 24.3 vs 33.8 p=0.27,1.0,25199759,,,Clinical activity,173.0,37.0,136.0,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,COSO28394862,2021Dec08,COSO28394862,breast,NS,NS,NS,carcinoma,NS,NS,NS
18162.0,PIK3CA,PIK3CA_unspecified,,,,breast / carcinoma / NS,1.0,Retrospective/Meta-analysis,Trastuzumab,,Unknown,,,,,Comparison with wt,Yes,pCR 24.3 vs 33.8 p=0.27,1.0,25199759,,,Clinical activity,173.0,37.0,136.0,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,COSO28394862,2021Dec08,COSO28394862,breast,NS,NS,NS,carcinoma,NS,NS,NS
18163.0,PIK3CA,PIK3CA_unspecified,,,,breast / carcinoma / NS,1.0,Retrospective/Meta-analysis,Trastuzumab,,Unknown,,,,,Comparison with wt,Yes,pCR 24.3 vs 33.8 p=0.27,1.0,25199759,,,Clinical activity,173.0,37.0,136.0,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,COSO28394862,2021Dec08,COSO28394862,breast,NS,NS,NS,carcinoma,NS,NS,NS
18164.0,PIK3CA,PIK3CA_unspecified,,,,breast / carcinoma / NS,1.0,Retrospective/Meta-analysis,Trastuzumab,,Unknown,,,,,Comparison with wt,Yes,pCR 24.3 vs 33.8 p=0.27,1.0,25199759,,,Clinical activity,173.0,37.0,136.0,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,COSO28394862,2021Dec08,COSO28394862,breast,NS,NS,NS,carcinoma,NS,NS,NS
18165.0,PIK3CA,PIK3CA_unspecified,,,,breast / carcinoma / NS,1.0,Retrospective/Meta-analysis,Trastuzumab,,Unknown,,,,,Comparison with wt,Yes,pCR 24.3 vs 33.8 p=0.27,1.0,25199759,,,Clinical activity,173.0,37.0,136.0,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,COSO28394862,2021Dec08,COSO28394862,breast,NS,NS,NS,carcinoma,NS,NS,NS
18166.0,PIK3CA,PIK3CA_unspecified,,,,breast / carcinoma / NS,1.0,Retrospective/Meta-analysis,Trastuzumab,,Unknown,,,,,Comparison with wt,Yes,pCR 24.3 vs 33.8 p=0.27,1.0,25199759,,,Clinical activity,173.0,37.0,136.0,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,COSO28394862,2021Dec08,COSO28394862,breast,NS,NS,NS,carcinoma,NS,NS,NS
18167.0,PIK3CA,PIK3CA_unspecified,,,,breast / carcinoma / NS,1.0,Retrospective/Meta-analysis,Trastuzumab,,Unknown,,,,,Comparison with wt,Yes,pCR 24.3 vs 33.8 p=0.27,1.0,25199759,,,Clinical activity,173.0,37.0,136.0,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,COSO28394862,2021Dec08,COSO28394862,breast,NS,NS,NS,carcinoma,NS,NS,NS
18168.0,PIK3CA,PIK3CA_unspecified,,,,breast / carcinoma / NS,1.0,Retrospective/Meta-analysis,Trastuzumab,,Unknown,,,,,Comparison with wt,Yes,pCR 24.3 vs 33.8 p=0.27,1.0,25199759,,,Clinical activity,173.0,37.0,136.0,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,COSO28394862,2021Dec08,COSO28394862,breast,NS,NS,NS,carcinoma,NS,NS,NS
18169.0,PIK3CA,PIK3CA_unspecified,,,,breast / carcinoma / NS,1.0,Retrospective/Meta-analysis,Trastuzumab,,Unknown,,,,,Comparison with wt,Yes,pCR 24.3 vs 33.8 p=0.27,1.0,25199759,,,Clinical activity,173.0,37.0,136.0,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,COSO28394862,2021Dec08,COSO28394862,breast,NS,NS,NS,carcinoma,NS,NS,NS
18170.0,PIK3CA,PIK3CA_unspecified,,,,breast / carcinoma / NS,1.0,Retrospective/Meta-analysis,Trastuzumab,,Unknown,,,,,Comparison with wt,Yes,pCR 24.3 vs 33.8 p=0.27,1.0,25199759,,,Clinical activity,173.0,37.0,136.0,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,COSO28394862,2021Dec08,COSO28394862,breast,NS,NS,NS,carcinoma,NS,NS,NS
18171.0,PIK3CA,PIK3CA_unspecified,,,,breast / carcinoma / NS,1.0,Retrospective/Meta-analysis,Trastuzumab,,Unknown,,,,,Comparison with wt,Yes,pCR 24.3 vs 33.8 p=0.27,1.0,25199759,,,Clinical activity,173.0,37.0,136.0,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,COSO28394862,2021Dec08,COSO28394862,breast,NS,NS,NS,carcinoma,NS,NS,NS
18172.0,PIK3CA,PIK3CA_unspecified,,,,breast / carcinoma / NS,1.0,Retrospective/Meta-analysis,Trastuzumab,,Unknown,,,,,Comparison with wt,Yes,pCR 24.3 vs 33.8 p=0.27,1.0,25199759,,,Clinical activity,173.0,37.0,136.0,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,COSO28394862,2021Dec08,COSO28394862,breast,NS,NS,NS,carcinoma,NS,NS,NS
18173.0,PIK3CA,PIK3CA_unspecified,,,,breast / carcinoma / NS,1.0,Retrospective/Meta-analysis,Trastuzumab,,Unknown,,,,,Comparison with wt,Yes,pCR 24.3 vs 33.8 p=0.27,1.0,25199759,,,Clinical activity,173.0,37.0,136.0,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,COSO28394862,2021Dec08,COSO28394862,breast,NS,NS,NS,carcinoma,NS,NS,NS
18460.0,PTEN,PTEN_unspecified,,,,breast / carcinoma / NS,3.0,Retrospective/Meta-analysis,Trastuzumab,,Unknown,,BCIRG-005/6,,,Expression confirmed,Yes,Response not correlated with expression status,1.0,25649019,,,"Disease free survival, relapse free survival, regression free survival, recurrence free survival",2364.0,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,COSO28394862,2022Nov18,COSO28394862,breast,NS,NS,NS,carcinoma,NS,NS,NS
18461.0,PTEN,PTEN_unspecified,,,,breast / carcinoma / NS,3.0,Retrospective/Meta-analysis,Trastuzumab,,Unknown,,BCIRG-005/6,,,Expression confirmed,Yes,Response not correlated with expression status,1.0,25649019,,,"Disease free survival, relapse free survival, regression free survival, recurrence free survival",2364.0,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,COSO28394862,2022Nov18,COSO28394862,breast,NS,NS,NS,carcinoma,NS,NS,NS
18462.0,PTEN,PTEN_unspecified,,,,breast / carcinoma / NS,3.0,Retrospective/Meta-analysis,Trastuzumab,,Unknown,,BCIRG-005/6,,,Expression confirmed,Yes,Response not correlated with expression status,1.0,25649019,,,"Disease free survival, relapse free survival, regression free survival, recurrence free survival",2364.0,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,COSO28394862,2022Nov18,COSO28394862,breast,NS,NS,NS,carcinoma,NS,NS,NS
18463.0,PTEN,PTEN_unspecified,,,,breast / carcinoma / NS,3.0,Retrospective/Meta-analysis,Trastuzumab,,Unknown,,BCIRG-005/6,,,Expression confirmed,Yes,Response not correlated with expression status,1.0,25649019,,,"Disease free survival, relapse free survival, regression free survival, recurrence free survival",2364.0,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,COSO28394862,2022Nov18,COSO28394862,breast,NS,NS,NS,carcinoma,NS,NS,NS
18464.0,PTEN,PTEN_unspecified,,,,breast / carcinoma / NS,3.0,Retrospective/Meta-analysis,Trastuzumab,,Unknown,,BCIRG-005/6,,,Expression confirmed,Yes,Response not correlated with expression status,1.0,25649019,,,"Disease free survival, relapse free survival, regression free survival, recurrence free survival",2364.0,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,COSO28394862,2022Nov18,COSO28394862,breast,NS,NS,NS,carcinoma,NS,NS,NS
18465.0,PTEN,PTEN_unspecified,,,,breast / carcinoma / NS,3.0,Retrospective/Meta-analysis,Trastuzumab,,Unknown,,BCIRG-005/6,,,Expression confirmed,Yes,Response not correlated with expression status,1.0,25649019,,,"Disease free survival, relapse free survival, regression free survival, recurrence free survival",2364.0,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,COSO28394862,2022Nov18,COSO28394862,breast,NS,NS,NS,carcinoma,NS,NS,NS
18466.0,PTEN,PTEN_unspecified,,,,breast / carcinoma / NS,3.0,Retrospective/Meta-analysis,Trastuzumab,,Unknown,,BCIRG-005/6,,,Expression confirmed,Yes,Response not correlated with expression status,1.0,25649019,,,"Disease free survival, relapse free survival, regression free survival, recurrence free survival",2364.0,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,COSO28394862,2022Nov18,COSO28394862,breast,NS,NS,NS,carcinoma,NS,NS,NS
18467.0,PTEN,PTEN_unspecified,,,,breast / carcinoma / NS,3.0,Retrospective/Meta-analysis,Trastuzumab,,Unknown,,BCIRG-005/6,,,Expression confirmed,Yes,Response not correlated with expression status,1.0,25649019,,,"Disease free survival, relapse free survival, regression free survival, recurrence free survival",2364.0,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,COSO28394862,2022Nov18,COSO28394862,breast,NS,NS,NS,carcinoma,NS,NS,NS
18468.0,PTEN,PTEN_unspecified,,,,breast / carcinoma / NS,3.0,Retrospective/Meta-analysis,Trastuzumab,,Unknown,,BCIRG-005/6,,,Expression confirmed,Yes,Response not correlated with expression status,1.0,25649019,,,"Disease free survival, relapse free survival, regression free survival, recurrence free survival",2364.0,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,COSO28394862,2022Nov18,COSO28394862,breast,NS,NS,NS,carcinoma,NS,NS,NS
18469.0,PTEN,PTEN_unspecified,,,,breast / carcinoma / NS,3.0,Retrospective/Meta-analysis,Trastuzumab,,Unknown,,BCIRG-005/6,,,Expression confirmed,Yes,Response not correlated with expression status,1.0,25649019,,,"Disease free survival, relapse free survival, regression free survival, recurrence free survival",2364.0,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,COSO28394862,2022Nov18,COSO28394862,breast,NS,NS,NS,carcinoma,NS,NS,NS
18470.0,PTEN,PTEN_unspecified,,,,breast / carcinoma / NS,3.0,Retrospective/Meta-analysis,Trastuzumab,,Unknown,,BCIRG-005/6,,,Expression confirmed,Yes,Response not correlated with expression status,1.0,25649019,,,"Disease free survival, relapse free survival, regression free survival, recurrence free survival",2364.0,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,COSO28394862,2022Nov18,COSO28394862,breast,NS,NS,NS,carcinoma,NS,NS,NS
18471.0,PTEN,PTEN_unspecified,,,,breast / carcinoma / NS,3.0,Retrospective/Meta-analysis,Trastuzumab,,Unknown,,BCIRG-005/6,,,Expression confirmed,Yes,Response not correlated with expression status,1.0,25649019,,,"Disease free survival, relapse free survival, regression free survival, recurrence free survival",2364.0,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,COSO28394862,2022Nov18,COSO28394862,breast,NS,NS,NS,carcinoma,NS,NS,NS
18472.0,PTEN,PTEN_unspecified,,,,breast / carcinoma / NS,3.0,Retrospective/Meta-analysis,Trastuzumab,,Unknown,,BCIRG-005/6,,,Expression confirmed,Yes,Response not correlated with expression status,1.0,25649019,,,"Disease free survival, relapse free survival, regression free survival, recurrence free survival",2364.0,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,COSO28394862,2022Nov18,COSO28394862,breast,NS,NS,NS,carcinoma,NS,NS,NS
